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ABSTRACT 
Cardiovascular disease is the leading cause of death, and understanding 
the pathophysiological changes that occur in response to injury is important for 
identifying novel drug targets and developing improved therapeutics. The 
process of cardiovascular remodeling, which occurs after injury and includes 
structural and functional changes has been identified as a target for therapeutic 
intervention.  
Reprogramming macrophages towards a reparative phenotype in 
cardiovascular remodeling is a potential therapeutic approach. Interleukin-4 
receptor (IL4R) signaling is an inducer of alternatively activated macrophages 
(AAM or M2), and M2 macrophages are critically involved in inflammation 
resolution, tissue repair and pathological development of fibrosis. IL-4 
administration can be beneficial, but the important IL-4 responsive cell types 
mediating the protection have not been identified. We hypothesized that 
macrophages are the critical target cell type of IL-4, and macrophage IL4R 
signaling plays an important role in cardiovascular remodeling by controlling 
macrophage polarization.  
In order to test this hypothesis, we generated myeloid 
(macrophage/monocyte and neutrophil)-specific IL-4 receptor α knockout 
(MyIL4RαKO) mice. Bone marrow derived macrophages from MyIL4RαKO mice 
showed a significantly blunted response to the M2 macrophage stimulus IL-4 and 
a markedly augmented response to the M1 macrophage stimulus LPS, indicating 
the importance of IL4Rα signaling in macrophage polarization in vitro. In addition, 
significant decreases of M2 macrophage markers at basal levels were shown in 
the heart suggesting that endogenous IL4R is required for appropriate 
macrophage polarization of resident cardiac macrophages. 
 In cardiac remodeling post myocardial infarction (MI), the infarct size of 
MyIL4RαKO mice at 1 week post-MI was significantly smaller than that of control 
xviii 
mice and infarct thickness at 3 weeks was significantly increased, indicating the 
involvement of myeloid IL4Rα signaling in cardiac remodeling post-MI. No 
changes in collage deposition were detected within the infarct, but there was 
evidence of an important role for endogenous cytokine action at the myeloid IL-
4R since there was greater cardiac dysfunction in MyIL4RαKO mice. 
Surprisingly, IL4Rα knockout in myeloid cells did not change the percentage or 
number of M2 macrophages in infarct tissues post-MI. This does not support the 
hypothesis that IL4Rα signaling mediates cardiac remodeling via its control of 
macrophage polarization, but rather that the effect on myeloid phenotype is 
considerably subtler. 
In angiotensin II and high salt-induced hypertensive cardiovascular injury, 
cardiac and vascular fibrosis was substantially decreased in MyIL4RαKO mice. 
This corresponded to significant changes in fibrosis-related signaling pathways 
including TGFβ, Gal3 and BMP9 signaling. MyIL4RαKO mice also showed 
significantly increased mRNA expression of reactive oxygen species (ROS) 
generation related genes. This suggests that myeloid IL4Rα signaling 
significantly alters cardiovascular remodeling post hypertensive injury by 
regulating collagen accumulation and ROS generation. Similar to what we found 
in the MI model, ablation of IL4Rα in myeloid cells did not induce changes in the 
polarization of M2 macrophages in the heart and aorta during hypertensive injury. 
This suggests that the changes in cardiovascular remodeling may not be 
attributed to a simple alteration in global macrophage polarization.  
In conclusion, results from both injury models suggest that myeloid cells 
are critical targets of endogenous IL4Rα signaling, and myeloid IL4Rα signaling 
is very important in modulating cardiovascular remodeling post injury. However, 
the mechanism by which myeloid IL4Rα signaling regulates cardiovascular 
remodeling is not simply through a global change in M2 macrophage polarization 
in vivo, and the exact mechanism needs to be determined further.  
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CHAPTER I 
INTRODUCTION 
 
Overview 
Cardiovascular disease (CVD) is the leading cause of death worldwide. 
Based on the statistics reported in 2016, globally more than 17.3 million people 
die from CVD per year1, representing 31% of all deaths2, and this number is 
projected to grow to 23.6 million by 20303. CVD is also the No. 1 cause of death 
in the United States. CVD accounted for 30.8% of all deaths in 2013 in the U.S, 
which is more than all forms of cancer combined4, 5. On average, about 2,200 
Americans die each day from CVD, one death every 40 seconds.  Moreover, the 
estimated annual direct cost of CVD in the U.S from 2011 to 2012 is $193.1 
billion, more than any major diagnostic disease, and this total direct cost is 
projected to grow to $918 billion by 20306, 7. These numbers indicate that CVD 
not only claims the most lives, but is also a serious financial burden, and its 
prevalence and cost are growing substantially.  
This raises the urgent need to improve our understanding of the 
pathophysiology or response to injury in cardiovascular remodeling in order to 
identify novel targets and develop therapies to advance CVD treatment. 
Cardiovascular remodeling is the response of heart and vessels to an injury such 
as myocardial infarction (MI) and hypertension. The remodeling involves changes 
in the structure of the organs, often proliferation or hypertrophy of cells, 
modulation of the extracellular matrix, and ultimately functional adaptation of the 
organ. In this dissertation, we focus on cardiovascular remodeling occurring 
following two of the most common CVDs: myocardial infarction and hypertension. 
We investigate the involvement of modifying macrophages in these remodeling 
processes.  
Macrophage
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Monocytes and macrophages are types of leukocytes that phagocytize 
any pathogens not recognized as healthy tissues, including necrotic cells, 
apoptotic cells, cell debris and microorganisms. They play a central role in 
inflammatory responses following injury/stress and are essential for wound 
healing and tissue repair. 
Macrophage Heterogeneity 
Macrophages are highly heterogeneous in function, with a lifespan varying 
from hours to months or even years for tissue resident macrophages8. There is a 
wide spectrum of macrophage activation states, but the two main types often 
discussed are based on different in vitro stimulation leading to different activation 
states (Figure 1.1). Macrophages stimulated by lipopolysaccharide (LPS) and/or 
T helper cell type 1 (Th1) cytokine interferon γ (IFNγ) and damage associated 
molecular patterns (DAMPs) undergo classical activation, resulting in the 
polarization state of the classical activated macrophage (CAM) also called M1 
macrophages9. They are characterized by production of reactive oxygen species 
(ROS), reactive nitrogen species (RNS) and pro-inflammatory cytokines such as 
tumor necrosis factor α (TNFα), interleukin-1β (IL-1β) and interleukin-6 (IL-6). 
They play a crucial role in inflammation and tissue injury10.  
In contrast, macrophages stimulated by T helper cell type 2 (Th2) 
cytokines interleukin-4 (IL-4) and/or interleukin-13 (IL-13) undergo alternative 
activation, resulting in the polarization state of the alternative activated 
macrophage (AAM), also named M2 macrophage (reflecting the Th1-Th2 
polarization). M2 macrophages are characterized by expression of mannose 
receptor C type 1 (MRC1 or CD206), arginase 1 (Arg1), and resistin-like 
molecule α that is found in inflammatory zone (Relmα/Fizz1), producing 
cytokines like interleukin-10 (IL-10) and transforming growth factor β (TGFβ)11, 
and are significantly involved in immunomodulation, wound healing and fibrosis9, 
12-16. Although distinct, both subsets contribute to the initiation and progression of 
cardiovascular, chronic inflammatory and autoimmune diseases17-19. 
Macrophages also have substantial plasticity in function depending on their 
microenvironment20. Macrophages evaluate the status of local tissue frequently  
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Figure 1.1 Graphical representation of classical and alternative activation 
of macrophages (M1 vs M2).  M1 is induced by stimulus like lipopolysaccharide 
(LPS) and/or damage-associated molecular patterns (DAMPs) and stimulates 
production of pro-inflammatory cytokines (red) and also contributes to the 
expression of some anti-inflammatory cytokines like IL-10 (green).  IL-4/IL-13 is 
the standard in vitro stimulus for activation of M2 macrophages and stimulates 
markers Arg1, Ym1, Fizz1 and the cell surface marker CD206 (mannose receptor 
C type 1) that is often used for histologic identification of M2-like macrophages. 
M1 macrophages are more involved in antigen presentation and tissue damage, 
while M2 macrophages are more involved in would healing and fibrosis, but both 
M1 and M2 macrophages can phagocytize pathogens, dead cells and debris et 
al. 
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and change their phenotype accordingly21. They have a reversible transcriptional 
program that allows transformation of an activated pro-inflammatory macrophage 
phenotype into an anti-inflammatory and pro-resolution phenotype in response to 
local stimuli22.  
Macrophage in Fibrosis 
Macrophages are also very important in secretion of extracellular matrix 
(ECM) components and ECM remodeling. They are the major cell type producing 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs)23, which are important in collagen degradation. Among phenotypically 
and functionally diverse macrophages, the M2 macrophage subtype is important 
in fibrosis24. M2 macrophages also ingest collagen by endocytosis via a mannose 
receptor, representing their pleiotropic role in ECM homeostasis25. In addition, 
immune cells like neutrophils, lymphocytes and eosinophils also contribute to 
fibrotic remodeling in multiple organs26. The communication between stromal 
cells, immune cells and the ECM actively modulates fibrosis in cardiovascular 
remodeling27-29.  
Origin of Macrophages 
Resident Homeostatic Macrophages: Macrophages exist in essentially 
all tissues but can have different origins (Figure 1.2). Resident cells can be either 
derived from embryonic yolk sac or later through definitive hematopoiesis from 
hematopoietic stem cells (HSCs). The portion derived from each source is 
different in each tissue. Many types of these resident macrophages have a 
location specific name, for example macrophages in the brain are named 
microglia, macrophages in the liver are named Kupffer cells30,31. In the absence 
of injury, the homeostasis of resident macrophages in many tissues is maintained 
by local proliferation without hematopoietic precursors32-35. In the steady state, 
macrophages have minimal inflammatory characteristics, for instance cardiac 
resident macrophages express high levels of 22 AAM-associated genes although 
they also express some inflammatory genes like IL-1β36.  
Macrophages after Injury: Macrophages present during inflammation 
can have a totally different origin. After injury, macrophages come from two  
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Figure 1.2 Macrophages can arise from two main sources: embryonic yolk 
sac and the hematopoietic stem cell (HSC) through definitive 
hematopoiesis.  Initially, tissue-resident macrophages come from the yolk sac 
but with age they can be replaced with HSC derived macrophages to different 
degrees depending on the tissue. Macrophages developed from yolk sac can be 
maintained through adult by self-renewal. Upon stress or injury, macrophages 
can also originate from resident macrophage via proliferation and maturation 
from HSC derived monocytes.  
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distinct processes: recruitment of circulating monocytes that then differentiate 
into macrophages and proliferation of resident macrophages. Stimulated by 
injury, a small fraction of HSCs in bone marrow become active and produce 
progenitors that give rise to monocytes. These monocytes migrate from blood 
into the injured tissue where they differentiate into macrophages37. The spleen 
also contributes to macrophages generation during inflammation. It is reported 
that the subcapsular red pump in spleen is a monocyte reservoir, which expels 
monocytes that then accumulate in infarcted tissue post MI, and differentiate and 
mature into macrophages38. In addition to the circulating monocytes, resident 
macrophages repopulate the inflamed tissue by proliferation. Tissue-resident 
macrophages are maintained locally by proliferative self-renewal during 
inflammatory responses33, 34, 39. Jenkins et al. demonstrated that IL-4 signaling 
directly drives resident macrophage proliferation during Th2-biased tissue 
infection33, 40. Meanwhile, resident macrophages also promote the recruitment of 
monocytes by communication with the surrounding parenchymal and non-
parenchymal cells41. Recruitment of C-C chemokine receptor type 2 (CCR2) 
positive inflammatory macrophages has been shown to be crucial in both acute 
and chronic inflammatory diseases42-45.  
Monocytes, as circulating precursors of macrophages, display 
heterogeneity based on the expression of lymphocyte antigen 6 complex 
(Ly6C)46-49. Monocytes are designated as inflammatory Ly6Chigh monocytes and 
less-inflammatory Ly6Clow monocytes. During inflammation post MI, inflammatory 
Ly6Chigh monocytes are abundantly recruited into the injured tissue as early as 30 
min after the onset of ischemia, exceeding even neutrophils50, although the 
number of neutrophils peaks earlier than monocytes. The recruitment of 
monocytes from blood relies on monocyte chemoattractant protein 1 (MCP1 or 
CCL2)/CCR2 signaling51, 52. Ly6Chigh monocytes then differentiate into 
inflammatory macrophages, and both monocytes and macrophages produce 
inflammatory cytokines that activate macrophages. Activated macrophages 
function to clear debris, necrotic myocytes, and apoptotic neutrophils. 
Recruitment of monocytes from the spleen is dependent on angiotensin II 
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(AngII)38, so splenic monocytes mobilization after MI can be suppressed by 
angiotensin-converting enzyme (ACE) inhibitor that inhibits AngII signaling53.  
IL-4 Receptor Signaling 
IL-4 and IL-13 
IL-4 and IL-13 are both Th2 cytokines and are produced by activated T 
lymphocytes including Th2 cells, NK T cells, γ/δ T cells, as well as several other 
cell types including mast cells, basophils, eosinophils, and natural killer (NK) 
cells54, 55, among which Th2 cells are particularly important sources, which also 
require IL-4 and IL-13 for their own differentiation. Although IL-4 and IL-13 only 
share 20-25% amino acid sequences, their tertiary structure are of high 
homology and they have a common subunit—IL-4 receptor α (IL4Rα) in their 
respective receptor complexes that they have numerous overlapping biologic 
properties, eliciting a diverse array of biologic responses in immune system56, 57. 
IL-4 Receptor 
IL-4 induces biological responses by binding to two receptor complexes: 
type I and type II IL-4 receptor (IL4R)57, 58 (Figure 1.3). The type I IL4R is 
composed of a 140kDa ligand-specific chain—IL4Rα and a common γ-signaling 
chain (γc) that is shared by some other cytokine receptors such as IL-2, IL-7, IL-9 
and IL-15. The type II IL4R consists of an IL4Rα subunit and an IL-13 receptor 
α1 (IL13Rα1) subunit59. Unlike the type I IL4R, which can only be bound by IL-4, 
the type II IL4R can bind both IL-4 and IL-13. IL-13 can also bind to a second 
receptor IL13Rα2 subunit although this does not initiate cell signaling60, as 
IL13Rα2 serves as a decoy receptor. IL4R is expressed on a wide range of cell 
types including T cells, B cells, monocytes/macrophages, fibroblasts61, 
keratinocytes, epithelial cells, endothelial cells, and hepatocytes62, 63.    
Signaling Pathways Mediated by IL-4 Receptor 
Both IL-4 and IL-13 signaling are mainly mediated via the IL4Rα chain and 
both include the activation of transcription factor signal transducing and activation 
transcription 6 (STAT6)58, 64. One of the pathways is initiated by Janus kinase 
(JAK) family members, JAK1 and JAK365. IL-4 binds to type I IL4R and induces 
the phosphorylation of JAK1 that is associated with the IL4Rα subunit, and the 
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Figure 1.3 Type I and Type II IL-4 receptor.  Type I IL-4 receptor is a 
heterodimer of subunits IL4Rα and γc.  Type II IL-4 receptor is a heterodimer of 
IL4Rα and IL13Rα1 that can bind both IL-4 and IL-13. Activation of IL-4 receptor 
results in STAT6 signaling and induction of alternative M2 macrophage genes. 
IL4Rα knockout will block IL-4 signaling through both types of receptors as well 
as IL-13 through the Type II IL-4 receptor. RE: response element.  
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phosphorylation of JAK3 associated with γc subunit. The phosphorylated JAKs in 
turn phosphorylate and activate IL4Rα chain itself and STAT6. Once activated by 
phosphorylation, cytoplasmic STAT6 dimerizes and translocates to the nucleus 
where it promotes the transcription of IL-4-responsive genes that contain STAT6 
binding site in their promoter region65.  
IL-4 and IL-13 also signal through type II IL4R and subsequently activate the 
JAK1/STAT6 downstream signaling. STAT6 functions to mediate most responses 
of IL-4, such as Th2 cell differentiation66, 67, B cell growth and immunoglobulin E 
(IgE) secretion68, 69.  
IL-4 and IL-13 activate a second signaling pathway when they interact with 
the membrane-bound form of IL4R65 through the phosphorylation of an insulin 
receptor substrate (IRS), referred as IRS-2.  Phosphorylated IL4Rα stimulates 
the recruitment and phosphorylation of IRS-2, which in turn activates the 
phosphoinositide 3-kinase (PI3K) pathway. This pathway is critical in IL-4/IL-13-
induced protection against apoptosis, cell survival and proliferation responses58, 
65, 68. Another signaling pathway triggered by binding of IL-4 to IL4R that 
contributes to cell growth and proliferation through phosphorylation of the adaptor 
protein Shc, resulting in recruitment of growth factor receptor-bound protein 2 
(Grb2) and son of sevenless (SOS), which then activate Ras/MAPK pathway. 
This IL4R dependent Ras/MAPK signaling occurs only in human keratinocytic 
cells but not in T cells70.  
The soluble form of IL4Rα does not mediate IL-4 signaling, but rather 
protects IL-4 from proteolytic degradation71, 72. IL-4 binds to the soluble receptor 
with a lower affinity and IL-4 soluble receptor performs as a carrier for IL-4 
promoting its presentation to the cell surface bound receptor72.  
Biological Activities of IL-4/IL-13 Signaling 
Although IL-4 and IL-13 have low amino acid sequence homology, they have 
similar tertiary structure and have a common IL4Rα chain in their receptors, so 
IL-13 mediates virtually all of the IL-4 actions in nonhematopoietic cells and, to 
some extent, in hematopoietic cells73. The functional differences between IL-4 
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and IL-13 are attributable to cell-dependent differential receptor expression and 
IL-13 shows similar but less effective biological activities than IL-461. 
The major function of IL-4 includes promoting Th2 cell differentiation57, 69, 
stimulating B lymphocyte growth and differentiation74, facilitating IgE secretion75, 
regulating eosinophil recruitment76, and an important role in myeloid cells such as 
monocytes/macrophages and neutrophils. IL-4 directly and predominantly 
promotes Th2 cell differentiation via type I IL4R, while IL-13 does not directly 
participate in Th2 cell development because Th0 cells do not express IL13Rα1 
on their surface. However, IL-13 is to some extent involved in Th2 differentiation 
as IL4Rα deficient mice display more severely diminished Th2 cell differentiation 
than IL-4 deficient mice, implying some indirect role of IL-13 in Th2 cell 
development77, 78. Moreover, mature CD4+ T cells from IL-13-/- mice produce 
significantly less Th2 cytokines77. IL-4 also antagonizes the IL-12-mediated Th1 
cell differentiation69, 79. IL-4 stimulates B cell growth and differentiation and drives 
B cells to produce IgE. IL-13 has similar biological functions to those of IL-4 in B 
cells. IL-13 knockout mice showed significantly lower basal level of IgE in 
serum77, suggesting the essential role of IL-13 in IgE secretion. IL-4 and IL-13 
are also growth factors for mast cells, and regulate allergic responses via IgE-
mediated mast cell degranulation.  
IL-4 and IL-13 also exert critical biologic activities in macrophages and 
neutrophils. Both IL-4 and IL-13 are potent anti-inflammatory cytokines with the 
capability to inhibit monocytes/macrophages from producing pro-inflammatory 
cytokines and chemokines such as TNFα and IL-1β, and interfere with their 
generation of ROS and nitrogen intermediates, and suppress IFNγ-induced 
expression of cellular adhesion molecules. IL-4 and IL-13 are also crucial 
inducers of alternative activation of macrophage (AAM or M2), which promotes 
tissue repair80-82 and is pathologically associated with type 2 immune responses 
like allergy and fibrosis81, 83, 84. Furthermore, the anti-inflammatory activity of IL-4 
and IL-13 is also partially mediated through their induction of anti-inflammatory 
interleukin 1 receptor antagonist (IL-1Ra). IL-4 and IL-13 can augment the 
production of IL-1Ra, which binds IL-1 receptor type 1 with similar affinity to that 
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of IL-1α and IL-1β but transduces no signal85, 86. Neutrophils were originally 
reported to express the type I (IL4Rα/γc) but not the type II (IL4Rα/IL13Rα1) 
IL4R 87-89, however it was reported recently that type II IL4R is also expressed in 
neutrophils90. IL-4 and IL-13 display both pro- and anti-inflammatory activities in 
neutrophils although neutrophils are less effective in response to IL-13. Similar to 
macrophages, neutrophils up-regulate the production of IL-1Ra in response to IL-
4 and IL-1391. Type II IL4R signaling antagonizes the expansion and migration of 
neutrophils during infection and inflammation90, which indicates an anti-
inflammatory role in IL4R signaling in neutrophils. Illustrating the pro-
inflammatory role of IL-4 in neutrophils, IL-4 delays neutrophil apoptosis and 
enhances neutrophil-derived IL-8 production89, which contributes to the 
recruitment of leukocytes to the inflammatory site. Moreover, neutrophil 
infiltration together with IL-4 elevation contributes to the severity of asthma92, 93.  
Although IL-13 can partially substitute for IL-4, it has its own independent 
properties, which was demonstrated by IL-4-/- mice94-97. There is an additive 
effect when both IL-4 and IL-13 are deleted97, indicating a unique role of IL-13 in 
type 2 immune responses. IL-13 plays a more important role than IL-4 in worm 
expulsion94, effector activity in asthma96, hepatic fibrosis and granuloma 
formation95. Moreover, although IL-13 normally participates in type 2 immunity, 
IL-13 also has a significant role in regulating type 1 immune responses. In 
parasite-infected IL-13-/- mice, IFNγ (Th1 cytokine) production was dramatically 
inhibited, while IL-4 and IL-10 (Th2 cytokines) production was significantly 
enhanced, supporting the involvement of IL-13 in type 1 responses98, 99. This is 
consistent with the increased parasite burdens in IL13-/- mice98. IL-13 has also 
been shown to prime monocytes for IL-12 production100 and exhibits a protective 
type 1 immune response during listeriosis101.  
IL-13 signaling is mediated by type II IL4R, which consists of IL4Rα and 
IL13Rα1, however, another IL-13 binding receptor IL13Rα2, which acts as a non-
signaling decoy receptor, shows strong suppression of IL-13 activity102. For 
example, IL13Rα2 overexpression inhibits the expression of fibrotic markers 
induced by IL-13 in vitro and suppresses bleomycin-induced pulmonary fibrosis, 
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highlighting the antagonism of IL13Rα2 to the pro-fibrotic effector function of IL-
13103. Animals lacking IL13Rα2 fail to attenuate granuloma inflammation in the 
chronic phase after infection, and develop severe IL-13-dependent fibrosis and 
show increased mortality104, 105, although IL13Rα2 has no effect on the 
inflammatory responses at the acute stage post infection105. As IL-13 binds both 
type II IL4R and IL13Rα2 with high affinity, when IL13Rα2 is induced by IL-13, it 
acts as a inhibitor of IL-13 via negative feedback by competing for its interaction 
with type II IL4R 106. Conversely, there are also conflicting result showing that IL-
13 plays an important role in mediating fibrosis partially via IL13Rα2 in chronic 
infectious and autoimmune diseases107. Blocking both IL4R and IL13Rα2 
signaling in double knockout mice IL4/IL13-/- may be responsible for the 
augmented protection against chronic pancreatitis progression, compared with 
blocking IL4R signaling only in the IL4Rα-/- mice108. Therefore, IL13Rα2, originally 
regarded as a decoy receptor, probably also has the ability to mediate signaling. 
This is further supported by the ability of IL13Rα2 to signal on cell surface or in 
the cytoplasm with the soluble form in inducing TGFβ1 production in 
macrophages and mediating fibrosis109.  
IL4Rα signaling also functions in cells outside of the immune system. 
IL4Rα deficient mice exhibited significantly decreased bone marrow-derived 
fibroblasts (myeloid fibroblasts) and myofibroblasts in their kidneys110, indicating 
that IL4Rα signaling is involved in renal fibrosis via bone marrow-derived 
fibroblasts.  
IL-4 Receptor Signaling in Macrophage 
IL-4 and IL-13 promote alternative macrophage activation12, 111. Compared 
with their wild-type counterparts, macrophage/neutrophil-specific IL4Rα knockout 
mice revealed significant suppression of parasite infection progression, indicating 
the significance of IL-4/IL-13-IL4R signaling induced M2-like macrophage 
polarization in inflammatory disease112. IL4Rαflox/-LysMcre mice, subjected to 
worm infection, showed impaired alternative macrophage activation with 
significantly decreased CD206 expression and enhanced Inducible nitric oxide 
synthase (iNOS) production113. In addition, M2 macrophages activated by IL-4 
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and/or IL-13 mediate fibrotic remodeling through IL4R. When activated by IL-4 
and/or IL-13, macrophages secret proteins that are directly involved in tissue 
repair, such as collagen type 1 α 1 (Col1A1) that is deposited in the ECM. These 
proteins also include relmα, which eventually acts to cross-link collagen with 
fibrils, developing strength or stiffness to the tissue114. However, IL-4 and/or IL-13 
are not sufficient to induce tissue repair in vivo. IL-4 or IL-13 stimulated 
macrophages are not able to initiate the tissue-repair program until they receive 
signals showing the presence of apoptotic (dying) neutrophils115. Loss of the 
ability to sense of apoptotic cells by genetic ablation impairs proliferation of 
tissue-resident macrophages and the expression of genes involved in 
inflammation resolution and tissue repair in infected lung or gut with colitis115. 
After clearing pathogens and debris in the wounded or infected tissue, 
macrophages switch to repair mode and activate tissue repair programs, by 
sensing local tissue-specific cues or signals from dying cells, and then result in 
the production of tissue-building factors116.  
In addition to macrophage polarization, IL4R signaling may also be 
involved in macrophage proliferation. Compared with wild type mice, myeloid-
specific IL4Rα knockout (IL4Rαflox/- LysMCre) mice display a decrease in the 
absolute and relative number of macrophages (CD11b+F4/80+) during the early 
and middle phase of repair, which may be attributable to the decreased potential 
of macrophage proliferation caused by IL4Rα deficiency114.  
Models of Cardiovascular Remodeling 
We are using two widely used models of cardiovascular damage, 
permanent myocardial infarction and pressure overload by treatment with 
angiotensin-II, in order to test the role of IL-4 stimulated macrophages in the 
pathophysiology. 
Myocardial Infarction 
Myocardial infarction (MI) is the irreversible death of heart muscle due to 
blood flow deprivation (ischemia). MI strikes Americans approximately once 
every 42 seconds117. About 550,000 Americans have a first-time attack annually, 
and about 200,000 have recurrent attacks117. Each year, about 116,000 people 
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die of MI in the U.S117. Patients who survived the first MI are at high risk of 
having a secondary injury (second MI) because of complications, so prevention 
of secondary injury is very important in reducing mortality. Around 47% of the 
decrease in heart disease mortality in America is attributed to secondary injury 
prevention4. Inhibiting secondary injury can also substantially decrease the 
indirect cost of MI caused by loss of future productivity, which is estimated to 
reach $308.2 billion by 2030117. Benefitting from medical advances, annual death 
from MI has declined over time, however the development of heart failure (HF) 
post MI is alarmingly high and continues to increase118. Based on pooled data, 
people who are 45 years old or older have a 20% chance of developing HF within 
five years after a first MI117. 
Cardiac Remodeling post Myocardial Infarction  
In response to MI, cardiomyocytes die by necrosis followed by a 
reparative process, which includes a series of complicated and finely 
orchestrated events. The whole process can be divided into three partially 
overlapping phases: inflammation, proliferation and maturation. These are 
summarized in Figure 4. 
In the inflammatory phase, the sudden death of cardiomyocytes rapidly 
activates transient but intense inflammatory responses characterized by 
neutrophil and monocyte/macrophage infiltration119. The death of myocytes 
results in the loss of passive tension leading to infarct expansion in the first few 
days, which is characterized by acute ventricular dilation, infarct wall thinning, 
and cardiomyocyte elongation. When infiltrating neutrophils undergo apoptosis, 
inflammation resolution is induced by anti-inflammatory and pro-fibrotic signals. 
In the proliferation phase, fibroblasts transdifferentiate into myofibroblasts, 
which proliferate, produce contractile and ECM proteins, and secret collagens. 
Macrophages participate in remodeling by activating mesenchymal reparative 
cells51, 119. Communication between macrophages and fibroblasts and 
myofibroblasts, together with Th2 responses, sustain the pro-fibrotic remodeling. 
Apoptosis of the majority of reparative cells marks the end of proliferative stage  
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Figure 1.4 Cardiac remodeling post MI. Ischemia in part of the heart cause 
sudden death of myocytes, which activates transient but intense inflammatory 
responses characterized by neutrophil and monocyte/macrophage recruitment. 
Initially the infarct expands and the infarct wall gets thinner and thinner as a 
result of losing cardiomyoctes and extracellular matrix degradation. The 
apoptosis of neutrophils represents the start of inflammation resolution that is 
induced by anti-inflammatory signals. Infiltrating macrophages phagocytize 
apoptotic neutrophils and M1 and M2 macrophages sequentially dominate in the 
late inflammatory phase and the following reparative and maturation phase.  
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and pro-fibrotic remodeling. Conversely, failure to undergo apoptosis or 
extension of pro-fibrotic signaling results in pathological remodeling.  
In the maturation phase, the infarct zone undergoes fibrotic replacement 
with the formation of cross-linked collagen, while the adjacent non-infarct zone 
exhibits perivascular and interstitial fibrosis. Scar forms to preserve the structural 
integrity and maintain cardiac pump function by preventing dilatation, aneurysm 
or myocardial rupture120. Depending on the infarct size and the quality of repair, 
the extent of cardiac remodeling post-MI varies.  
Cellular and Molecular Adaptation post MI 
The innate immune system plays an important role in the remodeling post 
MI. In the inflammatory response after injury, immune cells including neutrophils 
and monocytes/macrophages recognize DAMPs by toll-like receptors (TLRs), 
and then activate downstream inflammatory pathways. Inflammation is further 
prolonged by secretion of pro-inflammatory cytokines such as MCP1, TNFα and 
IL-6. MCP1 contributes to the recruitment of monocytes, and TNFα promotes 
adhesion and extravasation of leukocytes through endothelium. The role of IL-6 
in inflammation and cardiac remodeling is ambiguous. Augmented IL-6 
expression aggravates the inflammatory responses and exacerbates deleterious 
effects of MI121. However, neither deficiency of IL-6 nor blocking the IL-6 receptor 
confers no protection122, 123. The neutrophils and monocytes/macrophages 
phagocytize and clear the dead cells and debris. In addition to these infiltrating 
immune cells, resident cells such as fibroblasts, surviving cardiomyocytes and 
resident macrophages contribute to the development of inflammation. 
Macrophages in the proliferation phase are less inflammatory and express M2 
macrophage-associated genes124. They secret cytokines and growth factors, and 
mediate tissue repair and neovasculogenesis51, 119. Galectin 3 (Gal3), a pro-
fibrotic protein predominantly produced by macrophages, is actively involved in 
post-MI remodeling125, 126. TGFβ, another major pro-fibrotic cytokine secreted by 
macrophages, suppresses inflammation, promotes hypertrophic cardiomyocyte 
growth, enhances ECM deposition by increasing collagen and fibronectin 
synthesis and down-regulates ECM degradation127, 128.  
	 17 
The importance of monocytes/macrophages in cardiac remodeling post MI 
is increasingly appreciated. In response to injury, Ly6Chigh monocytes efficiently 
migrate to the injured area and give rise to inflammatory macrophages129-131, 
while Ly6Clow monocytes infiltrate less efficiently and are believed to differentiate 
into resident macrophages. Clodronate-loaded liposome mediated depletion of 
monocytes/macrophages showed that both Ly6Chigh and Ly6Clow monocytes are 
essential for infarct healing132, 133. Depletion of monocytes/macrophages resulted 
in impaired dead cardiomyocytes removal, delayed matrix regeneration and 
inefficient angiogenesis51. In mice with MI, Ly6Chigh and Ly6Clow monocytes are 
sequentially recruited to the infarcted heart. Ly6Chigh monocytes dominate early, 
display phagocytic and inflammatory functions, and participate in damaged tissue 
digestion. In contrast Ly6Clow monocytes dominate later, exhibit blunted 
inflammatory properties, and contribute to tissue repair via myofibroblasts 
accumulation, collagen deposition and angiogenesis51. A similar time course of 
pro-inflammatory monocytes/macrophages in the inflammatory phase and less 
inflammatory monocytes/macrophages in the proliferation phase was also 
described in human patients with MI. CD14+CD16- (corresponding to Ly6Chigh) 
monocytes dominated early in blood and infarcted tissues, whereas abundance 
of CD14+CD16+ (corresponding to Ly6Clow) monocytes was only detected in 
infarcted tissues of patients who died later134, 135. Although macrophages are 
necessary for proper would healing and scar formation to preserve left ventricle 
geometry, excessive macrophages during the inflammation phase are harmful. 
Patients with more CD14+CD16- monocytes in blood in the acute inflammatory 
phase exhibited severely dilated left ventricles135, and monocyte cell counts are 
positively correlated with HF progression136, 137.  
During post MI remodeling, fibroblasts contribute to fibrosis by proliferation 
and transdifferentiation into myofibroblasts, which along with myeloid cells, 
account for a significant portion of the ECM138. Persistent activation by 
mechanical stress or pro-fibrotic molecules such as TGFβ and Gal3 released by 
neighboring myofibroblasts or macrophages drives quiescent fibroblast 
transformation into active collagen-producing myofibroblasts126, 127. Although 
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fibrosis initially benefits the injured myocardium, continued and uncontrolled 
fibrosis can be harmful and results in cell death and chronic inflammation, which 
consequently cause impaired cardiac function and organ failure139-141. One factor 
that limits fibrosis is that myofibroblasts are programmed to undergo apoptosis 
after accomplishing their reparative “tissue-building” task. Conversely, sustained 
myofibroblasts result in extensive fibrosis142.  
Limiting Inflammation and Fibrosis post MI 
To optimally repair the infarcted tissue, inflammatory or pro-fibrotic 
reactions have to be contained and resolved143, 144. Excessive inflammation, 
insufficient resolution, or excessive fibrosis leads to extended tissue damage, 
improper healing, defective scar formation, unnecessary cell loss and contractile 
dysfunction, all of which promote infarct expansion, adverse remodeling, 
chamber dilatation and the development of HF145. Inflammatory and pro-fibrotic 
signaling pathways are critically involved in dilative and fibrotic remodeling, and 
drive major events in the pathogenesis of post-MI HF119. Therefore, in order to 
understand the progression of HF post MI, and to develop novel therapeutic 
strategies to suppress the development of HF, investigation of the inflammation 
and fibrosis post MI is critical. The switch from pro-inflammatory macrophage 
phenotype that phagocytize necrotic tissue to macrophages with anti-
inflammatory and pro-fibrotic phenotype is thought to be critical to the proper 
healing of the damage.  IL4R signaling and the AAM/M2 macrophage is thought 
to be critical to this transition. 
Hypertension 
Hypertension or high blood pressure is a major risk factor for CVD146, 147. A 
systematic analysis using disability-adjusted life years (DALYs) showed that 
hypertension went from the number 4 leading risk factor in 1990 to the number 1 
risk factor in 2010148. Hypertension contributes to 40.6% and 34.7% of CVD and 
ischemic heart disease mortality, respectively, much higher than any other 
factor149. In America, about 33% of adults have high blood pressure117, and this 
will increase to ≈41.4% by 2030 (unpublished AHA computation, based on 
methodology described by Heidenreich et al7). Obviously, there is a considerable 
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financial burden in treating hypertension117, which is projected to be up to $274 
billion by 2030 (unpublished AHA computation, based on methodology described 
in Heidenreich et al7). Regardless, only 77 percent of people with hypertension 
are under current antihypertensive medication, and only 54% of those have their 
condition controlled117. Being a principal risk factor of CVD, hypertension can 
progressively lead to HF. Absence of hypertension in middle age is associated 
with lower risk of developing HF through the remaining life course, and 
prevention of hypertension during middle age substantially prolongs HF-free 
survival150. Adjusting for age and HF risk factors in a Framingham Heart Study, 
the chance of developing HF in hypertensive subjects compared with the 
normotensive ones is about 2-fold higher in men and 3-fold higher in women151. 
Hypertensive Cardiovascular Remodeling 
Hypertension induces the development of CVDs through cardiovascular 
remodeling such as cardiovascular hypertrophy, inflammation and cardiovascular 
fibrosis via direct hemodynamic mechanisms and/or overactivation of the renin-
angiotensin-aldosterone system (RAAS)152. For example, angiotensin II (AngII) 
increases significantly in Dahl salt-sensitive hypertensive rats in the phase of 
compensated left ventricle hypertrophy, but does not show further increase in 
subsequent congestive heart failure153. In addition, both renin and aldosterone 
have been implicated in a causal relationship with cardiac remodeling caused by 
hypertension via fibrosis-dependent or –independent mechanisms154, 155, and 
directly inhibiting renin decreases myocardial fibrosis and improves cardiac 
function156. Persistent hypertension results in cardiovascular remodeling, which 
includes hypertrophy of cardiomyocytes and smooth muscle cells, cardiac and 
vascular inflammation, perivascular and interstitial fibrosis, and microvascular 
rarefaction.  
Hypertensive Cardiac Remodeling 
Hypertension can result from pressure or volume overload. Cardiac 
remodeling due to a predominantly pressure overload hypertension comprises 
concentric left ventricle hypertrophy characterized by thickening of the left 
ventricle wall and increase in heart mass at the expense of chamber volume157-
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159. In contrast, cardiac remodeling due to a volume overload hypertension 
consists of eccentric cardiac hypertrophy characterized by increase in both heart 
mass and chamber volume157, 160. Left ventricle hypertrophy is an intermediate 
phenotype in the progression of hypertension-induced HF. If pressure overload 
persists, diastolic dysfunction progresses, the concentric remodeled left ventricle 
decompensates, and hypertensive HF with preserved ejection fraction (HFpEF) 
ensues. Patients with HFpEF exhibit left ventricle hypertrophy, epicardial 
coronary artery lesions, coronary microvascular rarefaction, and myocardial 
fibrosis150, 161. If volume overload persists, left ventricle dilatation progresses, the 
eccentric remodeled left ventricle decompensates, and HF with reduced ejection 
fraction (HFrEF) ensues150, 162, 163. Longstanding pressure or volume overload 
ultimately leads to cardiovascular diseases that consist of dilated cardiomyopathy 
with diastolic dysfunction and reduced ejection fraction150, 151. In animal models, 
changes are more dramatic in sudden pressure overload-induced hypertension, 
with earlier onset of cardiac fibrosis and accelerated cardiomyocyte loss164.   
Hypertensive Vascular Remodeling 
In vascular remodeling (Figure 1.5), pathological changes occur in all 
three compartments of the vessel wall: the innermost layer intima, middle layer 
media, and the outermost layer adventitia, and their respective resident 
mesenchymal cells: endothelial cells (EC), smooth muscle cells (SMC) and 
fibroblasts. Local signals secreted by stressed or injured cells antagonize 
vascular homeostasis with cell-cell communications between mesenchymal cells 
like SMCs and/or fibroblasts and macrophages. As a result, these cells are 
persistently activated in a pro-inflammatory and pro-remodeling phenotype, 
which promotes the progression of non-resolving chronic inflammation and 
remodeling of vessel22. Coronary microvascular dysfunction may conceivably 
attribute to a systemic inflammatory state and oxidative stress accelerated by 
complications of HFpEF165, 166. Animals with severe hypertension showed 
significant intimal fibrosis, dramatic medial thickening along with adventitia 
fibrosis, and eventually died from heart failure167, 168.  
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Figure 1.5 Vascular remodeling induced by Angiotensin II. The haematoxylin 
and eosin (H&E) stained aorta (up left) shows significant hypertrophic and 
hyperplasia remodeling in the middle layer media and the outermost layer 
adventitia. The picrosirius red staining (up right) of the same aorta section shows 
the substantial fibrosis (red) in adventitia, and the lower panel is the comparison 
of aorta cross section between sham and angiotensin II exposure.  
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Upon hypertension, changes in intima are characterized by endothelial 
hypertrophy, subendothelial edema and fibrosis due to collagen deposition169, 
intimal thickening because of endothelial hypertrophy and hyperplasia and 
thickening of the subendothelial space170-172. Endothelial injuries caused by shear 
stress induce ECs to produce vasoactive mediators, inflammatory molecules and 
growth factors173-175, and increase the permeability of endothelial cells, which 
consequently promotes the influx of plasma proteins, vasoactive substances and 
vascular wall protease176. Increase of endothelial permeability also exposes 
SMCs to vasoactive mediators and leads to subendothelial edema. Stressed or 
injured endothelial cells also produce more laminin, fibronectin and elastin, 
contributing to pro-fibrotic remodeling that consequently impairs EC and SMC 
function. Direct changes of ECs as well as molecules and cytokines secreted by 
ECs lead to intimal thickening, recruitment of circulating cells, local cell 
proliferation, smooth muscle contraction, hypertrophy and hyperplasia, all of 
which contribute to intima-related vasculature remodeling and stiffness22.  
The hypertrophic and hyperplasia responses of SMCs in media of large 
vessels and collagen deposition in the ECM contribute to medial thickening, 
which leads to compliance reduction of the vessels177. Cumulative data suggest 
that, non-resident smooth muscle-like cells that are with the potential of 
differentiating into “mature SMCs”, cumulated in the distal media of large vessels 
and proliferate22. These smooth muscle-like cells are of high proliferation 
potential, resistant to apoptosis, and secrete factors to continually stimulate pro-
proliferative and pro-signaling pathways178. The recruitment of these cells 
contributes to extended, severe vascular remodeling.  
The adventitia is the outermost layer of the vessel, and is also the most 
heterogeneous compartment of the vessel wall due to its cellular and structural 
complexity. The Adventitia contains lymphatic vessels, vasa vasorum, trophic 
nerves and resident cells including progenitor cells, fibroblasts and immune cells 
such as macrophages and dendritic cells. In response to hypertensive stress, the 
adventitia undergoes substantial remodeling: dramatic expansion of vasa 
vasorum, activation and proliferation of residential cells like progenitor cells, 
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fibroblasts and possibly macrophages, transdifferentiation of fibroblasts into 
myofibroblasts, recruitment of circulating progenitor cells and leukocytes such as 
macrophages and lymphocytes, as well as significant increase of collagen and 
ECM protein deposition179. The expansion, activation, proliferation and infiltration 
of cells in the adventitia synergistically promote remodeling, and the sustained 
hypertension persists this process, and finally causes massive fibrosis.  
Immune Cells in Hypertensive Cardiovascular Remodeling  
Hypertensive stimuli promote oxidative stress and up-regulate pro-
inflammatory molecules and cytokines, which leads to rolling, adhesion, and 
transcytosis of inflammatory immune cells180, 181. As a result, a robust 
accumulation of immune cells in the cardiovascular system is induced in 
hypertension182-184, including monocytes, macrophages, neutrophils and 
lymphocytes.  
Monocytes/Macrophages 
Increases in monocytes and macrophages have been repeatedly 
demonstrated in experimental hypertension185-189. Circulating monocytes 
increase in AngII-induced hypertension188, 190, and monocyte elimination results 
in decrease of hypertension severity, reduction of vascular reactive oxygen 
species (ROS) generation and improvement of vascular function188. Monocytes 
are circulating precursors of macrophages that accumulate in perivascular 
adipose tissue and adventitia during hypertension153, 191. Infiltrating macrophages 
release pro-inflammatory cytokines, produce ROS and disrupt vascular 
homoeostasis192-194. Wenzel et al. used myeloid (monocytes/macrophages and 
neutrophils)-specific LysM-diphtheria toxin receptor mice and completely 
eliminated neutrophils and monocytes/macrophages by exposing the mice to 
diphtheria toxin, and they found that the hypertensive responses to AngII were 
abrogated, as well as hypertrophy, ROS production and vascular dysfunction 
caused by hypertension188. Replacement of monocytes, but not neutrophils 
reversed hypertension188, indicating the importance of monocyte/macrophage 
lineage cells in hypertension.  
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Infiltrating macrophages during hypertension differentiate from circulating 
monocytes that are initially produced by hematopoietic stem cells (HSCs) in bone 
marrow37, 195. These macrophages are distinct from yolk sac macrophages that 
are developed in the embryo before the appearance of HSCs30. In monocyte 
development, HSCs first give rise to cell progenitor intermediates such as 
macrophage and dendritic cell progenitors (MDPs), and then finally differentiate 
into monocytes196. These hematopoietic stem and progenitor cells (HSPCs) can 
differentiate into monocytes, macrophages and dendritic cells et al. Besides 
proliferation and differentiation in bone marrow, HSPCs also constitutively exit 
bone marrow during inflammation and undergo myelopoiesis in tissues outside of 
the medulla of the bone196-198. Spleen tissue is identified experimentally and 
clinically in patients with CVDs199-201. Myelopoiesis from HSPCs in spleen supply 
a reservoir of monocytes38, which is able to mobilize and contribute to 
macrophage infiltration in distant lesions202, 203. AngII, independent of 
hemodynamics, plays a critical role in splenic release of monocytes204. AngII 
administration significantly induces the amplification of HSPCs in spleen instead 
of bone marrow204. By amplifying the HSPCs, AngII maintains splenic monocyte 
reservoir and allows tissue outside of medulla of bone to constantly supply new 
inflammatory macrophages, which highlights the central role of AngII as 
upstream of an effective macrophage amplification program. Instead of 
proliferation, AngII controls splenic monocyte/macrophage amplification by 
reprograming HSPC trafficking, and increasing their retention in spleen197, 204. It’s 
worth mentioning that the monocytes generated from splenic HSPCs driven by 
AngII are mostly Ly6Chigh204, indicating their pro-inflammatory characteristic. 
Although the production of monocytes in spleen is mediated by AngII, the 
recruitment of monocytes from circulation is not through AngII but thought via the 
MCP1/CCR2 axis205, 206, which suggests the production and recruitment of 
mononuclear phagocytes are two distinct processes that are managed 
separately.  
Neutrophils 
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The involvement of neutrophils in hypertension is unclear. Selective 
depletion of circulating neutrophils protects against oxidative stress although has 
no effect on AngII-induced hypertension207, which suggests neutrophils may be 
not involved in blood pressure regulation, but are probably associated with 
hypertension-induced inflammation. Restoration of neutrophils into myeloid cells 
(monocytes/macrophages and neutrophils)-depleted mice did not restore 
pathophysiological action of AngII188, which is inconsistent with the involvement 
of neutrophils in hypertension or hypertension-induced inflammation.  
T Cells 
In addition to the innate immune system, the adaptive immune system 
also contributes to hypertension and hypertension-induced cardiovascular 
remodeling. T cells, as major components of adaptive immune system, contribute 
to the development of hypertension by infiltrating into organs that control blood 
pressure such as vessels and kidney188, 189, 208. Infiltrating T cells, contribute to 
hypertension and renal glomerular and tubular damages via production of ang-II. 
Hypertensive stimuli like AngII and deoxycorticosterone acetate (DOCA)-salt, 
induce T cell accumulation in kidney and vasculature. Higher T cell infiltration 
results in higher production of pro-inflammatory cytokines and ROS, which 
further enhances leukocyte recruitment, and leads to renal and vascular 
dysfunction and exacerbates hypertension208-211. A landmark study by Guzik et 
al. showed that recombinase-activating gene 1 (RAG1) deficient mice, which fail 
to develop B and T cells, were protected from hypertension induced by AngII or 
DOCA-salt. Hypertensive responses were restored in these mice by adoptively 
transferring T but not B cells189, which confirms the significance of T cells in 
hypertension. Furthermore, they demonstrated that the T cells are recruited into 
perivascular adipose tissue and adventitia of these mice189.  
Molecules in Hypertensive Cardiovascular Remodeling 
Molecular pathways are essential for hypertension-induced cardiovascular 
remodeling. These pathways include reactive oxygen species (ROS) and 
inflammatory cytokines that promote inflammation and TGFβ signaling that 
promotes pro-fibrotic remodeling.  
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Reactive Oxygen Species  
ROS generation has been shown in multiple organs during hypertension, 
including brain, kidney, heart and the vasculature212, which contributes to the 
comorbidities of hypertension. ROS enhance inflammation, induce hypertrophy of 
cardiomyocytes and vascular smooth muscle, and mediate pathophysiological 
remodeling of stressed/injured tissues119, 184, 212-214. ROS generation is attributed 
to the endothelium, SMC, neutrophils, macrophages, epithelium and fibroblasts, 
and the production of ROS promotes recruitment of monocytes/macrophages, 
which in turn generates more ROS, substantially exaggerating the impact of 
ROS179, 215, 216. ROS also modulate the phenotype of resident cells and infiltrating 
cells by regulating their proliferation, migration, differentiation and matrix 
production, meanwhile, ROS function as molecular signals to activate 
downstream signaling pathways. A substantial clinical challenge targeting ROS 
production is that routine antioxidant administration is not effective in preventing 
cardiovascular diseases and hypertension and their treatment, which is likely due 
to the non-targeted fashion in which the drugs act, they clear away not only the 
harmful ROS but also those needed in normal cell signaling212.  
Inflammatory Cytokines 
The inflammatory cytokine TNFα is one of the principal cytokines 
regulating inflammation. TNFα activates nuclear factor κ B (NFκB) and 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase217, which 
importantly contribute to the induction of oxidative stress and up-regulation of 
chemokines and adhesion molecules218. TNFα signaling is also involved in 
macrophage recruitment. In AngII-induced hypertensive cardiac injury, the pro-
fibrotic response mediated by M2 macrophages is dependent on TNFα signaling, 
although the primary inflammatory stage characterized by M1 macrophages is 
TNFα signaling independent219.  
The pro-inflammatory cytokine IL-6 also promotes hypertension and 
hypertension-related remodeling. High levels of IL-6 correlate with blood 
pressure increase and may be an independent risk factor for hypertension220-224. 
Brands et al. demonstrated that IL-6 is essential for hypertension induced by 
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AngII222, which is supported by a human study showing that acute AngII infusion 
caused dramatically exaggerated plasma IL-6225. Higher levels of circulating IL-6 
were found in hypertensive patients and blocking AngII signaling by AngII 
receptor inhibition or AngII downstream product antagonist reduced circulating 
IL-6224, 226. Moreover, IL-6 ablation attenuates AngII and high salt-induced 
hypertension227, and IL-6 deficiency prevents cardiac inflammation, fibrosis and 
dysfunction without affecting myocyte hypertrophy and angiogenesis228. IL-6 also 
controls vascular remodeling by mediating superoxide production, endothelial 
impairment229, vascular SMC proliferation and migration, which contributes to 
vascular medial hypertrophy230, 231. 
AngII also stimulates MCP1 secretion232. By activating the receptor of 
MCP1–CCR2, chemokine MCP1 elicits the activation and migration of 
monocytes and leukocytes to inflammatory sites.  
Fibrosis Associated Signaling Pathways 
Instead of a single signaling pathway, multiple pathways contribute to the 
pro-fibrotic remodeling following cardiovascular injury. We summarized the ones 
that are associated with our study (Figure 1.6).  
Transforming Growth Factor β 
Inflammatory response is usually followed by pro-fibrotic remodeling in 
hypertensive cardiovascular diseases, in which transforming growth factor β 
(TGFβ) signaling plays an important role. Patients with essential hypertension 
show significantly higher levels of both active and total TGFβ1 in plasma than 
normotensive subjects233. Compared with normotensive rats, spontaneously 
hypertensive rats (SHR) with HF displayed significant increase in TGFβ1 mRNA 
expression in left ventricle, although SHR without HF did not show any 
increase234. Higher TGFβ1 mRNA level was also shown in aorta and kidney of 
DOCA-salt-induced hypertensive rats235. TGFβ1 promotes the deposition of ECM 
proteins236, which reduces the cardiovascular compliance and aggravates the 
stiffness.  
TGFβ Pathway – PDGF-A and PAI-1 
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Figure 1.6 Signaling pathways involved in AngII-induced fibrotic 
remodeling. Pro-fibrotic signaling TGFβ pathway (including TGFβ itself, PDGF-A 
and PAI-1) and Gal3 pathway, and anti-fibrotic signaling BMP9 pathway are all 
involved in AngII-induced fibrotic remodeling. BMP9 binds with its receptor activin 
receptor-like kinase 1 (ALK1); PAI-1 regulates fibrosis through its inhibition of tPA 
that activates fibril degradation; TGFβ functions via itself or its downstream 
signals like PDGF-A and PAI-1; and Gal3 can signal through Gal3-IL-6 axis. All 
of those signaling converge into their modulation of collagen synthesis and 
degradation by matrix metalloproteinases (MMPs) to regulate fibrotic remodeling.  
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The signaling pathways through which AngII/Salt induces fibrosis include 
both TGFβ1-dependent and –independent signaling237. Platelet derived growth 
factor subunit A (PDGF-A) is one of the downstream mediators in TGFβ signaling 
pathway to promote fibrosis238, 239.  
TGFβ and AngII can also induce plasminogen activator inhibitor-1 (PAI-1, 
or serpin E1)240. PAI-1 is a serine protease inhibitor (serpin) that serves as the 
principal inhibitor of tissue-type plasminogen activator (t-PA) and urokinase-type 
plasminogen activator (u-PA), the activators of plasminogen and hence fibrin 
degradation240, 241. This is consistent with the substantial fibrotic upregulation in 
PAI-1 null mice242, but converse to the pro-fibrotic role of PAI-1243, 244, which 
suggests the plastic role of PAI-1 depending on context and specific tissue type.  
In macrophages, PAI-1 expression can inhibit uPA and abrogate proteolytic 
activity by the macrophage 245 
Galectin 3 Signaling 
AngII also induces fibrosis through TGFβ-independent signaling such as 
AngII-galectin 3 (Gal3)-IL-6 axis237. Gal3 is a matricellular glycan-binding protein 
and involved in cardiac pro-fibrotic remodeling125, 246. Genetic ablation or 
pharmacologically blocking Gal3 ameliorated cardiac fibrosis induced by 
hypertension, highlighting the causative role of Gal3 in hypertension-related 
fibrosis247, 248. Therefore, targeting the AngII-Gal3 axis utilizing Gal3 inhibitor or 
by neutralizing IL-6 could be a therapeutic method to decrease cardiac fibrosis228, 
247.  Gal3 is also required in myofibroblasts for pro-fibrotic response to TGFβ249. 
In addition to the well-known pro-fibrotic signaling pathways, S100 
calcium-binding protein a8/a9 (S100a8/a9) produced by neutrophils was also 
found to activate fibroblasts in initiation of AngII-induced inflammation and 
fibrosis in the heart250. Moreover, osteopontin251 and syndecan-1252 have also 
been implicated in AngII-induced cardiac fibrosis.  
Bone Morphogenetic Protein 9 Signaling 
Bone morphogenetic protein 9 (BMP9) has been recently identified as a 
novel anti-fibrotic factor in a pressure overload hypertension model 253.  BMP9 
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can be synthesized in the liver but is also present in the heart.  Its receptor is the 
activin receptor-like kinase 1 (ALK1) and can oppose actions of TGFβ254.  
Matrix Metalloproteinase 
Fibrosis is essential for tissue healing and repair. Fibrosis occurs when 
ECM protein synthesis exceeds degradation. The proteolysis enzymes that 
regulate ECM protein (e.g. collagen) degradation are mainly matrix 
metalloproteinases (MMPs), such as the collagenase MMP1 that cleaves mature 
collagen fibers255. MMP2 acts to remodel nascent collagens to enable correct 
fibril formation256, 257. MMP9 is involved in inflammation-induced fibrosis via 
mediation of leukocyte migration. The activities of MMPs are antagonized by 
specific inhibitors: tissue inhibitors of metalloproteinases (TIMPs). The complex 
modulation between ECM protein synthesis, degradation by MMPs, and 
suppression of degradation by TIMPs coordinately determines the level of 
fibrosis.  Other MMPs can also participate in ECM degradation. 
Hypotheses Driving this Study 
In this thesis, we will address the role of the myeloid IL-4 receptor in the 
response to two injury models: permanent occlusion of the left coronary artery as 
a model of MI (Chapter II) and chronic angiotensin-II and high salt diet as a 
model of hypertension (Chapter III). For each we will determine the importance of 
the myeloid IL4Rα on a number of pathophysiological phenotypes of these two 
models.  It will separate out functions of endogenous IL-4 on the myeloid line to 
determine the important cell types responding and the consequences of that 
response. This is a critical study since IL4Rα is present on a variety of cell types 
including T cells, B cells, monocytes/macrophages, fibroblasts61, keratinocytes, 
epithelial cells, endothelial cells, and hepatocytes62, 63, all of which could be 
contributing to the phenotype of IL-4 action. While IL4Rα in macrophages is 
thought to play an important role, particularly in the polarization of macrophages, 
fibrosis and cardiovascular injury response, this assumption has not been tested 
in vivo. As a result, these studies will determine the importance of the 
macrophage response to endogenous IL-4 during the pathogenic processes. 
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1. We have tested the hypothesis that IL4Rα is important in determining the 
AAM/M2 macrophage phenotype.  While other cytokines and factors can 
influence macrophage polarization, IL-4 is thought to be a major 
determinant.  Certainly, it is clear that AAM/M2 macrophages increase 
with administration of IL-4.  We present analysis of both the number of 
macrophages and the level of expression of macrophage gene markers to 
detect changes in phenotype.  Our original hypothesis was that this 
receptor would be critical for the determination of macrophage phenotype, 
with knockouts showing decreased AAM/M2 macrophages and marker 
gene expression.  
2. Because of the AAM/M2 role in fibrosis and inflammation, we anticipated 
that cardiac remodeling would be aberrant with decreased fibrosis and the 
potential for increased tissue damage. To assess this, we analyzed 
collagen fibrosis by histology and gene expression. We also evaluated 
histology for evidence of increased tissue damage. To determine if fibrotic 
gene pathways were being activated, we determined the expression of 
pro- and anti-fibrotic genes and identified significant changes of these 
pathways in some circumstances. 
3. We further hypothesized that with the loss of AAM/M2, we would have 
increased inflammation. We analyzed this aspect by evaluation of 
CAM/M1 markers and other inflammatory cytokine genes were increased. 
4. Because IL-4 has been linked to improvements in cardiac function, we 
evaluated cardiac function and blood pressure.  Cardiac function was 
evaluated by echocardiography and structural changes in the heart were 
evaluated including heart size and cardiomyocyte hypertrophy. We 
proposed that function in the myeloid (monocyte/macrophage and 
neutrophil)-specific IL4Rα knockout (MyIL4RαKO) mice would be worse 
than control mice thus demonstrating that the phenotype had significant 
contributions from the IL-4 dependent induction of AAM/M2 phenotype. To 
assess vascular changes in the heart, we evaluated endothelial histology.  
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CHAPTER II 
MYELOID INTERLEUKIN-4 RECEPTOR SIGNALING IS NECESSARY FOR 
EFFICIENT CARDIAC REMODELING AND CARDIAC FUNCTION AFTER 
MYOCARDIAL INFARCTION  
 
Abstract 
Cardiac remodeling can be a critical determinant of outcome for patients 
after myocardial infarction (MI). Well-contained inflammation results in successful 
infarct healing while either inadequate or excessive inflammation can cause 
adverse remodeling and lead to heart failure. Reprogramming macrophages 
towards a resolving and reparative phenotype is a potential therapeutic 
approach. Interleukin-4 (IL-4) is a major inducer of alternative macrophage 
activation (M2) in vitro, and IL-4 treatment in MI has been shown to be beneficial 
although the target cell types have not been experimentally defined. We tested 
whether myeloid cells were important targets in a mouse model of MI using 
myeloid (monocyte/macrophage and neutrophil)-specific IL-4 receptor α knockout 
(MyIL4RαKO) mice.   
MyIL4RαKO and floxed control (FC) mice were subjected to permanent 
ligation of the left coronary artery. Initial infarct size at 2 day post-MI was not 
affected by IL4Rα knockout, but at 1 week post-MI, infarct size of MyIL4RαKO 
mice was significantly smaller than that of FC mice indicating changes in 
remodeling. At 3 week post-MI, infarct thickness of MyIL4RaKO mice was 
significantly increased compared with FC mice. These changes were 
accompanied by decreased expression of fibrosis markers: collagen 1A1 
(Col1A1) and procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 (Plod2). A 
significantly lower ejection fraction was observed in MyIL4RαKO mice compared 
with FC mice at 3 week. Importantly, MyIL4RαKO did not decrease the 
percentage of CD206+ M2-like macrophages post-MI and the expression of 
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macrophage markers was largely unchanged. 
Myeloid-specific IL4Rα knockout results in alterations in cardiac 
remodeling and decreased cardiac function post-MI, demonstrating that these 
cells are important targets of IL-4.  Importantly, macrophage polarization markers 
were not significantly changed, suggesting that the functional changes observed 
and the protection from IL-4 is not through global changes in macrophage 
polarization; thus a simple macrophage polarization model is inadequate. 
Introduction 
Patients with acute myocardial infarction (MI), who survive the initial 
ischemia, are at higher risk of developing heart failure in a process named 
cardiac remodeling1-4. Cardiac remodeling refers to structural changes in size 
and shape, such as dilation, sphericity, wall thinning, as well as epigenetic, 
molecular, cellular, compliant and functional changes that include both resident 
(cardiomyocytes, fibroblasts, macrophage) and non-resident (infiltrating 
leukocytes) cells of the heart, in the infarct area and in the peri-infarct and remote 
viable myocardium5, 6. In the initial few days post MI, the infarct expands, which is 
characterized by acute ventricle dilation (without additional necrosis), infarct wall 
thinning and cardiomyocyte enlargement7, 8. Extracellular matrix degradation 
augments cardiomyocyte slippage and infarct wall thinning. Cardiac fibroblasts 
and myofibroblasts produce a noncompliant collagne scar to maintain the 
ventricle geometry and prevent the development of aneurysm2, 3, 7, 9. Cardiac 
remodeling is a powerful prognostic factor after MI and has been identified as a 
target for intervention4, 8, 10.  
Adverse cardiac remodeling post-MI can lead to impaired cardiac function 
and ultimately cause heart failure. Immune cells are a critical component of post-
MI healing and have major regulatory effects on the healing and remodeling 
process. Following ischemic injury, there is an intense influx of leukocytes, 
mainly characterized by infiltration of neutrophils, followed by 
monocytes/macrophages and lymphocytes, which are involved in a complex 
inflammatory response to facilitate cardiac healing. Through interactions with 
cardiomyocytes and fibroblasts, these immune cells are directly involved in the 
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regulation of hypertrophic, fibrotic and wound healing responses during cardiac 
injury11.  
In addition to cardiomyocytes and fibroblasts, macrophages represent a 
major resident immune cell type in the heart that are maintained under normal, 
steady state conditions through local proliferation12, 13. Macrophages exist within 
a spectrum of phenotypes and have been previously characterized as ranging 
from classically activated macrophages (CAM or M1) to alternatively activated 
macrophages (AAM or M2). Importantly, these characterizations are clearly 
inadequate14, 15. At rest, the heart contains a heterogeneous population of 
resident macrophages with gene expression profiles that more closely resemble 
the AAM/M2 macrophage phenotype12, 16. After MI, there are dynamic changes in 
macrophage phenotype. Kinetic analysis has shown that the early inflammatory 
phase is composed of a high percentage of macrophages expressing CAM/M1 
markers, which most likely reflects the need for immune cell recruitment, 
phagocytosis and clearance of necrotic tissue17, 18. During the later phase of 
injury, macrophages expressing AAM/M2 markers predominate and are thought 
to be involved in wound healing, angiogenic and profibrotic cardiac remodeling18, 
19.   
Apoptosis of infiltrating neutrophils and a switch in macrophages from 
CAM/M1 to AAM/M2 phenotype are involved in the resolution of the inflammatory 
phase4, 18, 20. Neutrophils undergo apoptosis, indicating the start of inflammation 
resolution, and leads to a gradual stop of the infiltration. Macrophages remove 
apoptotic neutrophils by phagocytosis and release cytokines and growth factors 
to potentiate the resolution21, 22. Uncontrolled or delayed resolution of 
inflammation with an abundance of CAM/M1 is thought to be responsible for 
impaired wound healing and adverse cardiac remodeling post-MI. However, 
simply depleting or blocking macrophages does not appear to be a viable 
therapeutic strategy. Several studies have found that depleting macrophages 
results in decreased clearance of necrotic tissue, impaired collagen deposition, 
and decreased survival post-MI23-26. AAM/M2 macrophages are known to be 
involved in wound healing, and it is thought that enhanced AAM/M2 polarization 
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may be critical for efficient infarct remodeling; therefore, depletion of 
macrophages likely prevents this critical process.  
There is increasing evidence to suggest that AAM/M2 macrophages are 
important for efficient cardiac remodeling and function after MI, and numerous 
studies have shown that enhanced AAM/M2 phenotypes correlate with cardiac 
protection27, 28. Although there are many regulators of macrophage polarization, 
IL-4 and IL-13 are the major inducers of the AAM/M2 phenotype in vitro. These 
Th2 cytokines induce an AAM/M2 phenotype by activating the IL-4 and IL-13 
receptors, both of which initiate signal transduction through the common IL-4 
receptor α subunit (IL4Rα). Global deletion of IL-13 has been shown to decrease 
survival and impair cardiac remodeling after MI in male mice29. In addition, IL-4 
administration has been shown to increase survival and improve cardiac function 
after MI27. Importantly, tribbles homolog 1 (Trib1)-/- mice that have an impaired 
capacity for AAM/M2 polarization are not protected by IL-4 administration. 
However, in addition to myeloid cells, IL4Rα is expressed in a number of cell 
types including T cells30, endothelial cell, smooth muscle cells31, and 
cardiomyocytes32. In fact, macrophage IL4Rα inactivation did not affect allergic 
airway disease33 even though IL-4 deficiency does34.  
To delineate the contribution of macrophage phenotypes mediated by IL-4 
during cardiac injury and repair, we genetically ablated IL-4 receptor α in myeloid 
cells to prevent IL-4/IL-13-induced AAM/M2 polarization. We hypothesized that 
the myeloid cells are an important target of IL-4/IL-13 and that inhibition of IL4Rα 
signaling in myeloid cells would block AAM/M2 responses post-MI and would 
lead to ineffective cardiac remodeling and decreased cardiac function. 
Materials and Methods 
Animals 
IL4Rαflox/flox mice were previously produced on a BALB/c background35. 
IL4Rαflox/flox mice were first backcrossed to C57BL/6 background for more than 10 
generations, and then intercrossed with LysM-Cre mice (The Jackson 
Laboratory) to generate myeloid-specific IL4Rα knockout (MyIL4RαKO) mice. 
Experiments used 10-12 weeks old male MyIL4RαKO mice (IL4Rαflox/flox;LyzMCre) 
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and littermate floxed controls (FC, IL4Rαflox/flox). Numbers of mice for each 
experiment are shown in figure legends. Mice were randomly assigned to 
intervention (myocardial infarction, MI) or sham (no MI, NM) groups. Animal died 
from experimental MI within 24 hours (6.9%) or that displayed excessively small 
infarct size (2.7%) as a result of variations in vascular tree were excluded. All 
animal procedures were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals (8th Edition) and were approved by the 
Institutional Animal Care and Use Committee of the University of Michigan.  
Myocardial Infarction Model 
Myocardial infarction (MI) was induced in mice by permanent ligation of 
the left anterior descending (LAD) coronary artery. Mice were anesthetized with 
2% isoflurane, intubated, and maintained on mechanical ventilation while a 
thoracotomy was performed between the left 3rd and 4th intercostal space. The 
left ventricle was visualized and the LAD was ligated using 7-0 surgical silk 
suture. Occlusion of the LAD was confirmed by the presence of blanching of the 
myocardium in the LAD territory. The chest wall was closed with 6-0 silk suture, 
the intercostal and pectoral muscles were realigned, and the skin incision was 
closed with surgical staples. At the end of experiments, mice were euthanized by 
isoflurane. Simply, mice were first induced anesthesia by 3-4% isoflurane, once 
anesthesia was achieved, the isoflurane was increased to 5% to induce death. 
Mice were remained in the chamber for extra 3 minutes after no breath could be 
noticed. Afterwards euthanasia was further confirmed by exsanguination.  
Infarct Size and Thickness 
Infarct size at short-term (2 days and 1 week post-MI) was measured 
based on 2,3,5-triphenyltetrazolium chloride (TTC) stained heart sections with 
the area-based measurement. As the infarct wall thins over time, the area-based 
infarct size measurement is considerably compressed and becomes less 
appropriate, infarct size at late short-term to long-term (1 week and 3 week post-
MI) was measured based on picrosirius red (PSR) stained heart sections with 
length-based measurement.  
Area-based infarct measurement: Hearts were arrested in diastole by 
	 55 
intraventricular injection of saturated KCl, and then excised, rinsed and briefly 
frozen at -20°C. The frozen hearts were cut into 1 mm thick transverse sections, 
and then incubated with 1% TTC solution at 37°C for 10 minutes with flipping. 
The stained sections were fixed in 4% paraformaldehyde. The infarct area and 
the area of left ventricle (LV) were traced by a blinded observer and quantified 
using ImageJ 1.45s software, and the area-based infarct size was calculated as: 
infarct size= (total infarct area/total area of left ventricle) x 100%. 
Length-based infarct measurement: Hearts were arrested in diastole, fixed 
in 4% paraformaldehyde, and embedded in paraffin. Serial 5-µm sections were 
cut through the heart from apex to base with an interval of 500-µm distance. 
Heart sections were used for hematoxylin and eosin (H&E) and picrosirius red 
(PSR) staining. Infarct length and left ventricle (LV) circumference were traced 
and measured using ImageJ 1.45s software based on PSR stained sections. 
Epicardial infarct ratio = epicardial infarct length/epicardial LV circumference. 
Endocardial infarct ratio = endocardial infarct length/ endocardial circumference. 
Infarct size was then calculated as a ratio of [epicardial infarct ratio + endocardial 
infarct ratio)/2] x 100%.36, 37  
To measure infarct thickness, a representative PSR-stained heart section 
from the middle of the heart and with the most significant LV cavity dilatation was 
chosen. Nine evenly spaced radians were marked through the infarct with the 
section center as a reference. The Infarct thickness of each segment was 
measured by ImageJ 1.45s software and the average was calculated.36 
Histopathological Analysis   
Hearts were arrested in diastole, rinsed in PBS, fixed in 4% 
paraformaldehyde for 48 hours, and embedded in paraffin. Serial transverse 
sections (5 µm) were cut through the heart with an interval of 500 µm between 
sections, and then subjected to H&E and PSR staining. In order to determine 
myocyte cross-sectional area (CSA), pictures were taken of all regions in peri-
infarct zone and remote zone of left ventricle in H&E stained sections using a 
Zeiss Axio Imager 2 microscope (Carl Zeiss, Jena, Germany). Myocytes with 
similar-sized nuclei and intact cellular membranes were outlined by a blinded 
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observer, and CSA was calculated using ImageJ 1.45s software. The average 
CSA was calculated from approximately 200 myocytes per sample. For fibrosis 
analysis, pictures were taken of all regions in infarct zone, peri-infarct zone and 
remote zone in PSR stained heart sections. Fibrotic (PSR positive) areas and 
areas of cardiomyocytes were traced and measured with ImageJ 1.45s software. 
The percentage of fibrotic area was calculated as: area of fibrosis/(area of 
cardiomyocytes + area of fibrosis) x 100%.38 5-µm thick heart sections were also 
used for immunohistochemical staining for endothelial cells forming vasculature 
(CD31, DIA310, Diavona), and images captured. CD31-positive vessels were 
quantified using ImageJ 1.45s and reported as ‘percent per field’. 
Bone Marrow-Derived Macrophage 
Anesthesia was induced in mice by 3-4% isoflurane, once anesthesia was 
achieved, the isoflurane was increased to 5% to induce death. Mice were 
remained in the chamber for extra 3 minutes after no breath could be noticed. 
Afterwards euthanasia was further confirmed by exsanguination. When the death 
was confirmed, mice were dissected and bones were collected for producing 
bone marrow-derived macrophages, and peritoneal macrophages were collected 
by peritoneally flushing with ice cold PBS.  
Bone marrow-derived macrophages (BMDMs) were produced by flushing 
bone marrow from femurs and tibias. Briefly, bone marrow cells were flushed out 
with ice-cold PBS in a laminar flow hood. After centrifugation, cells were 
resuspended in RPMI 1640 medium with 10% fetal bovine serum (FBS), 100 
units/ml penicillin and streptomycin, 30% L929-conditioned medium, 1% Glutamax® 
and 0.1% Eagle’s basal medium (BME). The cells were then cultured in a humidified 
incubator under 95% air and 5% CO2 at 37°C for 4 days. On day 4, medium was 
replaced by fresh medium. After two more days culturing, BMDMs were 
differentiated and ready for experiments on day 6.   
Alternative macrophage activation was achieved by treatment with IL-4 (50 
ng/ml) for 24 h, while classical macrophage activation was achieved by treatment of 
100 ng/ml lipopolysaccharide (LPS) for 3 h.  
Immunofluorescence 
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After deparaffinization and rehydration, 5-µm thick sections of heart tissue 
were subjected to microwave epitope retrieval in 10 mM Tris-HCl (pH 9) 
containing 1 mM EDTA. After rinsing several times in 10 mM Tris-HCl buffer (pH 
8) containing 0.154 M NaCl (TBS), non-specific binding of the antibodies was 
extinguished by a 30 min incubation with ‘Background Sniper” (BioCare Medical, 
Concord, CA). The slides were labeled simultaneously with CD206 (Alexa Fluor® 
488, BioLegend, San Diego CA, #141710), and F4/80 (PE, BioLegend, San 
Diego CA, #123110) overnight at 4 °C. The slides were washed with 3 changes 
of TBS and stained with the nucleus staining dye 4’,6-diaminodo-2-phenylindole 
(DAPI) in a non-fading mounting media (ProLong Gold, Molecular probes, 
Carpinteria, CA).  
Gene Expression Analysis 
Relative mRNA expression was determined using quantitative reverse 
transcription–polymerase chain reaction (qRT-PCR). Total RNA was extracted 
using TRIzol reagent and RNA (1 µg) was reverse transcribed to cDNA with a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Quantitative polymerase chain reaction (qPCR) was performed using a 7900HT 
fast real-time PCR system (Applied Biosystems) and relative mRNA expression 
was analyzed using the comparative method and normalized to the internal 
control L32.  All qPCR primers are listed in Table 2.1. 
 
 
 
 
 
 
 
 
 
 
 
Gene  Forward Reverse 
ANP GCTTCCAGGCCATATTGGAG GGGGGCATGACCTCATCTT 
Arg1 ACCTGGCCTTTGTTGATGTCCCTA  AGAGATGCTTCCAACTGCCAGACT  
BNP ATGGATCTCCTGAAGGTGCTG GTGCTGCCTTGAGACCGAA  
CCL11 GAATCACCAACAACAGATGCAC  ATCCTGGACCCACTTCTTCTT  
CCL17 CATGAGGTCACTTCAGATGCTG CCTGGAACACTCCACTGAGG 
Col1A1 GCTCCTCTTAGGGGCCACT  CCACGTCTCACCATTGGGG  
Col3A1 CCTGGCTCAAATGGCTCAC  CAGGACTGCCGTTATTCCCG  
F13A1 GAGCAGTCCCGCCCAATAAC CCCTCTGCGGACAATCAACTTA 
Fizz1 ACTGCCTGTGCTTACTCGTTGACT AAAGCTGGGTTCTCCACCTCTTCA  
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
IL-1β AAGAGCTTCAGGCAGGCAGTATCA  TGCAGCTGTCTAATGGGAACGTCA  
IL4Rα TCTGCATCCCGTTGTTTTGC GCACCTGTGCATCCTGAATG 
L32       TTAAGCGAAACTGGCGGAAAC TTGTTGCTCCCATAACCGATG 
MCP1 TCACCTGCTGCTACTCATTCACCA  TACAGCTTCTTTGGGACACCTGCT  
Plod2 GAGAACTGGGCATGTTTCCTC CCCAAAGTGTAACGGAAGGAG 
TNFα CCCTCACACTCAGATCATCTTCT  GCTACGACGTGGGCTACAG  
Ym1 CACCATGGCCAAGCTCATTCTTGT  TATTGGCCTGTCCTTAGCCCAACT  
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Table 2.1. Sequences of all primers used in chapter II. They were synthesized 
by Integrated DNA Technologies. L32, 60S ribosomal protein L32, was used as 
internal control. 
 
Flow Cytometric Analysis 
Single cell suspensions were prepared from peripheral blood and by 
mincing heart tissue into small pieces followed by digestion in DMEM containing 
collagenase I (450 U/mL), collagenase II (600 U/mL), collagenase XI (125 U/mL), 
DNase I (60 U/mL), and hyaluronidase (60 U/mL) for 1 h at 37°C with agitation.  
Cells were incubated in Fc Block for 10 min and then stained on ice for 1 h with 
the following antibodies: anti-mouse CD45 Pacific Blue™ (clone 30-F11, 
Biolegend, cat # 103126), anti-mouse/human CD11b PE/Cy7 (clone M1/70, 
Biolegend, cat # 101216), anti-mouse F4/80 PE (clone BM8, Biolegend, cat # 
123110), anti-mouse Ly6C	PerCP/Cy5.5 (clone HK1.4, Biolegend, cat # 128011),	
anti-mouse CD206 Alexa Fluor® 488 (clone C068C2, Biolegend, cat # 141709), 
and anti-mouse CD301 APC (clone LOM-14, Biolegend, cat # 145707).  Stained 
cells were washed twice in PBS and fixed in 0.1% paraformaldehyde before 
analysis. Flow cytometry was performed using a BD FACS Canto II flow 
cytometer and analyzed with FlowJo V10.1 software. Neutrophils were defined 
as CD45+CD11b+F4/80-Ly6C-SSChighFSClow, macrophages as 
CD45+CD11b+F4/80+Ly6C-SSClow, and monocytes as CD45+CD11b+F4/80-
Ly6Chigh-lowSSClow, and monocytes were further divided into Ly6Chigh and Ly6Clow 
monocyte populations. Within macrophages, AAM/M2 macrophages were further 
defined as CD206+CD301+. For calculation of total cell numbers in heart, 
normalization to weight of indicated tissues was performed. The total number of 
each cell population per 100 milliliter of blood was calculated by multiplying the 
total cell number by the percentage of each cell population within the gate.  
Echocardiography 
Mice were anesthetized with isoflurane, and echocardiography was 
performed using a Vevo 2100 Micro-Imaging System (VisualSonics Inc.) with a 
18-38-MHz linear array ultrasound transducer. LV ejection fraction was 
determined from the two-dimensional long axis view. Ejection fraction and 
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fractional shortening were calculated based on the M-mode parasternal short 
axis view. Systolic and diastolic dimensions and wall thickness were determined 
by M-mode in the parasternal short axis view. Diastolic function was assessed by 
conventional pulsed-wave spectral Doppler analysis of mitral valve inflow 
patterns (early [E] and late [A] filling waves). Doppler tissue imaging (DTI) was 
used to measure the early (Ea) diastolic tissue velocities of the septal and lateral 
annuluses of the mitral valve in the apical 4-chamber view.  
Statistical Analysis 
Results are presented as mean ± SEM. For statistical analysis, one-way 
ANOVA, two-way ANOVA with a Bonferroni post-test and unpaired, two-tailed 
Student’s t test were used. All statistical analysis of data was performed in 
GraphPad Prism (version 6; GraphPad Software, Inc). P < 0.05 was considered 
significant.  
Results 
Myeloid IL4Rα deficiency changes macrophage polarization in vitro and 
cardiac macrophage markers at steady state in vivo 
To test the role that myeloid IL4Rα signaling and AAM/M2 polarization 
have during MI and post-MI cardiac remodeling, we used myeloid-specific IL-4 
receptor α knockout mice (MyIL4RαKO). As expected, bone marrow-derived 
macrophages (BMDMs) from MyIL4RαKO mice had a significant reduction in 
IL4Rα gene expression (Figure 2.1A), and importantly, this resulted in significant 
ablation of IL-4-induced AAM/M2 polarization. IL-4 treatment resulted in a 
significant increase in gene expression of AAM/M2 markers: Arg1, Ym1, and 
Fizz1 in macrophages from FC mice; however, this response was significantly 
abolished in MyIL4RαKO mice (Figure 2.1A). Like IL-4 stimulated AAM/M2 
markers activation, LPS significantly activated the gene expression of CAM/M1 
markers including TNFα, IL-1β, IL-6 and MCP1 (Figure 2.1A). Moreover, BMDMs 
from MyIL4RαKO mice showed significant increase in the mRNA level of TNFα, 
IL-1β and IL-6 (Figure 2.1A) although not in MCP1 (Figure 2.1A), which suggests 
the increase of CAM/M1 polarization as a result of IL4Rα deficiency. Taken 
together, myeloid-specific IL4Rα knockout significantly inactivates IL4Rα  
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Figure 2.1.  IL4Rα deficiency in myeloid cells efficiently inactivates IL4Rα 
signaling in macrophages and changes the macrophage markers expression 
in heart at steady state. (A) Bone marrow-derived macrophages (BMDMs) were 
produced from bone marrow of floxed control (FC) and myeloid-specific IL4Rα 
knockout (MyIL4RαKO) mice, and treated by M2 macrophage stimulus IL-4 or M1 
macrophage stimulus LPS. mRNA levels of IL4Rα, AAM/M2 markers: Arg1, Ym1 
and Fizz1 and CAM/M1 markers: TNFα, IL-1β, IL-6 and MCP1 were determined 
using qRT-PCR. (B) Baseline mRNA gene expression of AAM/M2 markers: Arg1, 
Ym1, Fizz1, F13A1 and CCL17 and CAM/M1 markers TNFα, IL-1β, MCP1, IL-6 and 
CCL11 was analyzed in intact hearts by qRT-PCR. Results are presented as means 
± SEM. n = 5-6. Two-way ANOVA and Student’s t test were used for statistical 
analysis. *P <0.05; **P <0.01; ***P <0.001; ****P < 0.0001.  
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signaling in macrophages, and induces less AAM/M2 macrophage polarization 
and more CAM/M1 macrophage polarization in vitro. 
In order to test whether the IL4Rα signaling in myeloid cells also changes 
macrophage polarization in vivo especially in resident macrophages in heart, we 
analyzed the basal expression of selected AAM/M2 markers (Arg1, Ym1, Fizz1, 
F13A1 and CCL17) in the hearts of MyIL4RαKO mice, then we measured the 
basal expression of CAM/M1 markers (TNFα, IL-1β, MCP1, IL-6 and CCL11) by 
qRT-PCR. The mRNA level of AAM/M2 markers Arg1, F13A1 and CCL17 was 
significantly decreased in MyIL4RαKO mice, although Ym1 and Fizz1 oppositely 
showed increase (Figure 2.1B). The mRNA level of CAM/M1 markers was 
consistently increased in MyIL4RαKO mice (Figure 2.1B). This basal level 
increase in CAM/M1 markers and the decrease in several AAM/M2 markers 
indicate the disturbance of macrophage polarization in vivo by IL4Rα deficiency 
in myeloid cells, with more CAM/M1 polarization and relatively less AAM/M2 
polarization, although the Ym1 and Fizz1 mRNA were increased in MyIL4RαKO 
mice, which may indicate not only macrophages, but also the other cell types 
contribute to the mRNA expression of Ym1 and Fizz1.  
Myeloid IL4Rα knockout has differential effects on infarct size and 
hypertrophy post-MI 
We subjected mice to experimental MI by left anterior descending 
coronary artery ligation and first determined the effect that MyIL4RαKO had on 
early infarct development at 2 days and 1 week after MI. For early infarct size 
estimation, area measurement based on 2,3,5-triphenyltetrazolium chloride 
staining was used, whereas for later time points, as a result of wall thinning, the 
area measurement approach becomes less appropriate that length measurement 
based on picrosirius red staining was used.37 Results showed that there was no 
difference in infarct size between MyIL4RαKO and FC mice at 2 days post-MI 
(Figure 2.2A and B). However, both area- and length-based measurement of 
infarct size displayed a significant decrease in MyIL4RαKO mice 1 week post-MI 
(Figure 2.2A and B), although there was no significant change detected at 3 
weeks post-MI (Figure 2.2B and C). Consistent with the decreased infarct size of  
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Figure 2.2. Myeloid IL4Rα knockout changes infarct size and thickness. (A) 
Representative images of serial 2,3,5-triphenyltetrazolium chloride (TTC) stained 
heart sections at 2 day and 1week post-MI. Infarct areas were outlined in white. (B) 
Measurement of infarct size. Area-based infarct size measurement of hearts at 2 
day (n = 5-6) and 1 week (n = 11-16) post-MI based on TTC staining and length-
based infarct measurement of hearts at 1 week (n = 5-8) and 3 week (n = 7-9) post-
MI based on picrosirius red (PSR) staining. (C) Representative images of serial PSR 
stained heart sections at 3 week post-MI, and their hematoxylin and eosin (H&E) 
counterstaining. (D) Representative photomicrographs of PSR stained heart 
sections showing infarct thickness at 3 week post-MI, and their counterstaining of 
H&E and infarct thickness determination based on PSR stained heart sections (n = 
9-11). Results are shown as means ± SEM. Unpaired Student’s t test was used for 
statistical analysis. *P <0.05; **P <0.01. 
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MyIL4RαKO mice at 1 week post-MI, infarct thickness was shown significant 
increase in MyIL4RαKO mice at 3 weeks post-MI compared to FC mice (Figure 
2.2D), suggesting that IL4Rα signaling in myeloid cells may have an important 
role in post-MI cardiac remodeling.   
Since immune cells can influence the hypertrophic response to cardiac 
injury, we next investigated whether myeloid IL4Rα inactivation altered cardiac 
hypertrophy post-MI. We detected significant increases in heart weight to body 
weight ratio (HW/BW) in FC mice at 2 days, 1 week and 3 weeks post-MI and a 
significant increase in heart weight to tibia length ratio (HW/TL) at 1 week post-MI 
when compared to mice with no MI (Figure 2.3A). A small decrease in HW/BW 
was shown in MyIL4RαKO mice at 1 week post-MI when compared to FC mice, 
however this difference was undetectable by 3 week (Figure 2.3A). Similarly, 
cardiomyocyte size was significantly increased due to MI, but no difference was 
detected between FC and MyIL4RαKO mice (Figure 2.3B). We also analyzed the 
expression of hypertrophy-induced fetal genes atrial natriuretic peptide  (ANP) 
and brain natriuretic peptide (BNP) in heart tissues by qRT-PCR. Although there 
was significant induction of ANP and BNP by MI, there was no difference 
detected between FC and MyIL4RαKO mice post-MI (Figure 2.3C). To be 
noticed, among mice with no MI, MyIL4RαKO showed significant increase in BNP 
expression compared with FC mice (Figure 2.3C), suggesting the difference 
between FC and MyIL4RαKO mice at basal level. Collectively, these data 
indicate that myeloid IL4Rα inactivation does not significantly alter the 
hypertrophic response post-MI.  
Myeloid IL4Rα signaling is involved in fibrosis post-MI 
IL-4 is thought to play an important role in fibrosis although whether 
effects are mediated through an AAM/M2-like macrophage phenotype in vivo has 
not been determined39-41. We, therefore, determined the effect of IL4Rα 
inactivation on fibrosis during the remodeling response post-MI. Cardiac 
interstitial fibrosis and perivascular fibrosis were examined using picrosirius red 
staining. The interstitial fibrosis did not show any change due to the lack of IL4Rα 
in myeloid cells whether in infarct zone, peri-infarct zone or remote zone (Figure  
	 64 
	
Figure 2.3. Myeloid-specific IL4Rα is not involved in hypertrophic cardiac 
remodeling. (A) Heart weight to body weight ratio (HW/BW) and heart weight to 
tibia length ratio (HW/TL) were measured at 2 day, 1 week and 3 week post-MI. 
Mice with no MI (NM) were served as controls. (FC, n = 8 and MyIL4RαKO, n = 13 
in no MI controls; FC, n = 6 and MyIL4RαKO, n = 4 at 2 day; FC, n = 49 and 
MyIL4RαKO, n = 42 at 1 week; FC, n = 18 and MyIL4RαKO, n = 22 at 3 week). (B) 
Representative images of H&E stained heart sections 3 week post-MI and the 
cardiomyocyte cross-sectional area in peri-infarct (PIZ) and remote zone (RZ) was 
determined. n = 9-12. (C) The mRNA expression of fetal genes ANP and BNP of 
heart tissues at 1 week and 3 week post-MI was analyzed by qRT-PCR at infarct 
zone (IZ), peri-infarct zone (PIZ) and remote zone (RZ) respectively.  Hearts from 
mice with no MI (NM) were dissected similarly into apical (Api), middle (Mid) and 
basal (Bas) regions and served as controls. n = 4-8. All results are shown as means 
± SEM. Unpaired Student’s t test was used for statistical analysis.  *P <0.05; **P 
<0.01; ***P <0.001; ****P < 0.0001. 
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2.4A). However, perivascular fibrosis in peri-infarct zone was significantly 
increased in MyIL4RαKO mice compared to FC (Figure 2.4B). In order to find out 
whether the change in perivascular fibrosis results in any change in angiogenesis 
after infarction, we investigated the expression of CD31 by 
immunohistochemistry in heart sections post-MI. CD31 showed significantly 
higher expression in remote zone than in infarct or peri-infarct zone (Figure 
2.4D), indicating the deteriorated vasculogenesis system in infarct and peri-
infarct zone. However, the expression of CD31 did not show any difference 
between FC and MyIL4RαKO mice (Figure 2.4D), which is consistent with the 
CD31 expression between IL4Rαflox/flox and IL4Rαflox/-LysMCre mice during wound 
healing after injury in skin41. These results suggest that the change in 
perivascular fibrosis does not affect angiogenesis post-MI. 
We next quantified the mRNA expression of fibrotic markers like collagen 
1A1 (Col1A1), collagen 3A1 (Col3A1) and procollagen-lysine 2-oxoglutarate 5-
dioxygenase 2 (Plod2) in heart tissues post-MI. These genes were all 
significantly increased as a result of MI (Figure 2.4C), and MyIL4RαKO mice 
displayed a significant decrease in Col1A1 and Plod2 mRNA level in infarcted 
tissues at 3 weeks post-MI when compared with FC (Figure 2.4C), which is 
consistent with the pro-fibrotic role of IL-4 signaling in myeloid cells39, although 
the increase of perivascular fibrosis in MyIL4RαKO mice is surprisingly the 
opposite. These suggest the possibility that without anti-inflammatory activity of 
IL-4 action in myeloid cells, there is increased perivascular pro-fibrotic effect from 
persistent inflammatory stimulation, and this may be unrelated to angiogenesis.  
Myeloid IL4Rα deficiency deteriorates cardiac function post-MI 
To determine if the changes in cardiac remodeling caused by IL4Rα 
knockout in myeloid cells result in functional deficits, we performed 
echocardiography on mice at 3 weeks post-MI to assess cardiac function (Figure 
2.5A). No differences were detected in baseline cardiac function in FC and 
MyIL4RaKO mice without MI (Figure 2.5B). When compared with mice with no 
MI, mice at 3 weeks post-MI had significantly reduced ejection fraction and 
fractional shortening (Figure 2.5B). More importantly, a significant decrease in  
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Figure 2.4. IL4Rα signaling in myeloid cells is involved in fibrotic cardiac 
remodeling post-MI. Representative images of picrosirius red stained heart 
sections at 3 week post-MI to show interstitial (A) and perivascular (B) fibrosis in 
hearts at 3 week post-MI, and their respective quantification. n = 7-9. (C) mRNA 
gene expression of fibrosis markers Col1A1, Col3A1, and Plod2 by qRT-PCR at 1 
week and 3 week post-MI.  Heart tissues were dissected into remote zone (RZ), 
peri-infarct zone (PIZ) and infarct zone (IZ), and hearts of mice with no MI (NM) 
were dissected similarly into basal (Bas), middle (Mid) and apical (Api) region. n = 6-
8. (D) Representative images of heart sections 3 week post-MI by CD31 staining 
and the quantification of the percentage of CD31 positive areas. n = 6-7. All results 
are shown as means ± SEM. Unpaired Student’s t test was used for statistical 
analysis. *P <0.05; **P <0.01; ***P <0.001; ****P < 0.0001.  
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Figure 2.5. Myeloid IL4Rα knockout impairs cardiac function after MI. Cardiac 
function was analyzed at 3 week post-MI by echocardiography. (A) Representative 
echocardiographic images of FC and MyIL4RαKO mice 3 week post-MI. (B) 
Quantitative evaluation of echocardiography data collected 3 week post-MI including 
ejection fraction (EF), fractional shortening (FS), left ventricle end diastolic volume 
(LVEDV), left ventricle end systolic volume (LVESV), left ventricular internal diameter 
diastole (LVIDd), and left ventricle internal diameter systole (LVIDs).  Mice that did 
not receive MI are labeled as NM (no MI) and served as controls. n = 4-5. Results 
are presented as means ± SEM. Unpaired Student’s t test was used for statistical 
analysis.  *P <0.05; **P <0.01; ***P <0.001. 
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ejection fraction and fractional shortening was detected in MyIL4RαKO mice 3 
weeks post-MI when compared to FC mice (Figure 2.5B). Similarly, MyIL4RαKO 
mice had significantly increased left ventricle end diastolic volume, left ventricle end 
systolic volume, left ventricular internal diameter diastole, and left ventricle internal 
diameter systole (Figure 2.5B), indicating that MyIL4RαKO mice have impaired 
cardiac function. In conclusion, these results suggest that IL4Rα signaling in 
myeloid cells is critical in cardiac remodeling that loss of this signaling impairs 
cardiac function.  
Myeloid IL4Rα inactivation does not change macrophage polarization post-
MI 
Although we found impaired cardiac function in MyIL4RαKO mice, the 
mechanism by which myeloid IL4Rα deficiency decreases cardiac function is still 
unknown. In order to test our hypothesis that IL4Rα signaling in myeloid cells 
changes macrophage polarization, we measured the mRNA expression of 
CAM/M1 and AAM/M2 markers in heart tissues post-MI. There was increased 
expression of both CAM/M1 markers and AAM/M2 markers at 1 week and 3 
weeks post-MI with highest levels found predominantly in the infarct zone (Figure 
2.6). However, no differences in CAM/M1 marker expression were detected 
between FC and MyIL4RαKO mice post-MI (Figure 2.6). Similarly, no difference 
was found in the expression of the AAM/M2 marker: Arg1, but increased 
expression of Ym1 was found in infarct tissues of MyIL4RαKO mice at 1 week, 
and increased expression of Fizz1 in both infarct and peri-infarct tissues at 1 
week and in infarct tissues at 3 weeks post-MI (Figure 2.6). Expectedly, the 
expression of CAM/M1 markers and AAM/M2 markers in heart tissues with no MI 
was consistent with the basal level expression (Figure 2.1B), which showed 
increase in CAM/M1 markers and decrease (Arg1) or increase (Ym1 and Fizz1) 
in AAM/M2 markers, indicating the disturbance of macrophage polarization in 
vivo by IL4Rα deficiency in myeloid cells with more CAM/M1 polarization at 
steady state. Collectively, these data suggest that IL4Rα deficiency in myeloid 
cells significantly changes macrophage polarization at steady state with increase 
of inflammation in heart; however, most of the changes disappear in  
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Figure 2.6. Gene expression analysis of pro-inflammatory CAM/M1 and anti-
inflammatory AAM/M2 markers in heart tissues post-MI. The mRNA level of anti-
inflammatory AAM/M2 markers: Arg1, Ym1 and Fizz1 and pro-inflammatory 
CAM/M1 markers: TNFα, IL-1β and MCP1 was measured at 1 week and 3 week 
post-MI in tissues from heart. Hearts post-MI were dissected into remote zone (RZ), 
peri-infarct zone (PIZ) and infarct zone (IZ) while mice with no MI (NM) were 
dissected similarly into basal (Bas), middle (Mid) and apical (Api) regions. n = 5-8. 
Results are presented as means ± SEM. Unpaired Student’s t test was used for 
statistical analysis.  *P <0.05; **P <0.01; ***P <0.001. 
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inflammatory state (post-MI).  
In order to further determine if myeloid-specific IL4Rα knockout changes 
macrophage polarization during MI, we used flow cytometry to characterize the 
macrophage subtypes defined by cell surface markers expression. At 1 week 
post-MI, there was a marked decrease in the percentage of CD301+CD206+ 
AAM/M2 macrophages in infarct tissues compared with non-infarct tissue or 
heart tissues with no MI, but no differences were detected as a result of myeloid 
IL4Rα inactivation (Figure 2.7A). This is supported by the results that neither the 
percentage of Ly6Chigh nor Ly6Clow monocytes showed any difference between 
FC and MyIL4RαKO mice (Figure 2.7B and C). The number of CD206+CD301+ 
AAM/M2 macrophages was significantly increased in infarct tissues (Figure 
2.7A), indicating the recruitment of AAM/M2 macrophages into the infarcts, 
however similarly, no difference was shown between MyIL4RαKO and FC mice, 
as well as the number of macrophages, neutrophils and Ly6Chigh and Ly6Clow 
monocytes (Figure 2.7B), which suggests that the inactivation of IL4Rα signaling 
in myeloid cells does not change the recruitment and trafficking of myeloid cells 
to infarct tissue, neither their polarization. This was further confirmed by the 
quantification of neutrophils and monocytes in blood of mice post-MI. The 
number of neutrophils and monocytes was significantly increased in blood 
because of MI (Figure 2.7D), indicating the circulation and trafficking of myeloid 
cells after MI, however the percentage or the number of neutrophils and 
monocytes in blood did not change as a result of IL4Rα knockout in myeloid cells 
(Figure 2.7D). We also performed immunofluorescent staining of heart sections 
to independently investigate the effect of IL4Rα knockout on macrophage 
polarization. F4/80 and CD206 were used to identify macrophage and AAM/M2 
macrophages respectively, and showed no changes due to IL4Rα deficiency in 
myeloid cells (Figure 2.8). These results again indicate that myeloid-specific 
IL4Rα inactivation does not change the polarization of AAM/M2 macrophages 
post-MI, although it did cause significant changes in cardiac remodeling and 
function.  
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Figure 2.7. Myeloid IL4Rα knockout does not alter myeloid cells recruitment or 
macrophage polarization. Flow cytometric analysis of macrophages, neutrophils 
and monocytes in intact hearts of control mice (NM, no MI), infarcted and non-
infarcted (including remote and peri-infarct) heart tissues of FC and MyIL4RαKO 
mice 1 week post-MI. Representative FACS contour plots of CD206+CD301+ M2-like 
macrophages gated from macrophages (A) and Ly6Chigh and Ly6Clow monocytes 
gated from total monocytes (C) and the quantification of their percentage and 
number per milligram of indicated tissues. (B) Total number of macrophages, 
neutrophils and Ly6Chigh and Ly6Clow monocytes per milligram of indicated tissues. 
n=5-7. (D) The percentage of neutrophils and monocytes in total CD45+ leukocytes 
in blood from mice 1 week post-MI, and the number of neutrophils and monocytes 
per 100 microliter of blood. n=5-7. Results are shown as means ± SEM. Unpaired 
Student’s t test and one-way ANOVA were used for statistical analysis. ***P <0.001.  
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Figure 2.8. Immunofluorescent analysis of F4/80+CD206+ M2-like macrophages 
in heart sections post-MI. (A) Representative immunofluorescent photos of remote 
zone (RZ), peri-infarct zone (PIZ) and infarct zone (IZ) of heart sections 3 wk post-
MI. F4/80+CD206+ macrophages were detected by co-localization of 
immunofluorescent signals from F4/80 and CD206 antibodies. (B) Quantification of 
F4/80+ macrophages and F4/80+CD206+ M2-like macrophage subpopulation. n = 5. 
Results are shown as means ± SEM. Unpaired Student’s t test was used for 
statistical analysis. **P <0.01. 
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Taken together, IL4Rα knockout in myeloid cells significantly changes 
macrophage polarization in vitro and changes macrophage polarization at steady 
state in heart with increase in inflammation. It impairs cardiac function post-MI by 
increasing the adverse cardiac remodeling, however, this is not caused by 
altering the M1/M2 macrophage polarization balance or myeloid cells recruitment 
post-MI, which suggests IL4Rα signaling in myeloid cells is very important in 
cardiac remodeling in inflammatory state, but through a more subtle mechanism 
rather than changing the number of polarized macrophages or myeloid cells 
trafficking.   
Discussion 
Adverse cardiac remodeling after MI is a major contributor to heart failure 
and is a significant cause of cardiovascular morbidity and mortality. Inflammation 
occurs rapidly after MI, and immune cells have important roles in post-MI cardiac 
remodeling. IL-4 is a major inducer of AAM/M2 macrophage polarization, and 
while IL-4 administration has been recently shown to be protective in post-MI 
cardiac remodeling, the target cell types have not been identified.  
In the present study, we investigated how myeloid IL4Rα changes cardiac 
remodeling and function post-MI by cell-type specific knockout of this receptor 
subunit. We found that myeloid-specific knockout of IL4Rα does not change 
cardiac hypertrophy or initial infarct size. It does alter remodeling leading to a 
smaller infarct at 1 week and by 3 weeks there is increased scar thickness. 
These results show that IL4Rα in myeloid cells is an important target for IL-4/IL-
13 and that its activity is required for normal infarct healing. In addition, IL4Rα 
knockout in myeloid cells increases perivascular fibrosis although it does not 
change interstitial fibrosis in the heart indicating a direct or indirect role in the 
peri-infarct area. All of these changes in cardiac remodeling result in decreased 
cardiac function, which suggests myeloid IL4Rα itself is protective in MI. 
Importantly, this is not a simple global change in AAM/M2 macrophages since 
the number or percentage of cells with AAM/M2 markers remains mostly 
unchanged. Despite the lack of global AAM/M2 changes, without IL4Rα signaling 
in myeloid cells there is impaired healing resulting in decreased cardiac function.  
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Cardiac hypertrophy occurs after MI,36, 42 showing as an increase in 
ventricle wall mass and cardiomyocyte size. Increases of HW/BW and HW/TL 
were detected in our data as a result of MI, but there was no difference between 
FC and MyIL4RαKO mice, indicating that IL4Rα knockout in myeloid cells does 
not affect cardiomyocyte growth. The only difference in HW/BW between FC and 
MyIL4RαKO mice was at 1 week post-MI, which showed decreased HW/BW in 
MyIL4RαKO mice, but the difference was not confirmed in HW/TL. Further, the 
expression of cardiac fetal genes associated with cardiac hypertrophy, did not 
show significant difference between FC and MyIL4RαKO mice. Fetal gene BNP 
mRNA level was higher in hearts from MyIL4RαKO mice, but the increase only 
was present in hearts without surgery and there were no differences in heart 
tissues post-MI. The expression of ANP mRNA did show increase at 3 weeks 
post-MI, but it was only in the area remote from the infarct. Overall these data do 
not support the involvement of myeloid IL4Rα in cardiomyocyte growth post-MI.  
Infarct size and infarct thickness correlate with the prognosis of MI.37 IL-4 
administration before MI was recently shown to reduce infarct size and increase 
infarct wall thickness.27 It was also found that the mice injected with IL-4 showed 
improved cardiac function post-MI. However, in our study, knockout of IL4Rα 
from myeloid cells caused abnormal remodeling and decreased infarct size 1 
week post-MI. By 3 week, the infarct size was comparable in knockout and wild 
type animals. The infarct thickness increased in MyIL4RαKO mice at 3 week, but 
was associated with decreased cardiac function in MyIL4RαKO mice. The 
change in infarct thickness may be similar to the impaired collagen fibril 
assembly seen in a wound-healing model.41 Since IL-4 administration also 
resulted in increased scar thickness and improved function, infarct thickness may 
not be a universal measure of improved healing. Potential explanations include 
that the increased thickness is due to altered remodeling that is not complete. 
Alternatively, the protective effect that resulted from IL-4 administration may not 
be through or only through myeloid cells, but also the involvement of the other 
cell types. It is possible that the changes in infarct size and infarct wall thickness 
are time point-dependent.  Importantly, the improved cardiac function after IL-4 
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administration in the literature27 is consistent with the decreased cardiac function 
in our MyIL4RαKO mice, which suggests that the protective effect of IL-4 
administration is significantly through IL4Rα signaling in myeloid cells.  
At the later stages of cardiac remodeling post-MI, inflammatory reactions 
are typically suppressed and reparative processes dominate. Fibroblasts 
proliferate and transdifferentiate into myofibroblasts, extracellular matrix 
deposition occurs in the injured area, and fibrosis is enhanced to form supportive 
tissue and scarring to maintain the structure and function of ventricles. Although 
the mRNA levels of Col1A1 and Plod2 were significantly decreased in the infarct 
tissues of MyIL4RαKO mice, the interstitial fibrosis based on picrosirius red 
staining did not show any difference whether in infarct area, peri-infarct area, or 
remote area. It was reported that administration of IL-4 increased both the 
number and the activation of fibroblasts after MI, which resulted in increased 
fibrosis27.  The differences between IL-4 treatment and our study using myeloid-
specific IL4Rα knockout may reflect other target cell types for IL-4 or that other 
effects may be due to IL-13, which is also a ligand for IL4Rα and has been 
shown to be involved in cardiac remodeling after MI.29  
It was previously found that IL-4 administration during MI increased the 
number of CD206+ macrophages (sometimes used to identify AAM/M2-like 
macrophages) post-MI27. We found no change in either the number or the 
percentage of CD206+ cells due to myeloid IL4Rα knockout. While this is not a 
full characterization of the macrophage phenotype, this staining is the almost 
universally used measure of M2 macrophages. This indicates two important 
points: first, that the presence of the CD206+ cells is not dependent on IL-4 
signaling effects in myeloid cells, and second, that global changes in 
macrophage polarization are not necessary for important effects of IL-4 and that 
IL-4 is not a required determinant of “M2” macrophage polarization. This points to 
inadequacy in this system of the M1-M2 paradigm as has recently been shown.15 
Although neither the number or the percentage of classically defined CD206+ 
AAM/M2 macrophages showed any significant differences in MyIL4RαKO mice, 
we did see significantly impaired responses in BMDMs and PEMs treated with IL-
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4, confirming that IL4Rα signaling in myeloid cells contributes to cardiac 
remodeling post-MI.  
We did not detect any large, consistent differences in pro- and anti-
inflammatory macrophage markers after MI, although we did find significant 
differences at baseline. In uninjured hearts, there was a clear pattern of 
increased pro-inflammatory markers and decreased anti-inflammatory markers in 
MyIL4RαKO mice. There were no differences in the pro-inflammatory markers in 
heart tissues post-MI, and the differences in anti-inflammatory markers varied 
depending on marker. The decrease in Arg1 mRNA disappeared in tissues post-
MI, while both Ym1 and Fizz1 mRNA increased in heart tissues both in steady 
state and post-MI although the increase of Ym1 only showed up at 1 week post-
MI. Part of the differences may be due to differential dependence of resident and 
recruited macrophages. This raises a very important question of different role of 
myeloid IL4Rα signaling in resident macrophages and circulating macrophages, 
but to clarify this question will require further investigation with experiments of 
linage tracing, which will be a promising direction of study in the future.  
Previous reports using MyIL4RαKO mice in other injury models did not 
specifically show a reduction in the number or percentage of AAM/M2 
macrophages, but they did find that the expression of the AAM/M2 marker 
CD206 was decreased in macrophages induced by pancreatitis or skin injury in 
MyIL4RαKO mice.39, 41 MyIL4RαKO mice in models of pancreatitis and skin injury 
showed decreased or perturbed collagen fibril formation that is different from 
ours, suggesting a model-dependent function of myeloid IL4Rα.39, 41 IL4Rα was 
also shown significantly decreased in neutrophils in MyIL4RαKO mice35, and IL-4 
signaling restricts neutrophil expansion in bone marrow and their migration from 
bone marrow to tissues43, which suggests the IL4Rα signaling-induced changes 
in neutrophils might contribute to the altered cardiac remodeling of MyIL4RαKO 
mice. Although we did not find any change in neutrophil recruitment and 
circulation, it worth further clarification of the contribution of IL4Rα signaling in 
neutrophils, either by isolating primary neutrophils in vitro or neutrophil-specific 
IL4Rα knockout in vivo by MRP8Cre. 
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In conclusion, myeloid IL4Rα is important for efficient cardiac remodeling 
and cardiac dysfunction after MI, indicating that it is likely an important target for 
IL-4-mediated protection during MI.  However, despite being necessary for IL-4 
induced AAM/M2 macrophage polarization in vitro, myeloid IL4Rα is not required 
for the polarization of CD206+ macrophages in vivo during MI. 
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CHAPTER III 
MYELOID INTERLEUKIN-4 RECEPTOR SIGNALING IS IMPORTANT FOR 
CARDIOVASCULAR REMODELING INDUCED BY ANGIOTENSIN II AND 
HIGH SALT  
 
Abstract 
Hypertension is the first leading risk factor for death from cardiovascular 
diseases. Hypertension-induced cardiovascular remodeling results in chronic 
low-grade inflammation, fibrosis and tissue stiffness, which lead to development 
and progression of cardiovascular diseases. Macrophages are the central 
participants in remodeling, and modulating the remodeling process by 
reprogramming macrophages is a potential strategy to prevent cardiovascular 
diseases.  
We investigated the role of myeloid IL4Rα in cardiac and vascular 
remodeling in angiotensin II (AngII) and high salt-induced hypertension. Myeloid-
specific knockout of IL4Rα (MyIL4RαKO) did not show any effect on hypertrophic 
remodeling in the cardiovascular system, but it increased the expression of 
reactive oxygen species (ROS) generation related genes. MyIL4RαKO also 
resulted in substantial decreases in cardiovascular fibrosis through systemic 
suppression of pro-fibrotic pathways including TGFβ and Gal3 signaling and 
enhancement of anti-fibrotic BMP9 signaling, which indicates an important role 
for myeloid IL4Rα signaling in cardiovascular remodeling. The pathophysiologic 
alterations in inflammation and fibrosis resulted in a relatively mild preservation of 
cardiac function in MyIL4RαKO mice while that of floxed control mice was 
significantly impaired by AngII and high salt. However, no change in macrophage 
polarization was shown in injured heart and aorta tissues. Neither the percentage 
or cell number of M2 macrophages was decreased by IL4Rα deficiency although 
IL-4 receptor signaling is very important in M2 macrophage activation. These 
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results suggest that the decreased fibrosis and functional preservation in 
MyIL4RαKO mice is not simply due to a change in macrophage polarization.  
In conclusion, myeloid IL4Rα signaling is significantly involved in 
cardiovascular remodeling induced by AngII and high salt, but it is not simply 
through blocking the M2 macrophage activation in vivo, suggesting a more 
complicated change in macrophages, which needs to be determined in the future.  
Introduction 
Hypertension is a major risk factor for cardiovascular disease1. Being the 
first-leading risk factor, hypertension contributes to 40.6% of total cardiovascular 
mortality2. Antihypertensive therapy has been shown to reduce the risk of death 
from cardiovascular disease, but only half of hypertensive patients using 
antihypertensive medication have controlled hypertension, and 25% of 
hypertensive patients do not take any type of antihypertensive medication3. 
Based on recent reports from preclinical research and clinical trials, none of the 
newly developed drugs or interventions have been successful in preventing 
cardiovascular disease outcomes or death in hypertensive patients4. Novel 
therapeutic targets need to be identified and target-based therapeutic strategies 
need to be developed to improve cardiovascular outcomes.  
Uncontrolled hypertension can exert deleterious effects on the 
cardiovascular system by adverse cardiovascular remodeling, which includes a 
complex spectrum of pathophysiological events including cardiovascular 
hypertrophy, inflammation and fibrosis. These remodeling events result in 
myocardial stiffening, vascular stiffness, oxidative stress, and long-term low-
grade systemic inflammation, which promote the pathological transition from 
hypertension to hypertensive cardiovascular diseases5. 
In response to hypertension, left ventricle and vasculature geometry 
undergoes structural remodeling, which is a pro-inflammatory and pro-fibrotic 
process that leads to adverse accumulation of collagen. Collagen deposition in 
extracellular matrix gives rise to interstitial fibrosis, which initially reduces 
myocardial compliance without cardiomyocyte loss, and clinically displays as 
heart failure with preserved ejection fraction6. As advanced hypertension 
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progresses, cardiomyocytes undergo pathological hypertrophy and 
cardiomyocyte loss occurs.  This results in irreversible replacement by fibrosis 
and collectively leads to impairment of cardiac systolic function and clinically 
manifests as heart failure with reduced ejection fraction7-9. Shear stress and low-
grade systemic inflammation during hypertension also cause endothelial damage 
and results in perivascular fibrosis with substantial collagen accumulation in the 
adventitia of intramural arteries. This leads to a reduction in vascular compliance 
and changes in permeability10. Low-grade systemic inflammation also elicits 
structural and functional alterations in the microvasculature, which cause 
microvasculature remodeling and rarefaction10.  
In addition to structural remodeling, hypertension also induces 
cardiovascular consequences via neurohumoral activation – renin-angiotensin-
aldosterone system (RAAS). RAAS functions to maintain blood pressure 
homeostasis, however stimulating RAAS exerts detrimental consequences such 
as high blood pressure, adverse cardiovascular remodeling and increase of 
cardiovascular morbidity and mortality11, 12. Angiotensin II (AngII) is a crucial 
component in the system and is commonly used in experimental models of 
hypertension or hypertensive cardiovascular diseases13, 14.  
Macrophages are one of the central cell types that mediate cardiovascular 
remodeling induced by hypertension. Macrophages accumulate and infiltrate into 
injured tissues through two distinct mechanisms: recruitment of monocyte 
precursors from circulation and proliferation of resident macrophages. Selective 
ablation of monocyte/macrophage and neutrophil using inducible diphtheria toxin 
receptor driven by lysozyme M (LysM) resulted in blunted oxidative stress, 
reduced arterial hypertension and attenuated vascular dysfunction induced by 
AngII, in contrast, adoptive transfer of monocytes but not neutrophils restored the 
adverse effects suggesting an essential role of monocytes/macrophages in 
AngII-induced hypertension15.  
There is a wide spectrum of macrophage phenotypes with two main 
extremes: classically activated macrophage (CAM/M1) and alternatively activated 
macrophage (AAM/M2). M1 macrophages are characterized by the production of 
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reactive oxygen species (ROS), reactive nitrogen species (RNS) and pro-
inflammatory cytokines including tumor necrosis factor α (TNFα), interleukin-1β 
(IL-1β) and interleukin-6 (IL-6), and are considered to play a crucial role in 
inflammation and tissue damage16. M2 macrophages are defined as 
macrophages stimulated by Th2 cytokines such as interleukin-4 (IL-4) and 
interleukin-13 (IL-13) in vitro. They are characterized by expression of mannose 
receptor C type 1 (MRC1/CD206), arginase 1 (Arg1), and resistin-like molecule α 
that also named found in inflammatory zone (Relmα/Fizz1), and are significantly 
involved in would healing and fibrosis17-22. Although distinct, both populations 
contribute to the initiation and progression of cardiovascular diseases23-25. 
IL-4 and IL-13 function by binding to IL-4 receptor (IL4R), so IL4R 
signaling plays a very important role in cardiovascular remodeling potentially 
through its control of macrophage polarization. IL4R includes type I and type II 
IL4R: type I IL4R consists of IL-4 receptor α (IL4Rα) chain and common γ chain 
(γc), while type II IL4R consists of IL4Rα and IL-13 receptor α1 (IL13Rα1) 
subunits, highlighting the importance of IL4Rα subunit that is required by both 
type I and type II IL4R. IL-4 can signal through both receptors, while IL-13 can 
only signal through type II IL4R. IL4Rα-/- mice and IL-4/IL-13 double knockout 
mice showed significantly decreased fibrosis in chronic pancreatitis, indicating 
the critical role of IL4R signaling in fibrosis26. In AngII-induced hypertension,      
IL-4-/- mice exhibited significantly reduced interstitial myocardial fibrosis and 
protected left ventricle chamber dilatation27. A pro-fibrotic role for IL-4 signaling in 
cardiac remodeling is further supported by data showing that inhibition of IL-4 
with neutralizing antibodies significantly reduces cardiac fibrosis during 
transverse aortic constriction28.  
Alternative macrophage activation through IL4Rα signaling has been 
proposed as a mechanism by which IL-4 and/or IL-13 mediate tissue fibrosis17, 22, 
29, 30, and M2-like macrophages have been hypothesized as regulators of 
fibrosis29, 31. Mice lacking myeloid (monocyte/macrophage and neutrophil)-
specific IL4Rα (LysMcreIL4Rαflox/flox) were less susceptible to pancreatic fibrosis, 
and compared with wild type mice, IL4Rα-/- and LysMcreIL4Rαflox/flox mice 
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displayed similar decrease in fibrosis, which suggests the principal role of 
myeloid or probably macrophage IL4Rα in pro-fibrotic remodeling26. Moreover, 
pancreatic macrophages from both IL4Rα-/- and LysMcreIL4Rαflox/flox mice showed 
comparable and significantly decreased expression of the M2 macrophage 
marker CD206, implicating that IL4Rα deletion in myeloid cells reduces fibrosis 
likely by limiting M2 macrophage activation and polarization26. Work by the 
Sabine laboratory also showed attenuated alternative macrophage activation in 
LysMCreIL4Rαflox/- BALB/c mice in skin wound healing, and they demonstrated 
that the M2 macrophage marker Relmα (Fizz1) is critical for collagen fibril 
assembly, which further suggests an important role of myeloid-specific IL4Rα 
signaling and M2-like macrophages in adverse pro-fibrotic remodeling32.  
In addition to pro-fibrotic remodeling, IL4R signaling and IL4R signaling-
medicated M2 macrophage activation are also importantly involved in 
inflammation, although their role in inflammation in vivo is ambiguous. Both IL-4 
and IL-13 were up-regulated in hypoxic pulmonary hypertension, as well as early 
recruitment of alveolar macrophages characterize by M2 macrophage markers 
Arg1, Fizz1, chitinase-3-like protein 3 (Ym1) and CD206, all of which contributed 
to the development of pulmonary hypertension33. Schistosoma mansoni infected 
LysMCreIL4Rαflox/- mice showed massive inflammatory cell infiltration in intestine, 
associated with enhanced production of the type 1 cytokine interferon γ (IFNγ) in 
gut, supporting the anti-inflammatory role of myeloid IL4Rα signaling34. 
Furthermore, it was demonstrated that macrophages but not neutrophils 
stimulated by IL-4/IL-13 are essential for the survival in acute schistosomiasis, 
and LysMCreIL4Rαflox/- mice showed impaired M2 macrophage activation with 
reduced CD206 levels. This indicates that IL4R signaling-mediated M2 
macrophage activation protects against schistosomiasis by down-regulation of 
inflammation34. 
In this study, we generated myeloid (macrophage/monocyte and 
neutrophil)-specific IL4Rα knockout (MyIL4RαKO) mice, and then subjected them 
to AngII and high salt-induced hypertension to investigate the role of myeloid-
specific IL4Rα signaling in hypertensive injury-induced cardiovascular remodeling. 
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We hypothesized that IL4Rα signaling in myeloid cells promotes fibrosis but 
inhibits inflammation in cardiovascular remodeling by regulating M2 macrophage 
activation and polarization; therefore blocking IL4Rα signaling in myeloid cells 
may reduce cardiovascular fibrosis but enhance systemic inflammation and 
eventually result in cardiac function alterations. In order to test this hypothesis, 
we determined the hypertrophy, fibrosis, expression of inflammatory cytokines 
and ROS generation-related genes in heart and vessel (aorta), as well as cardiac 
function in hypertensive MyIL4RαKO mice to detect the effect of myeloid IL4Rα 
deficiency on cardiovascular remodeling. In addition, we performed flow 
cytometry analysis to examine macrophage polarization in injured tissues and the 
migration and recruitment of myeloid cells in order to determine of myeloid IL4Rα 
knockout induces phenotypic and functional changes in myeloid cells during 
cardiovascular remodeling.   
Materials and Methods 
Animals 
IL4Rαflox/flox mice were previously generated on a BALB/c background34. 
IL4Rαflox/flox mice were then backcrossed to a C57BL/6 background for at least 10 
generations, and further mated with LysM-Cre C57BL/6 mice (The Jackson 
Laboratory) to generate myeloid (macrophage and neutrophil)-specific IL4Rα 
knockout (MyIL4RαKO) mice. Male MyIL4RαKO (IL4Rαflox/flox; LyzMCre) mice at 
the age of 10-12 weeks were used for experiments, and their littermate floxed 
control mice (IL4Rαflox/flox, referred to as FC) were used as wild type equivalents. 
Animals of each genotype were randomly assigned to treatment (hypertension) 
and sham groups. Hypertension was induced by subcutaneously implanting 
micro-osmotic pump (Alzet, Cupertino, CA, Model 1002) into each mouse to 
infuse angiotensin II (AngII, Sigma-Aldrich, St. Louis, MO, at. A9525) at a dose of 
1.5mg/kg/day, and by feeding 4% NaCl high salt diet (Envigo, Cat. TD.03095) for 
4 weeks. The pumps were implanted twice as they only last for 2 weeks. The 
mice in sham group were also subcutaneously implanted the pumps twice but 
with saline (0.9% NaCl) and were fed with regular chow. At the end of 
experiments, mice were euthanized by isoflurane. In brief, mice were first 
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induced anesthesia by 3-4% isoflurane, once anesthesia was achieved, the 
isoflurane was increased to 5% to induce death. Mice were remained in the 
chamber for extra 3 minutes after no breath could be noticed. Afterwards 
euthanasia was further confirmed by exsanguination. All animal procedures were 
performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (8th Edition) and were approved by the Institutional Animal Care and Use 
Committee of the University of Michigan.  
Histological Analysis   
After euthanization, hearts and aortas were collected from mice following 
perfusion with PBS. The collected tissues were fixed in 4% paraformaldehyde for 
48 hours, and then processed and embedded in paraffin for histological analysis. 
Tissue blocks were cut transversely and sections (5 µm thick) were subjected to 
hematoxylin and eosin (H&E) staining. In order to measure myocyte cross-
sectional area (CSA), pictures were taken of all regions through the H&E stained 
sections using a Zeiss Axio Imager 2 microscope (Carl Zeiss, Jena, Germany). 
Myocytes with similar-sized nuclei and intact cellular membranes were outlined 
by a blinded observer, and myocyte CSA was calculated using ImageJ 1.45s 
software. The average myocyte CSA was calculated from approximately 200 
myocytes per heart. To determine wall thickness and medial area of aorta, digital 
images of H&E stained aorta cross sections were also obtained from the Zeiss 
Axio Imager 2 microscope. Similar to what was shown before35, perpendicular 
lines were drawn from internal elastic lamina to the external lamina at a minimum 
of ten locations of the aorta section to measure the distance, and average 
distance was calculated as wall thickness of aorta. For medial area of aorta, the 
internal and external perimeters of elastic laminas were traced and the area 
between those two perimeters was quantified and reported as the aortic medial 
wall area. All measurements were performed using ImageJ 1.45s software.  
Fibrosis Evaluation  
Hearts, aortas and kidneys were harvested from euthanized mice after 
perfusion, and fixed in 4% paraformaldehyde for 48 hours, and then processed 
and embedded in paraffin to make tissue blocks. Tissue sections (5 µm thick) 
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were then transversely cut from the blocks and subjected to picrosirius red (PSR) 
staining for further fibrosis determination. To quantify fibrosis, pictures were 
taken of all regions through each section using a Zeiss Axio Imager 2 microscope 
(Carl Zeiss, Jena, Germany). For fibrosis in heart sections, cardiac interstitial 
fibrosis and cardiac perivascular fibrosis were measured separately. To measure 
interstitial fibrosis, the red-stained interstitial area (fibrotic area) and the area of 
cardiomyocytes were traced respectively and quantified using ImageJ 1.45s, and 
the percentage of fibrotic area was calculated as: area of fibrosis/(area of 
cardiomyocytes + area of fibrosis) x 100%36. To measure cardiac perivascular 
fibrosis, all vessels across the section were traced and the area that was 
positively stained and immediately surrounding the intramyocardial vessel was 
considered perivascular fibrotic area, and perivascular fibrosis was calculated as 
the ratio between perivascular fibrotic area and luminal media area37. Fibrosis in 
aorta was expressed as the ratio between the red-stained collagen area in aorta 
and the total area of aorta including tunica intima, tunica media and tunica 
adventitia. For kidneys, glomerular, tubulointerstitial and perivascular fibrosis 
were analyzed respectively. All glomeruli (matrix, cells, capillary loops and space 
surrounding glomerular segments) across the kidney section were included, and 
glomerular fibrosis was calculated as: PSR positively stained area/ glomerular 
area x 100%38, while the tubunointerstitial fibrosis was expressed as the ratio 
between PSR positively stained area and total area. In order to determine the 
perivascular fibrosis in kidney, all intraparenchimal vessels with a diameter of ≤ 
100um across the section were taken into account, and the fibrosis was 
calculated as: collagen area surrounding the vessel/ luminal media area x 100%.  
Gene Expression Analysis 
Relative mRNA expression was determined using quantitative reverse 
transcription–polymerase chain reaction (qRT-PCR). Total RNA was extracted 
using TRIzol reagent and RNA (1 µg) was reverse transcribed to cDNA with a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Quantitative polymerase chain reaction (qPCR) was performed using a 7900HT 
fast real-time PCR system (Applied Biosystems) and relative mRNA expression 
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was analyzed using the comparative method and normalized to the internal 
control L32.  All qPCR primers are listed in Table 3.1.  
 
Table 3.1. Sequences of primers used in chapter III. The primers were 
synthesized by Integrated DNA Technologies. L32, 60S ribosomal protein L32, 
was used as internal control. 
 
Echocardiography 
Mice were anesthetized with isoflurane, and echocardiography was 
performed using a Vevo 2100 Micro-Imaging System (VisualSonics Inc.) with a 
18-38-MHz linear array ultrasound transducer. LV ejection fraction was 
determined by the two-dimensional long axis view.  Ejection fraction and 
fractional shortening were calculated based on the M-mode parasternal short 
axis view. Systolic and diastolic dimensions and the LV wall thickness were 
determined by M-mode in the parasternal short axis view at the level of the 
papillary muscles. Diastolic function was measured by conventional pulsed-wave 
Gene  Forward Reverse 
ANP GCTTCCAGGCCATATTGGAG GGGGGCATGACCTCATCTT 
Arg1 ACCTGGCCTTTGTTGATGTCCCTA  AGAGATGCTTCCAACTGCCAGACT  
BMP9 CAGAACTGGGAACAAGCATCC GCCGCTGAGGTTTAGGCTG 
BNP ATGGATCTCCTGAAGGTGCTG GTGCTGCCTTGAGACCGAA  
Col1A1 GCTCCTCTTAGGGGCCACT  CCACGTCTCACCATTGGGG  
Col3A1 CCTGGCTCAAATGGCTCAC  CAGGACTGCCGTTATTCCCG  
Fizz1 ACTGCCTGTGCTTACTCGTTGACT AAAGCTGGGTTCTCCACCTCTTCA  
Gal3 GGAGAGGGAATGATGTTGCCT TCCTGCTTCGTGTTACACACA 
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
IL-1β AAGAGCTTCAGGCAGGCAGTATCA  TGCAGCTGTCTAATGGGAACGTCA  
L32       TTAAGCGAAACTGGCGGAAAC TTGTTGCTCCCATAACCGATG 
MMP2 CAAGTTCCCCGGCGATGTC TTCTGGTCAAGGTCACCTGTC 
MMP8 TCTTCCTCCACACACAGCTTG CTGCAACCATCGTGGCATTC 
MMP9 GGACCCGAAGCGGACATTG CGTCGTCGAAATGGGCATCT   
MMP12 AATGCTGCAGCCCCAAGGAAT CTGGGCAACTGGACAACTCAACTC 
MMP13 CTTCTTCTTGTTGAGCTGGACTC CTGTGGAGGTCACTGTAGACT 
Nox1 GGTGGTCACGGAGTTAAAAACA TCGGCATCCATTGGGGTCT 
Nox4 ACTTTTCATTGGGCGTCCTC AGAACTGGGTCCACAGCAGA 
p22phox TGCCAGTGTGATCTATCTGCT TCGGCTTCTTTCGGACCTCT 
p47phox ACACCTTCATTCGCCATATTGC TCGGTGAATTTTCTGTAGACCAC 
PAI-1 GCTTGGCAACCCACGTTAAAGGAA    ACAGCAGCCGGAAATGACACATTG    
PDGFα GAGGAAGCCGAGATACCCC  TGCTGTGGATCTGACTTCGAG 
TGFβ1 CTCCCGTGGCTTCTAGTGC GCCTTAGTTTGGACAGGATCTG 
TIMP1 CCTAGAGACACACCAGAGCA TACCGGATATCTGCGGCATT 
TIMP2 GGCAACCCCATCAAGAGGA CCTTCTGCCTTTCCTGCAATTAG 
Timp3 CTTCTGCAACTCCGACATCGT  GGGGCATCTTACTGAAGCCTC  
TNFα CCCTCACACTCAGATCATCTTCT  GCTACGACGTGGGCTACAG  
Ym1 CACCATGGCCAAGCTCATTCTTGT  TATTGGCCTGTCCTTAGCCCAACT  
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spectral Doppler analysis of mitral valve inflow patterns. The early diastolic tissue 
velocities of the septal and lateral annuluses of the mitral valve were measured 
by Doppler tissue imaging with the apical 4-chamber view.  
Flow Cytometric Analysis 
Preparation of single cell suspensions: after euthanization, whole blood 
was collected in a heparinized blood collection tube (BD Vacutainer, Ref 
367871), and then 100ul blood was subjected to red blood cell (RBC) lysis with 
the diluted 1X RBC lysis buffer (Biolegend, Cat 420301). After the RBC lysis, 
peripheral blood single cell suspension was ready for further procedures. Organs 
including spleen, heart and aorta39 were harvested from the euthanized mice 
after perfusion via left ventricle by 5ml of 2mM EDTA buffer and 2x10ml PBS. 
Single cell suspension from spleen was obtained by trituation followed by RBC 
lysis. Single cell suspensions from heart and aorta were achieved by mincing 
hearts and aortas into small pieces followed by digestion with a cocktail of 450 
U/ml collagenase I (Worthington, Lakewood, NJ), 125 U/ml collagenase XI 
(Worthington, Lakewood, NJ), 60 U/ml DNase I and 60 U/ml hyaluronidase 
(Worthington, Lakewood, NJ) for 1 h at 37°C while agitating. The number of total 
viable cells was counted using Trypan Blue (Gibco, Ref 15250-061).  
Cells were then blocked by incubating with anti-CD16/32 (Biolegend, San 
Diego, CA, Cat. 101302) for 5 min on ice. Antibodies including: anti-CD45-
PerCP/Cy5.5 (Biolegend, San Diego, CA, Cat 103131), anti-CD45-PE/Cy7 
(Biolegend, San Diego, CA, Cat 103113), anti-CD45-Pacific Blue™ (Biolegend, 
San Diego, CA, Cat 103126), anti-CD3-APC (Biolegend, San Diego, CA, Cat 
100236), anti-CD11b-Brilliant Violet 605TM (Biolegend, San Diego, CA, Cat 
101257), anti-Ly6G-FITC (Biolegend, San Diego, CA, Cat 127606), anti-Ly6C-
PerCP/Cy5.5 (Biolegend, San Diego, CA, Cat 128011), anti-F4/80-PE 
(Biolegend, San Diego, CA, Cat 123110), anti-CD206-Alexa Fluor® 488 
(Biolegend, San Diego, CA, Cat 141710), anti-TNFα-PE/DazzleTM 594 
(Biolegend, San Diego, CA, Cat 506345) were used for flow cytometric analysis 
in this study. T cells were identified as CD45+CD3+CD11b-Ly6G- Ly6C- in blood 
and spleen, and were identified as CD45+CD3+CD11b-Ly6G- F4/80- in heart and 
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aorta. Neutrophils were identified as CD45+CD3-CD11b+Ly6G+Ly6C- in blood and 
spleen, and CD45+CD3-CD11b+Ly6G+F4/80- in heart and aorta. Monocytes were 
identified as CD45+CD3-CD11b+Ly6G- Ly6C+, and within the monocyte 
population, monocytes were further divided into Ly6Chigh and Ly6Clow monocytes 
based on the expression of Ly6C. Macrophages were identified as CD45+CD3-
CD11b+Ly6G-F4/80+, and within the macrophage population, macrophages were 
further divided into M1-like macrophages (CD206-TNFα+) and M2-like 
macrophages (CD206+TNFα-). Cells were incubated with indicated antibodies on 
ice (light protected) for 30 min without permeabilization except anti-TNFα-
PE/DazzleTM 594. Until after fixation and permeabilization (eBioscience, Cat 88-
8824), cells were incubation with anti-TNFα-PE/DazzleTM 594 for 30 min on ice. 
Flow cytometry was performed using a BD LSRFortessa™ flow cytometer (BD 
Biosciences) and data were analyzed using FlowJo V10.1 software. For 
calculation of total cell numbers in heart and aorta, normalization to weight of 
indicated tissues was performed. The total cell number of each population was 
calculated by multiplying the total cell number by the percentage of each cell 
population within the gate.  
Statistical analysis 
Results are presented as mean ± SEM. For statistical analysis, one-way 
ANOVA, and unpaired, two-tailed Student’s t test were used. All statistical 
analysis of data was performed in GraphPad Prism (version 6; GraphPad 
Software, Inc). P < 0.05 was considered significant.  
Results 
Myeloid IL4Rα signaling has no impact on cardiovascular hypertrophy 
AngII infusion and high salt diet has been used as an experimental model 
for hypertension40, 41, so we exposed myeloid-specific IL4Rα knockout 
(MyIL4RαKO, LysMCreIL4Rαflox/flox) mice and the floxed control mice (FC, 
IL4Rαflox/flox) to AngII and high salt to induce hypertensive cardiovascular injury. 
As shown in Figure. 3.1A, the systolic blood pressure of both FC and 
MyIL4RαKO mice were significantly increased in response to AngII and high salt, 
although there was no significant difference between FC and MyIL4RαKO mice, 
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Figure 3.1. Myeloid-specific IL4Rα knockout does has no effect on 
cardiovascular hypertrophy. (A) The systolic blood pressure of sham mice and 
mice subjected to AngII and high salt (n=5-6) was determined. The heart weight to 
body weight ratio (HW/BW, n=20-24) and heart weight to tibia length ratio (HW/TL, 
n=17-25), and the cardiomyocyte cross-sectional area were measured to determine 
the cardiac hypertrophy of sham mice and mice after AngII and high salt treatment. 
Representative images of hematoxylin and eosin (H&E) stained heart sections to 
show the size of cardiomyocytes (n=7-9). The mRNA level of fetal genes ANP and 
BNP in hearts of sham and AngII and high salt-treated mice was determined by 
qRT-PCR (n=5-9). (B) Representative pictures of H&E stained aorta sections, and 
the wall thickness and medial area of aorta were measured to determine the aortic 
hypertrophy (n=5-9). Results are shown as means ± SEM. Unpaired student’s t test 
and one-way ANOVA were used for statistical analysis. **P <0.01; ***P <0.001; ****P 
< 0.0001.  
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which suggests that myeloid IL4Rα does not control blood pressure.  
As hypertrophy is one of the most important events in cardiovascular 
remodeling induced by hypertension, we determined both cardiac and vascular 
hypertrophy. Heart weight to body weight ratio (HW/BW) and heart weight to tibia 
length ratio (HW/TL), and the size of cardiomyocytes were measured. HW/BW, 
HW/TL (Figure. 3.1A), and cardiomyocyte size shown as myocyte cross-sectional 
area (Figure. 3.1A) were significantly increased in mice exposed to AngII and 
high salt, however no difference was shown between FC and MyIL4RaKO mice, 
which suggests that myeloid IL4Rα signaling is not involved in hypertrophic 
cardiac remodeling. This is further supported by the expression of hypertrophy-
induced fetal genes atrial natriuretic peptide  (ANP) and brain natriuretic peptide 
(BNP) expression at mRNA level, which exhibited significant increase after AngII 
and high salt, but no difference between hypertensive FC and MyIL4RaKO mice 
(Figure. 3.1B). Of note, the expression of BNP mRNA was significantly increased 
in heart of sham MyIL4RαKO mice (Figure. 3.1B), and this is consistent with what 
was found in the acute myocardial infarction model showing higher basal level 
BNP mRNA in sham MyIL4RαKO mice (Figure. 2.3C).  
Vascular hypertrophy was analyzed by measuring the wall thickness and 
medial area of aorta. Compared with the sham mice, mice treated by AngII and 
high salt displayed significant increase in aortic wall thickness and aortic medial 
area (Figure. 3.1B), but similar to the cardiac hypertrophy, there was no obvious 
difference between FC and MyIL4RαKO mice, indicating the comparable 
hypertrophic remodeling in aorta. Taken together, all results above indicate that 
AngII and high salt can successfully induce hypertension, cardiac hypertrophy 
and vascular hypertrophy, however IL4Rα signaling in myeloid cells does not 
contribute to either blood pressure or hypertrophic cardiovascular remodeling.  
Myeloid IL4Rα signaling contributes to pro-fibrotic remodeling  
IL-4 signaling has been shown to promote fibrosis26, 32, so we 
hypothesized that knockout of IL4Rα in myeloid cells suppresses cardiovascular 
fibrotic remodeling induced by AngII and high salt. To test this hypothesis, we 
analyzed the fibrosis in heart and aorta by picrosirius red staining, and quantified 
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the percentage of fibrotic areas. As shown in Figure. 3.2A, fibrosis was 
distinctively induced in aorta of hypertensive mice, and more importantly, 
hypertensive MyIL4RαKO mice showed significantly less fibrosis than 
hypertensive FC mice. As well as aorta, both cardiac interstitial and perivascular 
fibrosis were substantially induced by AngII and high salt, and compared with FC 
mice, the interstitial and perivascular fibrosis in heart of MyIL4RαKO mice were 
considerably decreased (Figure. 3.2B). The interstitial fibrosis in heart of 
MyIL4RαKO mice was only half of that in FC mice (Figure. 3.2B). These results 
strongly indicate that IL4Rα signaling in myeloid cells contributes to pro-fibrotic 
cardiovascular remodeling induced by hypertension.  
Prolonged hypertension also causes end organ damage in kidney42-46, 
which is associated with progressive fibrosis, so we also determined the fibrosis 
in kidney based on picrosirius red staining. The glomerular, tubulointerstitial and 
perivascular fibrotic areas were traced separately and the percentage of fibrotic 
areas in each region was calculated. AngII and high salt induced considerably 
increase in glomerular, tubulointerstitial and perivascular fibrosis, and the fibrosis 
in all three regions was significantly decreased when IL4Rα was ablated in 
myeloid cells (Figure. 3.3). The tubulointerstitial fibrosis in kidney of MyIL4RαKO 
mice was even comparable to the basal level (Figure. 3.3).  
In conclusion, these results suggest that myeloid IL4Rα signaling critically 
contributes to a systemic pro-fibrotic remodeling in a variety of organs after 
hypertensive injury, and blocking IL4Rα signaling in myeloid cells can protect 
heart and vasculature from adverse fibrotic remodeling and ameliorate kidney 
damage.  
Signaling pathways mediating the decreased fibrosis in MyIL4RαKO mice 
Accumulation of collagen in extracellular matrix (ECM), and ECM 
degradation by matrix metalloproteinases (MMPs) regulate the fibrotic 
cardiovascular remodeling 47, 48. Increase of collagen synthesis, decrease in the 
activity of MMPs but increase of tissue inhibitors of metalloproteinases (TIMPs) 
result in the accumulation of collagen. In order to investigate whether the fibrosis  
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Figure 3.2. IL4Rα deficiency in myeloid cells decreases fibrosis in aorta and 
heart. (A) Representative images of picrosirius red stained aorta sections to show 
the fibrosis (red) in aorta, and the percentage of fibrotic areas in the whole section 
was quantified in sham and AngII and high salt-induced hypertensive mice (n=9-14). 
(B) Representative pictures of picrosirius red stained interstitial and perivascular 
region of heart to display the cardiac interstitial and perivascular fibrosis (red) 
induced by AngII and high salt, and the quantification of interstitial and perivascular 
fibrosis in heart. Sham mice: n=6; AngII and high salt-treated mice: n=17. Results 
are shown as means ± SEM. Unpaired student’s t test and one-way ANOVA were 
used for statistical analysis. *P <0.05; **P <0.01; ***P <0.001; ****P < 0.0001.  
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Figure 3.3. IL4Rα deficiency in myeloid cells decreases fibrosis in kidney. 
Representative images of glomerular, tubulointerstitial and perivascular region of 
picrosirius red stained kidney after exposure to AngII and high salt and the 
quantification of glomerular, tubulointerstitial and perivascular fibrosis in kidney 
based on the picrosirius red staining in kidney. Sham mice: n=5-6; AngII and high 
salt-treated mice: n=13-14. Results are shown as means ± SEM. Unpaired student’s 
t test and one-way ANOVA were used for statistical analysis. *P <0.05; **P <0.01; 
***P <0.001; ****P < 0.0001.  
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reduction in MyIL4RαKO mice attribute to the expression changes of collagens, 
MMPs and TIMPs, we determined the mRNA level of collagen 1A1 (Col1A1), 
collagen 3A1 (Col3A1), MMP2, MMP8, MMP9, MMP12, MMP13, TIMP1, TIMP2 
and TIMP3 by qRT-PCR.  
In heart tissues, both Col1A1 and Col3A1 were significantly up-regulated 
by AngII and high salt, but only Col3A1 mRNA showed significant decrease as a 
result of IL4Rα deficiency in myeloid cells (Figure. 3.4). The expression of MMPs 
varies, MMP2 showed significant increase after exposing to AngII and high salt, 
while MMP9 and MMP13 exhibited significant decrease, and no change was 
noticed in MMP8 and MMP12 (Figure. 3.4). No significant differences were 
shown between FC and MyIL4RαKO mice in the expression of MMPs except 
MMP13 with dramatic increase in MyIL4RαKO mice (Figure. 3.4). The mRNA 
level of TIMP1 was up-regulated by AngII and high salt, but not TIMP2 and 
TIMP3, and there was no change induced by the knockout of myeloid IL4Rα 
(Figure. 3.4). Taken together, the decreased fibrosis in heart of MyIL4RαKO mice 
attributes at least partially to the decreased expression of Col3A1 and increase in 
MMP13.  
Regarding the signaling pathways through which AngII and high salt 
induces fibrosis, both TGFβ-dependent and -independent signaling are 
involved49. PDGFα is one of the downstream mediators in TGFβ signaling 
pathway to promote fibrosis50, 51, as well as plasminogen activator inhibitor-1 
(PAI-1, or serpin E1)52, which is a serine protease inhibitor (serpin) that functions 
as the principal inhibitor of tissue-type plasminogen activator (t-PA) and 
urokinase-type plasminogen activator (u-PA), the activators of plasminogen and 
hence fibrin degradation52, 53. AngII/galectin3 (Gal3)/IL-6 axis is one of the TGFβ-
independent signaling pathways that facilitate fibrosis in cardiovascular 
remodeling54, 55. Genetically ablate IL-6 or Gal3, or pharmacologically neutralize 
IL-6 or block Gal3 reduces hypertension-related fibrosis13, 14, 56. Another TGFβ-
independent signaling bone morphogenetic protein 9 (BMP9) pathway has been 
recently identified as a novel anti-fibrotic pathway in a pressure overload 
hypertension model57. 
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Figure 3.4. The fibrosis-related genes contributing to cardiac fibrosis 
decrease in MyIL4RαKO mice. The expression of collagens including Col1A1 and 
Col3A1 (n=11-18), matrix metalloproteinases (MMPs) including MMP2 (n=12-14), 
MMP8 (n=6-7), MMP9 (n=12-14), MMP12 (n=6-7) and MMP13 (n=13-14), tissue 
inhibitor of metalloproteinases (TIMPs) including TIMP1, TIMP2 and TIMP3 (n=6-7) 
and genes included in the fibrosis signaling pathways TGFβ1 (n=12-13), PDGFα 
(n=5-7), PAI-1 (n=12-14), Gal3 (n=12-14), and BMP9 (n=12-14) at mRNA level was 
determined in heart tissues of sham and AngII and high salt-induced hypertensive 
mice. Results are shown as means ± SEM. Unpaired student’s t test and one-way 
ANOVA were used for statistical analysis. *P <0.05; **P <0.01; ***P <0.001; ****P < 
0.0001. 
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Based on the known pathways contributing to AngII and high salt-induced 
fibrotic remodeling, we determined the mRNA level of TGFβ1, PDGFα, PAI-1, 
Gal3 and BMP9 in order to identify the signaling pathways that are responsible 
for the fibrosis decrease resulted from myeloid-specific IL4Rα deficiency. In heart 
tissues, TGFβ1 did not show any difference upon AngII and high salt, neither 
between FC and MyIL4RαKO mice (Figure. 3.4). PDGFα, PAI-1 and Gal3 all 
displayed significant increase after AngII and high salt, and more importantly, all 
of them showed significant decrease as a result of IL4Rα ablation in myeloid cells 
(Figure. 3.4). As BMP9 limits cardiac fibrosis, BMP9 mRNA in heart was 
significantly reduced in response to AngII and high salt, furthermore, compared 
with hypertensive FC mice, hypertensive MyIL4RαKO mice exhibited significantly 
increased BMP9 mRNA (Figure. 3.4). In conclusion, instead of a single signaling 
pathway, TGFβ signaling via the decrease of PDGFα and PAI-1, Gal3 signaling 
with reduced Gal3, and BMP9 signaling with increased BMP9 mRNA 
cooperatively mediate the cardiac fibrosis decrease induced by myeloid IL4Rα 
deletion. This suggests that the reduced cardiac fibrosis because of IL4Rα 
deficiency in myeloid cells is rather a systemic change caused by multiple 
signaling pathways.   
In contrast to the gene expression in heart, both collagens (Col1A1 and 
Col3A1), all MMPs (MMP2, MMP8, MMP12 and MMP13) except MMP9, and all 
TIMPs (TIMP1, TIMP2 and TIMP3) in aorta were dramatically increased by AngII 
and high salt at mRNA level, however none of them showed any difference 
between FC and MyIL4RαKO mice (Figure. 3.5), suggesting the different 
mechanism contributing to cardiac or vascular fibrosis decrease.  In terms of the 
signaling pathways involved in fibrosis induced by hypertension, the mRNA level 
of TGFβ1, PDGFα, PAI-1, Gal3 and BMP9 all showed significant increase in 
aorta in response to AngII and high salt, however none of these genes showed 
any difference between hypertensive FC and MyIL4RαKO mice except PAI-1 
(Figure. 3.5). PAI-1 mRNA, instead of the expected decrease in hypertensive 
MyIL4RαKO mice based on fibrosis quantification in aorta, it surprisingly showed 
significant increase compared with hypertensive FC mice (Figure. 3.5). This is  
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Figure 3.5. The fibrosis-related genes contributing to aortic fibrosis decrease 
in MyIL4RαKO mice. The expression of collagens including Col1A1 and Col3A1 
(n=12-15), matrix metalloproteinases (MMPs) including MMP2 (n=12-20), MMP8 
(n=12-14), MMP9 (n=13-20), MMP12 (n=5-8) and MMP13 (n=12-19), tissue inhibitor 
of metalloproteinases (TIMPs) including TIMP1 (n=5-8), TIMP2 (n=5-8) and TIMP3 
(n=13-14) and genes included in the fibrosis signaling pathways TGFβ1 (n=12-16), 
PDGFα (n=6-8), PAI-1 (n=14), Gal3 (n=12-13), and BMP9 (n=14) at mRNA level 
was determined in aorta tissues of sham and AngII and high salt-induced 
hypertensive mice. Results are shown as means ± SEM. Unpaired student’s t test 
and one-way ANOVA were used for statistical analysis. *P <0.05; **P <0.01; ***P 
<0.001; ****P < 0.0001. 
	 102 
consistent with the substantial fibrotic up-regulation in PAI-1 null mice58, but 
contrary to the pro-fibrotic role of PAI-159, 60, which suggests the plastic role of 
PAI-1 depending on specific context. The increased PAI-1 mRNA in aorta of 
MyIL4RαKO mice is also opposite to what was shown in heart tissues (Figure. 
3.4), which again suggests the different mechanism of fibrotic remodeling in heart 
and aorta, although the exact mechanism in aorta is not clear yet. 
It’s also noteworthy that a lot fibrosis-related genes including Col1A1, 
MMP2, MMP8, PDGFα, PAI-1, Gal3 and BMP9 in aorta revealed a significant 
change at basal level between FC and MyIL4RαKO mice although not after 
hypertension induction (Figure. 3.5), which strongly suggests a different role of 
myeloid IL4Rα signaling at steady state and in the AngII and high salt-induced 
inflammatory state in fibrotic remodeling. Moreover, as most pro-fibrotic genes 
showed higher mRNA level in MyIL4RαKO mice at basal level, which probably 
suggests higher baseline inflammation as a result of the inactivation of anti-
inflammatory IL4Rα signaling in myeloid cells.  
IL4Rα deficiency in myeloid cells increases ROS-related genes expression  
In addition to fibrosis, hypertension also elicits up-regulation of low-grade 
systemic inflammation and oxidative stress, the pathophysiological events that 
promote the transition of hypertension to cardiovascular diseases.  
In order to investigate whether the ablation of IL4Rα in myeloid cells 
enhances inflammation induced by AngII and high salt, we measured the mRNA 
level of inflammatory cytokines including TNFα, IL-1β, and IL-6 in heart and 
aorta. As shown in Figure. 3.6, TNFα, IL-1β and IL-6 mRNA were all significantly 
increased by AngII and high salt, indicating the increased inflammation in 
hypertensive mice, however, no difference was caused by the knockout of IL4Rα 
in myeloid cells except IL-6 mRNA in aorta, suggesting that myeloid IL4Rα 
signaling might have no effect on the expression of hypertension-induced 
inflammatory cytokines. The reduction of IL-6 mRNA in aorta of MyIL4RαKO 
mice (Figure. 3.6) may contribute to the decreased fibrosis as IL-6 is involved in 
the AngII/Gal3/IL-6 axis that regulates fibrosis13, 14, 54-56. Although no difference 
was shown between hypertensive FC and MyIL4RαKO mice in heart, sham  
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Figure 3.6. The mRNA expression of inflammatory cytokines in heart and 
aorta. The mRNA level of inflammatory cytokines TNFα, IL-1β and IL-6 was 
measured in heart (n=11-17) and aorta (n=11-20) of sham mice and mice subjected 
to AngII and high salt. Results are shown as means ± SEM. Unpaired student’s t test 
and one-way ANOVA were used for statistical analysis. *P <0.05; **P <0.01; ***P 
<0.001; ****P < 0.0001.  
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MyIL4RαKO mice displayed significant increase of IL-1β and IL-6 mRNA in heart 
compared with sham FC mice (Figure. 3.6). This is consistent with what was 
shown in the acute myocardial infarction model (Figure 2.1B), which probably 
suggests the aggravated inflammation at baseline caused by deficiency of IL4Rα 
in myeloid cells. 
Oxidative stress plays an important role in inflammation. In order to detect 
whether deletion of IL4Rα in myeloid cells enhances inflammation by up-
regulating oxidative stress, we measured the mRNA level of ROS generation-
related genes including p22phox, p47phox, Nox1 and Nox4 by qRT-PCR. In 
heart tissues, the expression of p47phox, Nox1 and Nox4 were all significantly 
increased in hypertensive mice except p22phox, however no difference was 
detected between hypertensive FC and MyIL4RaKO mice (Figure. 3.7). 
However, both Nox1 and Nox4 exhibited significant increase at basal level of 
MyIL4RαKO compared with sham FC mice, what’s more, the Nox1 mRNA at 
basal level was even comparable to that induced by hypertension in MyIL4RαKO 
mice (Figure. 3.7), indicating the relatively exacerbated oxidative stress caused 
by IL4Rα deletion in myeloid cells. In aorta tissues, p22phox, p47phox and Nox4 
mRNA were significantly up-regulated by AngII and high salt, and more 
importantly they displayed significant increase in hypertensive MyIL4RαKO mice 
compared with hypertensive FC mice (Figure. 3.7), which suggests probably 
higher oxidative stress caused by IL4Rα ablation in myeloid cells. Moreover, 
Nox1 and Nox4 also showed significantly higher mRNA level in MyIL4RαKO mice 
at basal level than sham FC mice (Figure. 3.7), which also suggests probably 
higher basal level ROS in MyIL4RαKO mice.  
Taken together, ROS generation related genes revealed significant 
increase as a result of IL4Rα ablation in myeloid cells, suggesting the possible 
more ROS generation and higher oxidative stress, which in turn may result in 
aggravated inflammation. In conclusion, myeloid-specific IL4Rα signaling is also 
involved in inflammatory regulation by modulating the expression of ROS 
generation related genes and hence oxidative stress.  
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Figure 3.7. Myeloid-specific IL4Rα deletion induces increase of ROS 
generation-related genes mRNA expression. The mRNA expression of ROS 
generation-related genes: p22phox, p47phox, Nox1 and Nox4 was determined by 
qRT-PCR in hearts (n=15-20) and aortas (n=11-20) of sham mice and AngII and 
high salt-treated mice. Results are shown as means ± SEM. Unpaired student’s t 
test and one-way ANOVA were used for statistical analysis. *P <0.05; **P <0.01; 
***P <0.001; ****P < 0.0001.  
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Myeloid-specific IL4Rα knockout preserves cardiac function in response to 
AngII and high salt 
In order to clarify the overall impact of the myeloid-specific IL4Rα 
knockout, after charactering its effect on fibrosis and inflammation, cardiac 
function was determined by echocardiography.  
The ejection fraction of FC mice was significantly impaired by AngII and 
high salt, but MyIL4RαKO mice did not show any significant change with 
comparable ejection fraction of the sham mice (Figure. 3.8), indicating the 
preserved ejection fraction by IL4Rα deficiency in myeloid cells. Similarly, systole 
and diastole left ventricle internal diameter (LVID) were also preserved in 
hypertensive MyIL4RαKO mice, while significantly increased in hypertensive FC 
mice (Figure. 3.8), which supports the suggestive protection of cardiac function 
by IL4Rα deficiency in myeloid cells. In addition, compared with hypertensive FC 
mice, hypertensive MyIL4RαKO mice showed significant decrease in systole left 
ventricle area and left ventricle volume (Figure. 3.8), which indicates a stronger 
potential of cardiac contraction of MyIL4RαKO mice. In addition to left ventricle, 
MyIL4RαKO mice also displayed a protective role in the function of aorta. 
Compared with hypertensive FC mice, aorta velocity peak gradient was 
significantly increased in hypertensive MyIL4RαKO mice, which was even 
comparable to that of sham mice (Figure. 3.8). Ascending aorta diameter was 
also preserved in hypertensive MyIL4RaKO mice while that of hypertensive FC 
mice was significantly increased (Figure. 3.8).  
In conclusion, hypertensive MyIL4RαKO mice showed relatively improved 
cardiovascular function compared with the hypertensive FC mice, which basically 
indicates a overall protective role of myeloid-specific IL4Rα knockout by 
balancing the effect on fibrosis and inflammation.  
Myeloid-specific IL4Rα deletion does not change M2 macrophage 
polarization 
IL-4 or IL4R signaling regulates fibrosis through controlling the M2 
macrophages polarization26. In our study, knockout of IL4Rα in myeloid cells 
caused decreased fibrosis, so we hypothesized that this may through its down- 
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Figure 3.8. Myeloid IL4Rα deficiency helps to preserve cardiac function after 
AngII and high salt treatment. Cardiac function was analyzed in sham and AngII 
and high salt-induced hypertensive mice by echocardiography. Quantitative 
evaluation of echocardiography data including ejection fraction (EF), systole left 
ventricle area (LV area, s) and systole left volume (LV Vol, s), systole and diastole 
left ventricular internal diameter (LVIDs and LVIDd), aorta velocity peak gradient (Ao 
Peak Vel) and ascending aorta diameter (Asd Aorta Diam) were shown. n=6-8. 
Results are shown as means ± SEM. Unpaired student’s t test and one-way ANOVA 
were used for statistical analysis. *P <0.05; **P <0.01; ***P <0.001; ****P < 0.0001.  
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regulation of M2 macrophage activation. In order to test this hypothesis, we first 
measured the mRNA level of M2 macrophage markers in heart and aorta. 
Unexpectedly, no significant difference was shown between hypertensive FC and 
MyIL4RαKO mice in the mRNA level of M2 macrophage markers including Arg1, 
Fizz1 and Ym1 (Figure. 3.9), which suggests that myeloid IL4Rα deletion might 
not change M2 macrophages polarization at least in our model. It should be 
pointed out that, compared with sham FC mice, Arg1 showed significant 
decrease while Fizz1 showed significant increase in hearts of sham MyIL4RαKO 
mice (Figure. 3.9), which is consistent with the results in acute myocardial 
infarction model (Figure. 2.1B), strongly suggesting the control of macrophages 
at steady state by IL4Rα.   
As the gene expression of M2 macrophage markers were examined in 
heart and aorta tissues that consist of a wide range of cell types rather than 
macrophages only, the gene expression in non-macrophages may interfere with 
their expression profile in macrophages, which cannot truly manifest the M2 
macrophage polarization change caused by IL4Rα knockout. In order to 
specifically investigate the M2 macrophage polarization, flow cytometry analysis 
was performed to determine the M2-like macrophage population in heart. M1-like 
and M2-like macrophages were gated from CD11b+F4/80+ macrophages and 
characterized as TNFα+CD206- and TNFα-CD206+ respectively. As shown in 
Figure. 3.10, the percentage of M1-like (TNFα+CD206-) or M2-like (TNFα-
CD206+) macrophages was similar between FC and MyIL4RαKO mice as well as 
their cell numbers, although AngII and high salt induced a significant infiltration of 
both M1- and M2-like macrophages, which indicates that IL4Rα signaling 
inactivation in macrophages does not change the M2 macrophage polarization in 
vivo. In order to test whether IL4Rα signaling is involved in the regulation of 
macrophage recruitment, we examined macrophages in heart of sham and 
hypertensive mice. Both the percentage of macrophages in total leukocytes and 
the macrophage cell number were significantly increased upon AngII and high 
salt (Figure. 3.11), indicating the migration and infiltration of macrophages into 
hearts after hypertension, however, no significant change was shown between  
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Figure 3.9. The mRNA level of M2 macrophage markers in heart and aorta. The 
expression of M2 macrophage markers including Arg1, Fizz1 and Ym1 at mRNA 
level was determined in heart (n=9-17) and aorta (n=5-20) tissues of sham mice and 
mice exposed to AngII and high salt. Results are shown as means ± SEM. Unpaired 
student’s t test and one-way ANOVA were used for statistical analysis. *P <0.05; **P 
<0.01; ***P <0.001; ****P < 0.0001. 
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Figure 3.10. IL4Rα knockout does not change macrophage polarization in 
vivo. Representative FACS dot plots of M1-like (CD206-TNFα+) and M2-like 
macrophages (CD206+TNFα-) gated from macrophages and the quantification of the 
percentage of M1-like and M2-like macrophages in total macrophages and their cell 
number. All cell numbers are expressed per milligram tissue. n=5. Results are 
shown as means ± SEM. Unpaired student’s t test and one-way ANOVA were used 
for statistical analysis. **P <0.01; ****P < 0.0001.  
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FC and MyIL4RαKO mice (Figure. 3.11), suggesting that IL4Rα signaling 
inactivation in myeloid cells in vivo has no effect on macrophage recruitment 
either.  
As, in addition to macrophages, myeloid cells also include neutrophils that 
have IL4Rα deleted in MyIL4RαKO mice, it’s worth determining whether IL4Rα 
controls neutrophil infiltration into the heart. Like macrophages, neither the 
percentage of neutrophils in total leukocytes nor their number showed any 
change caused by IL4Rα deficiency (Figure. 3.12), suggesting that IL4Rα 
signaling in neutrophils does not affect their migration into the heart upon 
inflammation. This is consistent with the results from Eming lab, who reported no 
difference between IL4Rαflox/flox and LysMCreIL4Rαflox/- mice in the number of 
Ly6G+ cells in skin wound tissues32. No change was even shown in neutrophils 
as a result of AngII and high salt (Figure. 3.12), which may suggest that AngII 
and high salt does not significantly induce cardiac neutrophil infiltration or at least 
not at the time of examination.  
T cells are known importantly involved in AngII-induced hypertension and 
inflammation, so we were curious whether deletion of IL4Rα in myeloid cells 
changes T cells infiltration via the regulation of inflammation by IL4Rα signaling. 
We then quantified T cell population in heart tissues by flow cytometry. No 
change in the cell number of T cells was shown in response to AngII and high 
salt or as a result of IL4Rα deficiency in myeloid cells (Figure. 3.12), however, 
the percentage of T cells in total leukocytes in heart was decreased after AngII 
and high salt (Figure. 3.12), which probably attributes to the massive infiltration of 
macrophages that in turn decreases the fraction of T cells.  
Taken together, suppressing IL4Rα signaling in myeloid cells did not 
change M2-like macrophage polarization, neither macrophage or neutrophil 
recruitment, which suggests a more complicated microenvironment in vivo than 
in vitro, and the IL4Rα signaling may change the characteristics of macrophage 
rather than simply change the M2 macrophage polarization, and IL4Rα signaling 
may not be involved in the recruitment of myeloid cells into the heart in response 
to hypertension.    
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Figure 3.11. IL4Rα knockout does not change macrophage recruitment 
induced by AngII and high salt. Representative FACS dot plots of macrophages 
(CD11b+F4/80+) gated from leukocytes in heart tissues of sham and AngII and high 
salt-treated mice, with quantification of the percentage of macrophages in total 
leukocytes and their cell number. All cell numbers are expressed per milligram 
tissue. n=5. Results are shown as means ± SEM. Unpaired student’s t test and one-
way ANOVA were used for statistical analysis. **P <0.01; ***P <0.001; ****P < 
0.0001. 
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Figure 3.12. IL4Rα knockout does not change neutrophils and T cells 
recruitment induced by AngII and high salt. Representative FACS dot plots of 
neutrophils (Ly6G+) and T cells (CD3+) gated from leukocytes in heart tissues of 
sham and AngII and high salt-treated mice and the quantification of the percentage 
of neutrophils and T cells in leukocytes and their cell number. All cell numbers are 
expressed per milligram tissue. n=5. Results are shown as means ± SEM. Unpaired 
student’s t test and one-way ANOVA were used for statistical analysis. *P <0.05; **P 
<0.01; ***P <0.001; ****P < 0.0001.  
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In addition to heart tissues, we also determined the M2-like macrophage 
population in aorta, another important organ in cardiovascular remodeling 
induced by hypertension. Similar to the results in heart, no change in M2-like 
macrophages was caused by IL4Rα deletion (Figure. 3.13), which supports that 
IL4Rα signaling alone may not be able to change macrophage polarization in 
vivo. However, AngII and high salt significantly exerted an increase in both the 
percentage of M2-like macrophages in total macrophage and their cell number 
(Figure. 3.13), indicating the involvement of M2-like macrophages in 
hypertensive inflammatory and pro-fibrotic vascular remodeling.  
Macrophage and neutrophil population in aorta were also determined by 
flow cytometry. Both the percentage and number of macrophages were 
significantly up-regulated by AngII and high salt (Figure. 3.14), which indicates 
the migration and infiltration of macrophages into the hypertensive vasculature 
with enhanced inflammation. In contrast to the un-changed neutrophil in heart, 
both the percentage and the total number of neutrophils in aorta showed 
significant increase after exposure to AngII and high salt (Figure. 3.15), which 
indicates the recruitment of neutrophils into the vasculature and confirms the 
increased inflammation induced by AngII and high salt. Consistent with the 
results of heart tissues, no change in macrophage or neutrophil was induced by 
IL4Rα deletion (Figure. 3.14 and Figure. 3.15), which supports the conclusion 
that IL4Rα signaling may not contribute the recruitment of myeloid cells into 
injured tissues. Neither the percentage or number of T cells in aorta was 
changed by AngII and high salt or IL4Rα deficiency in myeloid cells (Figure. 3.15). 
Based on the above data from flow cytometry, knockout of IL4Rα in 
myeloid cells does not change M2 macrophage polarization in vivo, neither 
macrophage and neutrophil infiltration into injured tissues and the T cell 
recruitment, which suggests that the phenotypic and functional changes in heart 
and vasculature induced by myeloid-specific IL4Rα ablation does not simply 
attribute to a global change of M2-like macrophages as hypothesized. 
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Figure 3.13. IL4Rα deficiency does not change the polarization of 
macrophages in aorta. Representative FACS dot plots of M2-like macrophages 
(CD206+TNFα-) gated from macrophages and the quantification of the percentage of 
M2-like macrophages in total macrophages and their cell number.  All cell numbers 
are expressed per milligram tissue. n=9-10. Results are shown as means ± SEM. 
Unpaired student’s t test and one-way ANOVA were used for statistical analysis. ***P 
<0.001; ****P < 0.0001.	
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Figure 3.14. IL4Rα deficiency does not change the recruitment of 
macrophages induced by AngII and high salt into aorta. Representative FACS 
dot plots of macrophages (CD11b+F4/80+) gated from leukocytes in aorta tissues of 
sham and AngII and high salt-treated mice, and the quantification of the percentage 
of macrophages in leukocytes and their cell number. All cell numbers are expressed 
per milligram tissue. n=9-10. Results are shown as means ± SEM. Unpaired 
student’s t test and one-way ANOVA were used for statistical analysis. ***P <0.001; 
****P < 0.0001.  
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Figure 3.15. IL4Rα deficiency does not change the recruitment of neutrophils 
and T cells induced by AngII and high salt into aorta. Representative FACS dot 
plots of neutrophils (Ly6G+) and T cells (CD3+) gated from leukocytes in aorta 
tissues of sham and AngII and high salt-treated mice, and the quantification of the 
percentage of neutrophils and T cells in leukocytes respectively and their cell 
number. All cell numbers are expressed per milligram tissue. n=5. Results are 
shown as means ± SEM. Unpaired student’s t test and one-way ANOVA were used 
for statistical analysis. ****P < 0.0001. 
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Mildly enhanced circulating myeloid cells in MyIL4RαKO mice 
As the infiltrating macrophages in heart and aorta are mostly derived from 
circulating monocytes, we were wondering whether the ablation of IL4Rα would 
cause any change in circulation monocytes. In order to answer this question, we 
determined the monocytes in blood by flow cytometry. Not only the percentage 
but also the number of monocytes increased significantly after exposure to AngII 
and high salt (Figure. 3.16A), which indicates the increase of circulating 
monocytes and inflammation in response to hypertensive injury, and more 
intriguingly, increased monocytes were shown in hypertensive MyIL4RαKO mice 
compared with hypertensive FC mice (Figure. 3.16A), which suggests the 
exaggerated inflammation induced by lack of IL4Rα in myeloid cells.  
Because of the diversity and heterogeneity of monocytes61-64, it was 
shown in infarcted hearts that Ly6Chigh monocytes dominate early and undergo 
inflammatory functions to digest damaged tissue, while Ly6Clow monocytes 
dominate later and are less inflammatory to promote tissue healing and repair65, 
which is parallel with the property and function of M1 and M2 macrophages66, 67. 
In order to elucidate whether the knockout of IL4Rα disturbs the Ly6Clow and 
Ly6Chigh monocytes interplay, we determined the circulating Ly6Clow and Ly6Chigh 
monocytes in blood. The percentage of Ly6Clow or Ly6Chigh monocytes in total 
monocytes was not changed (Figure. 3.16B), although the numbers of Ly6Clow 
and Ly6Chigh monocytes were both increased and the number of Ly6Clow 
monocytes in MyIL4RaKO mice was higher than that in FC mice (Figure. 3.16B), 
which is likely attributable to the increase of total monocytes. Meanwhile, 
neutrophils in blood were also quantified by flow. Neutrophils were increased in 
hypertensive mice (Figure. 3.16C), indicating the increase of inflammation 
induced by AngII and high salt, but no difference was shown between 
hypertensive MyIL4RaKO and FC mice (Figure. 3.16C), however neutrophils at 
basal level were significantly increased in MyIL4RαKO mice (Figure. 3.16C), 
suggesting the enhanced inflammation at least at baseline by IL4Rα deficiency. 
No change was shown in T cells in blood (Figure. 3.16C), together with the  
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Figure 3.16. Myeloid-specific IL4Rα ablation mildly increases circulating 
myeloid cells in blood. (A) Representative FACS dot plots of monocytes 
(CD11b+Ly6C+) gated from leukocytes in blood of sham and AngII and high salt-
treated mice, and the quantification of the percentage of monocytes in leukocytes of 
blood and their cell number. n=9-10. (B) Representative FACS dot plots of Ly6Clow 
and Ly6Chigh monocytes gated from total monocytes and the quantification of the 
respective percentage of Ly6Clow and Ly6Chigh monocytes in total monocytes and 
their cell number per 100µl of blood. n=5. (C) Representative FACS dot plots of 
neutrophils (Ly6G+, n=8-10) and T cells (CD3+, n=5) gated from leukocytes in blood 
of sham and AngII and high salt-treated mice, and the quantification of the 
percentage of neutrophils and T cells in total leukocytes of blood and their cell 
number. All cell numbers are expressed per 100µl of blood. Results are shown as 
means ± SEM. Unpaired student’s t test and one-way ANOVA were used for 
statistical analysis. *P <0.05; **P <0.01; ***P <0.001; ****P < 0.0001.  
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quantification of T cells in heart and aorta, suggests that IL4Rα signaling in 
myeloid cells is not involved in T cell infiltration from blood.  
As spleen is also an important monocyte reservoir68, and AngII can induce 
the release of monocytes from splenic reservoir68, 69, and drive splenic 
macrophage progenitor amplification70, we also characterized the cell populations 
in spleen after AngII and high salt-induced hypertension. Monocytes in spleen 
were significantly increased upon AngII and high salt (Figure. 3.17A), which is 
the opposite of reported decreased total monocytes in spleen after AngII68, 
however, the increase of splenic monocytes is consistent with the enlargement of 
spleen in hypertensive mice (Figure. 3.17A). No difference was shown between 
FC and MyIL4RαKO mice in the number of monocytes in spleen or the size of 
spleen (Figure. 3.17A), suggesting that the IL4Rα signaling may not participate in 
the splenic monocyte circulation (at least in our model). 
As well as the Ly6Clow or Ly6Chigh monocytes in blood, no change was 
shown in their percentage in total monocytes in spleen (Figure. 3.17B), and the 
increase of both Ly6Clow and Ly6Chigh monocytes in response to AngII and high 
salt (Figure. 3.17B) is likely resulted from the increase of total monocytes (Figure. 
3.12B). Neutrophils were also increased in spleen in response to AngII and high 
salt, with significant increase in MyIL4RαKO mice at basal level compared with 
FC mice (Figure. 3.17C), which probably suggests the enhanced inflammation in 
MyIL4RαKO mice at least at basal level. T cells were also significantly induced in 
hypertensive mice, but compared with FC mice, the number of T cells in spleen 
was reduced in MyIL4RαKO mice (Figure. 3.17C), which may suggest the 
involvement of myeloid IL4Rα signaling in modulation of T cells in spleen.  
Taken all the results in circulation together, knockout of IL4Rα in myeloid 
cells showed increase in the number of neutrophils and monocytes in circulation, 
which suggests that myeloid-specific IL4Rα knockout causes a mild systemic 
inflammation increase.  
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Figure 3.17. Myeloid-specific IL4Rα knockout does not change the migration 
of myeloid cells from spleen after AngII and high salt. (A) Representative FACS 
dot plots of monocytes (CD11b+Ly6C+, n=9-10) gated from leukocytes in spleen of 
sham and AngII and high salt-treated mice, and the quantification of the percentage 
of monocytes and their cell number in spleen. The measurement of the spleen 
weight to body weight (BW) ratio and spleen weight to tibia length (TL) ratio. n=7-16. 
(B) Representative FACS dot plots of Ly6Clow and Ly6Chigh monocytes gated from 
total monocytes, and the quantification of respective percentage of Ly6Clow and 
Ly6Chigh monocytes in total monocytes of spleen and their cell number. n=5. (C) 
Representative FACS dot plots of neutrophils (Ly6G+) and T cells (CD3+) gated from 
leukocytes in spleen of sham and AngII and high salt-treated mice and the 
quantification of the percentage of neutrophils and T cells in leukocytes of spleen 
respectively and their cell number. n=8-10. Cell numbers indicated are per spleen. 
Results are shown as means ± SEM. Unpaired student’s t test and one-way ANOVA 
were used for statistical analysis. *P <0.05; **P <0.01; ***P <0.001; ****P < 0.0001.  
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Discussion 
In the present study, we investigated the role of myeloid IL4Rα signaling in 
cardiovascular remodeling during AngII and high salt-induced hypertension and 
cardiovascular remodeling. Knockout of IL4Rα in myeloid cells had no effect on 
cardiovascular hypertrophic remodeling, but increased the expression of ROS 
generation related genes, and substantially decreased cardiovascular fibrotic 
remodeling via a systemic change of signaling pathways that mediate the 
development of fibrosis, such as TGFβ, Gal3 and BMP9 signaling. These 
pathophysiologic changes lead to a relative mild preservation of cardiovascular 
function in MyIL4RαKO mice while that of FC mice was significantly impaired by 
AngII and high salt. However, the decreased fibrosis and the functional 
preservation in MyIL4RαKO mice are not simply due to the hypothesized M2 
macrophage polarization reduction, because no decrease in M2-like macrophage 
population was shown. In conclusion, myeloid IL4Rα signaling is significantly 
involved in cardiovascular remodeling induced by AngII and high salt, but it is not 
simply through blocking M2 macrophage activation in vivo, suggesting a more 
complicated change in macrophage phenotype that needs to be determined in 
the future.  
Hypertrophic Remodeling 
Hypertension is causally related to adverse cardiovascular remodeling, 
which includes hypertrophic structural changes. Clinical trials demonstrate that 
antihypertensive therapy prevents left ventricle hypertrophy. The prevention or 
reversal of left ventricle hypertrophy are correlated with cardiac function 
improvement and decline in risk of adverse cardiovascular outcomes. Cardiac 
hypertrophy, either from dilatation of left ventricle chamber or thickening of 
walls8, is an intermediate phenotype in the progression of hypertension to heart 
failure. Vascular smooth muscle hypertrophy is a critical component of vascular 
hypertrophic remodeling in hypertension71. In our study, hypertrophy was 
observed in both heart and aorta in AngII and high salt-induced hypertensive 
injury. Mice displayed increased heart weight, enlarged cardiomyocyte size, and 
increased aortic wall thickness (Figure. 3.1), which is consistent with previously 
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reports 72, 73. However, no change in hypertrophic remodeling was caused by 
myeloid IL4Rα deficiency, which is also consistent with a previous report showing 
that global IL-4 deficiency does not affect hypertrophy during AngII-induced 
cardiac remodeling 27. These results together suggest that myeloid IL4Rα 
signaling is not involved in cardiovascular hypertrophic remodeling.  
Fibrotic Remodeling 
In addition to hypertrophy, AngII and high salt also induces pro-fibrotic 
cardiovascular remodeling. Both hypertrophy74 and fibrosis75-77 contribute to 
myocardial and vascular stiffness, which plays a critical role in deleterious 
functional disorders. In our study, MyIL4Rα deficiency resulted in significant 
suppression of interstitial and perivascular fibrosis (Figure. 3.2) with modest 
changes in collagen gene expression (Figure. 3.4 and Figure. 3.5) during AngII 
and high salt treatment compared to floxed controls. In addition to collagens, 
MMPs and TIMPs also contribute to the pathogenesis of fibrosis. Decreased 
MMPs and increased TIMPs would lead to collagen accumulation. In heart 
tissues of AngII treated MyIL4RαKO mice, we detected decreased Col3A1 and 
increased MMP13 which could cooperatively contribute to the decreased fibrosis. 
No change in TIMP1 was found in hypertensive MyIL4RαKO mice compared with 
the sham, where as a significant increase in TIMP1 mRNA expression was 
shown in hypertensive floxed control mice (Figure. 3.4).  
Fibrosis Associated Signaling Pathways 
TGFβ signaling: TGFβ signaling is one of the classical pathways in 
fibrotic remodeling. TGFβ1 facilitates the deposition of extracellular matrix 
proteins on vascular walls in response to mechanical stress caused by 
hypertension78, which attenuates vasculature compliance and increases stiffness. 
In our study, TGFβ1 mRNA in heart did not show any change upon AngII and 
high salt treatment (Figure. 3.4). Consistent with our results, spontaneously 
hypertensive rats (SHR) without heart failure also do not show any difference in 
TGFβ1 mRNA in left ventricle compared with normotensive rats, although a 
significant increase was shown in SHR with heart failure79. Another study by Kim 
et al. showed that there is no significant difference in cardiac TGFβ1 mRNA 
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expression between deoxycorticosterone acetate (DOCA)-salt hypertensive rats 
and shams. However, TGFβ1 mRNA was significantly increased in aorta of 
DOCA-salt hypertensive rats80, which is consistent with our results showing a 
significant increase of TGFβ1 mRNA in aorta tissues but no change in hearts 
after AngII and high salt treatment (Figure. 3.4 and Figure. 3.5). These studies 
suggest that the expression of TGFβ1 varies depending on the severity of 
disease and the tissue. Fibrosis development may not absolutely require an 
increase in TGFβ1 since TGFβ1 mRNA did not change, but its downstream 
target gene PDGFα mRNA increased upon AngII and high salt (Figure 3.4). 
PAI-1 signaling: PAI-1 has been linked to both pro-fibrotic and anti-
fibrotic actions. The pro-fibrotic role was shown in renal fibrosis either induced by 
unilateral ureteral obstruction (UUO) or protein overload, which displayed 
significantly diminished fibrosis in kidney of PAI-1–/– mice59. Its anti-fibrotic role 
was shown in PAI-1–/– aging mice which revealed increased fibrosis in heart but 
not other major organs such as lung and kidney58. As PAI-1 is an inhibitor of t-PA 
and u-PA, spontaneous cardiac fibrosis in PAI-1 deficient mice is consistent with 
cardiac fibrosis in u-PA overexpressing mice58 and impaired collagenous scar 
formation in infarcted hearts of u-PA null mice81, which supports an anti-fibrotic 
role of PAI-1. This may explain the increased expression of PAI-1 mRNA in aorta 
in hypertensive MyIL4RαKO mice compared with hypertensive FC mice, but with 
decreased aortic fibrosis in our study (Figure. 3.2A and Figure. 3.5). PAI-1 
deficient mice with reduce perivascular fibrosis in infarcted hearts82 is consistent 
with PAI-1 overexpression resulting in augmented fibrosis, and PAI-1 deficiency 
or u-PA overexpression leads to decreased fibrosis in lung and kidney60, 83, which 
supports a pro-fibrotic role of PAI-1. This may partially explains the reduced PAI-
1 mRNA in heart of MyIL4RαKO mice with decreased cardiac fibrosis (Figure. 
3.2B and Figure. 3.4). However, it is not clear whether PAI-1 is pro- or anti- 
fibrotic in our model except using the PAI-1–/– mice to demonstrate.  
One of the possibilities is that the function of PAI-1 may vary depending 
on the severity of the damage or the progression of disease. PAI-1 inhibits 
fibrosis when fibrosis is harmful, but promotes fibrosis when fibrosis is required to 
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maintain the integrity of the injured tissue. A molecule may have opposite effects 
depending on the context. Another alternative explanation is that the role of PAI-
1 is possibly tissue-dependent. In a specific context, it is likely that both damage 
severity and tissue type contribute to the function of PAI-1 in fibrosis.  
BMP9 Signaling 
As a TGFβ1-independent signaling pathway, BMP9 signaling has been 
recently identified as a novel pro-fibrotic84-86 or fibrosis-limiting factor57, another 
molecule that may have opposite and context-specific effects. In our study, 
decreased cardiac fibrosis was shown in hypertensive MyIL4RαKO mice with 
increased BMP9 mRNA expression (Figure. 3.2B and Figure. 3.4), which 
probably supports the anti-fibrotic role of BMP9 in heart, however, this needs to 
be confirmed via a BMP9 knockout mouse model or pharmacologically blocking 
BMP9 signaling. BMP9 acts through the downstream target genes inhibitor of 
DNA binding 1 (ID1) and inhibitor of DNA binding 2 (ID2) via the Smad molecules 
to regulate the production of ECM proteins 87,57,88. However, in our study, 
compared with hypertensive FC mice, MyIL4RαKO mice did not show any 
difference in ID1 mRNA expression in heart, while showed significant decrease in 
ID2 mRNA (data not shown), which is not consistent with the increase in BMP9 
mRNA. This may suggest that there are more than one signaling in addition to 
BMP9 contributing to the transcription of ID1 and ID2. 
In contrast to the no change in ID1 and decrease in ID2 mRNA in heart of 
hypertensive MyIL4RαKO mice, ID1 significantly decreased while ID2 did not 
show any change in aorta (data not shown), which is not consistent with the 
expression of BMP9 in aorta either as BMP9 mRNA did not show any difference 
in hypertensive MyIL4RαKO mice compared with FC (Figure. 3.5). This may 
confirm that there may be other pathways contributing to the expression of ID1 
and ID2, in addition to BMP9. The difference in BMP signaling between heart and 
aorta tissues also supports the tissue-dependent mechanisms that control fibrotic 
remodeling.  
Inflammatory Responses 
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Hypertensive stimuli including AngII and high salt induce ROS production 
in a variety of tissues such as brain, heart, kidney and vasculature71, which 
promotes the pathological development of hypertensive remodeling like 
hypertrophy, inflammation and fibrosis. ROS generation related genes were 
increased in MyIL4RαKO mice (Figure. 3.7), suggesting there is increased 
inflammation as a result of IL4Rα deficiency in myeloid cells.  
Hypertensive stimuli also induce pro-inflammatory molecules, which then 
promote the rolling, adhesion and accumulation of inflammatory cells in injured 
tissues89-93. The pro-inflammatory molecules and oxidative stress mutually 
amplify each other. For instance, TNFα activates NADPH oxidase that further 
enhances oxidative stress94. Meanwhile, TNFα facilitates the overexpression of 
chemokines and adhesion molecules95. The migration of M2 macrophages at late 
stages of cardiac injury was shown to be TNFα signaling dependent96.  
IL-6, another major pro-inflammatory cytokine, also mediates superoxide 
production, which causes endothelial impairment97. IL-6 is fundamental for the 
development of hypertension98-103 and contributes to hypertension-induced 
cardiovascular remodeling. AngII and high salt-induced hypertension and cardiac 
injury was significantly abrogated in IL-6 deficient mice104, and high levels of 
circulating IL-6 can be considerably diminished by blocking AngII signaling103, 105. 
Deletion of IL-6 prevents macrophage infiltration, ameliorates fibrosis and 
improves cardiac function in AngII and high salt-induced hypertension13. IL-6 also 
involves in vascular remodeling by promoting vascular smooth muscle cells 
migration and proliferation, which results in vascular medial hypertrophy106, 107. In 
our study, TNFα was significantly induced by AngII and high salt, and a strikingly 
significant increase in IL-6 mRNA was also shown (Figure. 3.6).  
The chemokine MCP1 (also known as CCL2) activates monocytes and 
mediates their migration towards the inflammatory site. AngII can stimulate the 
production of MCP1 by activating CCR2 receptor108. A significant increase in 
MCP1 mRNA was observed in hypertensive aorta tissues in our study, however, 
no increase in heart has detected (data not shown), which indicates a differential 
remodeling mechanism in heart and aorta. No significant change in MCP1 
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expression was revealed in MyIL4RαKO mice compared with FC, suggesting that 
myeloid IL4Rα signaling effects on cardiovascular remodeling may not be 
through the MCP1/CCR2 axis. 
Immune Cells in Cardiovascular Remodeling 
The hypertrophic, inflammatory and fibrotic cardiovascular remodeling 
following hypertension is attributable to the interaction between cardiac- and 
vascular- parenchymal cells and inflammatory immune cells.  
Monocytes and Macrophages 
Circulating monocytes amplify in response to AngII15, 109, which is also 
supported by our results (Figure. 3.16), showing significant increase of 
monocytes in blood. Elimination of monocytes results in attenuated hypertension, 
decreased ROS generation and improvement of cardiovascular function15. 
Monocytes are circulating precursors of macrophages that accumulate in 
perivascular adipose tissue, adventitia, heart and kidneys during hypertension110, 
111. Stimulated by hypertension, infiltrating macrophages release pro-
inflammatory cytokines, produce ROS and promotes oxidative stress, disturb 
tissue homeostasis and initiate remodeling, all of which contributes to disease 
development and progression112-117. Massive infiltration of macrophages in the 
cardiovascular system was observed in our study (Figure. 3.11 and Figure. 3.14), 
characterized by a significant increase of macrophages in heart and aorta in 
hypertensive mice. In monocyte and neutrophil depleted LysMiDTR mice by 
diphtheria toxin administration, hypertensive responses such as hypertrophy, 
ROS production and cardiovascular dysfunction were blocked. Restoration of 
monocytes rather than granulocytes reversed the hypertension15, which supports 
the essential role of monocytes/macrophage in hypertension and hypertension-
induced cardiovascular remodeling.  
Macrophages are present during injury with distinctive phenotypes 
depending one the stage. Initially they migrate into the injured tissue and adopt a 
pro-inflammatory phenotype (M1 macrophages) that serves to clear dead cells 
and debris, later on they polarize to anti-inflammatory phenotype (M2 
macrophages) and produce cytokines against inflammation and other factors to 
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resolve inflammation and initiate tissue repair. Macrophages are more and more 
appreciated as master regulator of fibrosis29, 109. The type 2 immune response 
maintains tissue homeostasis, but if not appropriately regulated, it can result in 
fibrosis by amplification of macrophages118. It has recently been shown that IL-4 
or IL-13 alone is not sufficient to induced type 2 immune responses, but IL-4 or 
IL-13 together with signals from apoptotic cells activate macrophages to repair 
the damaged tissue119, i.e. IL-4 or IL-13 activated macrophages cannot initiate 
tissue repair program unless they receive signals from apoptotic neutrophils. 
Losing the ability to sense apoptotic cells interrupts the proliferation of tissue-
resident macrophages and inhibits the activation of anti-inflammatory genes 
involved in tissue repair119. The sensing process occurs between macrophages 
and local tissue-specific signals, by which macrophages integrating various 
signals and then switch to repair mode to produce tissue-building factors120. 
Macrophages generate proteins that are directly involved in tissue repair such as 
Col1A1 which deposits in ECM and Relmα which eventually acts to cross-link 
collagen with fibrils, enhancing the strength or stiffness of injured tissue32. Those 
macrophages participating in tissue repair are mostly M2-like macrophages.  
M2 Macrophage Polarization In Vivo 
M2 macrophages are importantly involved in the pro-fibrotic remodeling. 
Fibrosis in multiple tissues was found significantly decreased in MyIL4RαKO 
mice in our study (Figure. 3.2 and Figure. 3.3), and as IL4Rα signaling is very 
important for M2 macrophage activation and polarization, we hypothesized that 
the decreased fibrosis attributes to M2 macrophage polarization suppression as 
a result of IL4Rα deficiency. However, we were unable to demonstrate this 
hypothesis. Knockout of IL4Rα in myeloid cells dramatically attenuated M2 
macrophage polarization in vitro (Figure. 2.1A), but unfortunately not in vivo. 
First, no significant decrease was observed in the expression of M2 macrophage 
markers in heart or aorta tissues of hypertensive MyIL4RαKO mice (Figure. 3.9). 
On the contrary, one of the M2 macrophage markers Fizz1 displayed significant 
increase in heart of sham MyIL4RαKO mice compared with sham FC. This may 
contribute to the expression of Fizz1 in other cell types other than myeloid cells in 
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heart because Fizz1 also expresses in endothelial cells, vascular smooth muscle 
cells, T cells and myofibroblast-like cells121. Our result is supported by the 
comparable expression of Fizz1 in IL-4 knockout mice and WT mice in hypoxia-
induced hypertensive lung122, which together suggests that there are more than 
one signaling pathway in addition to IL-4 signaling that contribute to Fizz1 
expression. Second, no difference was shown in the percentage or number of M2 
macrophages in MyIL4RαKO mice based on the results from flow (Figure. 3.10 
and Figure. 3.13). These results conflict with data from other studies. 
Macrophages from LysMcreIL4Rαflox/- mice revealed significant reduction in genes 
characterizing M2 macropahges including CD206 and Fizz1 by qRT-PCR after 
specifically sorting CD11b+F4/80+ macrophages from wound tissues32. This 
inconsistency may attribute to the samples for gene expression: instead of 
macrophages only in vivo, we determined gene expression in tissues that include 
a lot other cell types. Macrophages from pancreas of LysMcreIL4Rαflox/flox mice 
also displayed significant decrease in CD206 expression in a chronic pancreatitis 
model26, which was determined by flow. In order to further pursue that whether 
IL4Rα deficiency changes the macrophages or not, sorting macrophages from 
heart and aorta and then characterize these macrophages by determining the 
mRNA expression profile of M2 and M1 macrophage markers with qRT-PCR will 
be very helpful.  
To reconcile the results we have so far, we propose a 4-part hypothesis. 
First: timing; macrophages from wounded skin showed decreased expression of 
M2 macrophage markers at 7-day post injury, but none of the markers was 
maintained at very late stage (after 14 days) of repair32, which suggests the time 
dependence of gene expression. Second: genetic background; both mouse 
models that showed decrease in M2 macrophage polarization are on a 
background of BALB/c (LysMcreIL4Rαflox/- mice in the skin wound model and 
LysMcreILR4αflox/flox mice in the chronic pancreatitis model), in contrast, what we 
used in our study are on a C57BL/6 background. Totally different phenotypes 
were shown in mice of different background but with the same knockout123, which 
highlights the importance of genetic background. Third: signaling pathways other 
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than IL4R signaling also contribute to M2 macrophage polarization in vivo. 
Instead of canonical IL-4/IL-13-STAT6 signaling, activated adventitia fibroblasts 
polarized naïve macrophages to a distinctive phenotype that promotes 
inflammation and fibrosis via IL-6-STAT3-HIF1-C/EBPβ axis, which challenges 
the present paradigm of IL-4/IL-13-STAT6-mediated macrophage alternative 
activation as the sole driver of reparative remodeling124. This is supported by 
other studies. Tumor-derived lactic acid from aerobic glycolysis enhanced Fizz1 
expression in tumor-associated macrophages, which is dependent on HIF1 but 
not IL-4/IL-13125. Feilding et al. demonstrated that IL-6 is required for the 
development of peritoneal fibrosis by switching acute inflammation to a chronic 
pro-fibrotic state126. Therefore, signaling like IL-6-STAT3-HIF1 axis may 
compensate the lack of IL4R signaling and contribute to the polarization of M2 
macrophages in vivo. Fourth: incomplete deletion of IL4Rα by LysMcre. Because 
of the heterogeneity, macrophages express LysM differently. Macrophages 
elicited by inflammatory stimuli have a lower level of LysM than the tissue 
resident macrophages, which was demonstrated by the results that naïve tissue 
resident macrophages from LysMCreIL4Rαflox/- mice almost completely lost IL4Rα 
function while a large fraction of inflammation-stimulated macrophages failed to 
repeal IL4Rα127. Taken together, the four mechanisms mentioned above 
probably synergize or work independently and result in the unchanged M2 
macrophage populations in vivo in our model.  
Neutrophils 
As LysMcreIL4Rαflox/flox also ablates IL4Rα in neutrophils, our results also 
reflect the effect of IL4Rα deletion in neutrophils. Based on our data from flow 
cytometry, no change was shown in neutrophils of heart and aorta as a result of 
IL4Rα ablation (Figure. 3.12 and Figure. 3.15), which suggests that IL4Rα 
deficiency in neutrophils does not at least change their migration into the injured 
tissues. This is consistent with the study by Wenzel et. Al. who showed that 
restoration of neutrophils in LysMiDTR driven myeloid cells ablated mice did not 
restore pathophysiological action of AngII15. However, more neutrophils were 
shown in blood and spleen of sham MyIL4RαKO mice, which indicates the higher 
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level of inflammation and this is supported by the result that selective depletion of 
circulating neutrophils protects against oxidative stress in AngII-induced 
hypertension128.  
T cells 
T cells have also been shown to be involved in hypertension via infiltrating 
into organs that control blood pressure129, 130. A landmark study by Guzik et al. 
demonstrated that recombinase-activating gene 1 (Rag1) deficient mice, which 
fail to develop B and T lymphocytes, were protected from hypertension induced 
by AngII or DOCA-salt. Importantly, the hypertensive responses were restored by 
adoptive transfer of T cells, but not B cells129. These results were confirmed by 
Mattson et al. who observed a similar phenotype in Rag1-/- mice131. T cells 
accumulate in the kidney and vasculature of hypertensive mice, release 
inflammatory cytokines, produce ROS, and promote renal and vasculature 
dysfunction132, 133. Blocking T cell infiltration by immunosuppressive drug 
mycophenolate acid reduces intrarenal AngII and prevents hypertension and 
kidney damage112, 134, 135. Furthermore, circulating T cells induced by AngII were 
described with effector phenotype in vivo and in vitro 129, 136. In addition to T 
effector cells, T regulatory cells are also involved in hypertension and play a role 
that is opposite of T effector cells. Adoptive transfer regulatory T cells (Tregs) 
diminished AngII-induced hypertension, vascular stiffening and inflammation, as 
Tregs are innate and adaptive immune responses suppressing cells137. Innate 
immune system release signals to activate T effector cells and their 
differentiation towards pro-inflammatory Th1 and Th17 phenotypes. These T 
effector cells promote low-grade inflammation by producing pro-inflammatory 
cytokines, which eventually lead to increase in blood pressure and end-organ 
damage. In contrast, Tregs counteract effects associated with hypertension by 
suppressing immune responses. Imbalance of T effector cells and Tregs 
aggravates inflammation, elicits increase in blood pressure and leads to end-
organ damage in hypertensive patients117. However, no significant increase of 
infiltrating T cells was shown in response to AngII and high salt in our study 
(Figure. 3.12, and Figure. 3.15), which partially can be explained technically. T 
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cells are know accumulating in perivascular fat 111, 129 to impair endothelial 
function and cause vascular fibrosis136, 138-140, but when we collect the aorta 
tissues, in order to more specifically analyze aorta, we tried to exclude the 
surrounding adipose tissues, where a lot T cells accumulate. Distinct from injured 
tissues and blood, more T cells were detected in spleen from hypertensive mice 
(Figure. 3.17C), which probably resulted from the enlargement of spleen (Figure. 
3.17A). This is consistent with the significant spleen hypertrophy and more 
proliferative immature lymphocytes in AngII-infused apolipoprotein E (ApoE)-/- 
mice141.  
Prospect in Future 
Overall, as IL4Rα signaling in myeloid cells is significantly involved in 
cardiovascular remodeling induced by hypertension, specifically targeting 
myeloid IL4Rα signaling pathway could suppress excess pro-fibrotic remodeling 
and protect cardiovascular function. However, the timing and the extent are very 
important. For example, attenuating inflammation in the early phase of 
myocardial infarction could be beneficial, however, inhibiting fibrosis initially could 
lead to cardiac rupture or aneurysm11, 142-144. Myeloid IL4Rα signaling involves 
both anti-inflammatory and pro-fibrotic pathways in cardiovascular remodeling. 
Targeting myeloid IL4Rα to limit the pro-fibrotic role but not suppress the anti-
inflammatory effect is not easy to control. Therefore, comprehensive and 
accurate spatio-temporal description of the components in the anti-inflammatory 
and pro-fibrotic pathways is necessary, and specific drugs that target these 
pathways need to be evaluated.  
 
	 133 
References  
 
1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, 
Jr., et al. Seventh report of the joint national committee on prevention, 
detection, evaluation, and treatment of high blood pressure. Hypertension. 
2003;42:1206-1252 
2. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. 
Trends in cardiovascular health metrics and associations with all-cause 
and cvd mortality among us adults. Jama. 2012;307:1273-1283 
3. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha 
MJ, et al. Heart disease and stroke statistics-2016 update: A report from 
the american heart association. Circulation. 2016;133:e38-360 
4. Oparil S, Schmieder RE. New approaches in the treatment of 
hypertension. Circulation research. 2015;116:1074-1095 
5. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal 
RS, et al. Treatment of hypertension in patients with coronary artery 
disease: A scientific statement from the american heart association, 
american college of cardiology, and american society of hypertension. 
Journal of the American College of Cardiology. 2015;65:1998-2038 
6. Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis 
in aging and hypertension: Molecular mechanisms and clinical 
implications. Can J Cardiol. 2016;32:659-668 
7. Piek A, de Boer RA, Sillje HH. The fibrosis-cell death axis in heart failure. 
Heart Fail Rev. 2016;21:199-211 
8. Drazner MH. The progression of hypertensive heart disease. Circulation. 
2011;123:327-334 
9. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 
(Greenwich). 2007;9:546-550 
10. Bleakley C, Hamilton PK, Pumb R, Harbinson M, McVeigh GE. Endothelial 
function in hypertension: Victim or culprit? J Clin Hypertens (Greenwich). 
2015;17:651-654 
11. Gonzalez GE, Cassaglia P, Noli Truant S, Fernandez MM, Wilensky L, 
Volberg V, et al. Galectin-3 is essential for early wound healing and 
ventricular remodeling after myocardial infarction in mice. International 
journal of cardiology. 2014;176:1423-1425 
12. Weber KT. Aldosterone in congestive heart failure. The New England 
journal of medicine. 2001;345:1689-1697 
13. Gonzalez GE, Rhaleb NE, D'Ambrosio MA, Nakagawa P, Liu Y, Leung P, 
et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and 
dysfunction without affecting blood pressure in angiotensin ii-high salt-
induced hypertension. Journal of hypertension. 2015;33:144-152 
14. Gonzalez GE, Rhaleb NE, D'Ambrosio MA, Nakagawa P, Liao TD, 
Peterson EL, et al. Cardiac-deleterious role of galectin-3 in chronic 
angiotensin ii-induced hypertension. American journal of physiology. Heart 
and circulatory physiology. 2016;311:H1287-H1296 
	 134 
15. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, 
Schuhmacher S, et al. Lysozyme m-positive monocytes mediate 
angiotensin ii-induced arterial hypertension and vascular dysfunction. 
Circulation. 2011;124:1370-1381 
16. Allen JE, Wynn TA. Evolution of th2 immunity: A rapid repair response to 
tissue destructive pathogens. PLoS pathogens. 2011;7:e1002003 
17. Gordon S. Alternative activation of macrophages. Nature reviews. 
Immunology. 2003;3:23-35 
18. Biswas SK, Chittezhath M, Shalova IN, Lim JY. Macrophage polarization 
and plasticity in health and disease. Immunol Res. 2012;53:11-24 
19. Lawrence T, Natoli G. Transcriptional regulation of macrophage 
polarization: Enabling diversity with identity. Nature reviews. Immunology. 
2011;11:750-761 
20. Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu ZG. Ros play 
a critical role in the differentiation of alternatively activated macrophages 
and the occurrence of tumor-associated macrophages. Cell Res. 
2013;23:898-914 
21. Ohmori Y, Hamilton TA. Requirement for stat1 in lps-induced gene 
expression in macrophages. Journal of leukocyte biology. 2001;69:598-
604 
22. Wynn TA. Fibrotic disease and the t(h)1/t(h)2 paradigm. Nature reviews. 
Immunology. 2004;4:583-594 
23. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage 
subsets. Nature reviews. Immunology. 2011;11:723-737 
24. Wynn TA, Barron L. Macrophages: Master regulators of inflammation and 
fibrosis. Semin Liver Dis. 2010;30:245-257 
25. Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger 
B, et al. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107-135 
26. Xue J, Sharma V, Hsieh MH, Chawla A, Murali R, Pandol SJ, et al. 
Alternatively activated macrophages promote pancreatic fibrosis in chronic 
pancreatitis. Nature communications. 2015;6:7158 
27. Peng H, Sarwar Z, Yang XP, Peterson EL, Xu J, Janic B, et al. Profibrotic 
role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension. 
2015;66:582-589 
28. Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A pro-fibrotic role for 
interleukin-4 in cardiac pressure overload. Cardiovascular research. 
2012;95:77-85 
29. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic 
translation for fibrotic disease. Nature medicine. 2012;18:1028-1040 
30. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated 
alternatively activated macrophages: Roles in homeostasis and disease. 
Annu Rev Immunol. 2013;31:317-343 
31. Carlson S, Helterline D, Asbe L, Dupras S, Minami E, Farris S, et al. 
Cardiac macrophages adopt profibrotic/m2 phenotype in infarcted hearts: 
Role of urokinase plasminogen activator. Journal of molecular and cellular 
cardiology. 2017;108:42-49 
	 135 
32. Knipper JA, Willenborg S, Brinckmann J, Bloch W, Maass T, Wagener R, 
et al. Interleukin-4 receptor alpha signaling in myeloid cells controls 
collagen fibril assembly in skin repair. Immunity. 2015;43:803-816 
33. Vergadi E, Chang MS, Lee C, Liang OD, Liu X, Fernandez-Gonzalez A, et 
al. Early macrophage recruitment and alternative activation are critical for 
the later development of hypoxia-induced pulmonary hypertension. 
Circulation. 2011;123:1986-1995 
34. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, 
Radwanska M, et al. Alternative macrophage activation is essential for 
survival during schistosomiasis and downmodulates t helper 1 responses 
and immunopathology. Immunity. 2004;20:623-635 
35. Weber DS, Rocic P, Mellis AM, Laude K, Lyle AN, Harrison DG, et al. 
Angiotensin ii-induced hypertrophy is potentiated in mice overexpressing 
p22phox in vascular smooth muscle. American journal of physiology. 
Heart and circulatory physiology. 2005;288:H37-42 
36. Hadi AM, Mouchaers KT, Schalij I, Grunberg K, Meijer GA, Vonk-
Noordegraaf A, et al. Rapid quantification of myocardial fibrosis: A new 
macro-based automated analysis. Cellular oncology. 2011;34:343-354 
37. Castoldi G, di Gioia CR, Bombardi C, Perego C, Perego L, Mancini M, et 
al. Prevention of myocardial fibrosis by n-acetyl-seryl-aspartyl-lysyl-proline 
in diabetic rats. Clinical science. 2009;118:211-220 
38. Castoldi G, di Gioia CR, Carletti R, Roma F, Zerbini G, Stella A. 
Angiotensin type-2 (at-2)-receptor activation reduces renal fibrosis in 
cyclosporine nephropathy: Evidence for blood-pressure independent 
effect. Biosci Rep. 2016 
39. Hu D, Yin C, Mohanta SK, Weber C, Habenicht AJ. Preparation of single 
cell suspensions from mouse aorta. Bio Protoc. 2016;6 
40. Lerman LO, Chade AR, Sica V, Napoli C. Animal models of hypertension: 
An overview. J Lab Clin Med. 2005;146:160-173 
41. Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after 
exposure to angiotensin is associated with inability to upregulate renal 
epoxygenases. Hypertension. 2003;42:775-780 
42. Kirchhoff F, Krebs C, Abdulhag UN, Meyer-Schwesinger C, Maas R, 
Helmchen U, et al. Rapid development of severe end-organ damage in 
c57bl/6 mice by combining doca salt and angiotensin ii. Kidney 
international. 2008;73:643-650 
43. Kumar V, Wollner C, Kurth T, Bukowy JD, Cowley AW, Jr. Inhibition of 
mammalian target of rapamycin complex 1 attenuates salt-induced 
hypertension and kidney injury in dahl salt-sensitive rats. Hypertension. 
2017;70:813-821 
44. Mehrotra P, Patel JB, Ivancic CM, Collett JA, Basile DP. Th-17 cell 
activation in response to high salt following acute kidney injury is 
associated with progressive fibrosis and attenuated by at-1r antagonism. 
Kidney international. 2015;88:776-784 
	 136 
45. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-
Saadi N, et al. Aldosterone synthase inhibitor ameliorates angiotensin ii-
induced organ damage. Circulation. 2005;111:3087-3094 
46. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, et al. 
Aldosterone antagonism or synthase inhibition reduces end-organ 
damage induced by treatment with angiotensin and high salt. Kidney 
international. 2009;75:936-944 
47. Spinale FG. Matrix metalloproteinases: Regulation and dysregulation in 
the failing heart. Circulation research. 2002;90:520-530 
48. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix 
metalloproteinase inhibition after myocardial infarction: A new approach to 
prevent heart failure? Circulation research. 2001;89:201-210 
49. Murphy AM, Wong AL, Bezuhly M. Modulation of angiotensin ii signaling in 
the prevention of fibrosis. Fibrogenesis Tissue Repair. 2015;8:7 
50. Bonner JC. Regulation of pdgf and its receptors in fibrotic diseases. 
Cytokine Growth Factor Rev. 2004;15:255-273 
51. Trojanowska M. Role of pdgf in fibrotic diseases and systemic sclerosis. 
Rheumatology (Oxford). 2008;47 Suppl 5:v2-4 
52. Ma LJ, Fogo AB. Angiotensin as inducer of plasminogen activator 
inhibitor-1 and fibrosis. Contrib Nephrol. 2001:161-170 
53. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. American 
journal of physiology. Renal physiology. 2002;283:F209-220 
54. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. 
Genetic and pharmacological inhibition of galectin-3 prevents cardiac 
remodeling by interfering with myocardial fibrogenesis. Circulation. Heart 
failure. 2013;6:107-117 
55. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling 
and heart failure. Current heart failure reports. 2010;7:1-8 
56. Martinez-Martinez E, Calvier L, Fernandez-Celis A, Rousseau E, Jurado-
Lopez R, Rossoni LV, et al. Galectin-3 blockade inhibits cardiac 
inflammation and fibrosis in experimental hyperaldosteronism and 
hypertension. Hypertension. 2015;66:767-775 
57. Kevin J Morine XQ, Vikram Paruchuri, Yali Zhang, Mark Aronovitz, 
Richard Karas, Navin K Kapur. Abstract 18640: Recombinant bone 
morphogenetic protein 9 is a novel therapeutic that rescues cardiac 
fibrosis and improves cardiac function in heart failure. Circulation. 
2016;134:A18640 
58. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. 
Overexpression of urokinase by macrophages or deficiency of 
plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. 
Circulation research. 2004;95:637-644 
59. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, et al. Pai-1 
deficiency attenuates the fibrogenic response to ureteral obstruction. 
Kidney international. 2001;60:587-596 
60. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, et al. 
Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack 
	 137 
or overexpress the murine plasminogen activator inhibitor-1 gene. The 
Journal of clinical investigation. 1996;97:232-237 
61. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets 
DA, et al. Subpopulations of mouse blood monocytes differ in maturation 
stage and inflammatory response. J Immunol. 2004;172:4410-4417 
62. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two 
principal subsets with distinct migratory properties. Immunity. 2003;19:71-
82 
63. Ziegler-Heitbrock L. The cd14+ cd16+ blood monocytes: Their role in 
infection and inflammation. Journal of leukocyte biology. 2007;81:584-592 
64. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nature 
reviews. Immunology. 2005;5:953-964 
65. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, 
Figueiredo JL, et al. The healing myocardium sequentially mobilizes two 
monocyte subsets with divergent and complementary functions. The 
Journal of experimental medicine. 2007;204:3037-3047 
66. Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic 
heart disease. Cardiovascular research. 2014;102:240-248 
67. Gombozhapova A, Rogovskaya Y, Shurupov V, Rebenkova M, 
Kzhyshkowska J, Popov SV, et al. Macrophage activation and polarization 
in post-infarction cardiac remodeling. Journal of biomedical science. 
2017;24:13 
68. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, 
Panizzi P, et al. Identification of splenic reservoir monocytes and their 
deployment to inflammatory sites. Science. 2009;325:612-616 
69. Shi C, Pamer EG. Monocyte recruitment during infection and 
inflammation. Nature reviews. Immunology. 2011;11:762-774 
70. Cortez-Retamozo V, Etzrodt M, Newton A, Ryan R, Pucci F, Sio SW, et al. 
Angiotensin ii drives the production of tumor-promoting macrophages. 
Immunity. 2013;38:296-308 
71. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin 
North Am. 2009;93:621-635 
72. Takayanagi T, Forrester SJ, Kawai T, Obama T, Tsuji T, Elliott KJ, et al. 
Vascular adam17 as a novel therapeutic target in mediating 
cardiovascular hypertrophy and perivascular fibrosis induced by 
angiotensin ii. Hypertension. 2016 
73. Nakamura T, Kataoka K, Fukuda M, Nako H, Tokutomi Y, Dong YF, et al. 
Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-
induced cardiac inflammation and fibrosis. Hypertension. 2009;54:544-551 
74. Schraeger JA, Canby CA, Rongish BJ, Kawai M, Tomanek RJ. Normal left 
ventricular diastolic compliance after regression of hypertrophy. Journal of 
cardiovascular pharmacology. 1994;23:349-357 
75. Matsubara LS, Matsubara BB, Okoshi MP, Cicogna AC, Janicki JS. 
Alterations in myocardial collagen content affect rat papillary muscle 
function. American journal of physiology. Heart and circulatory physiology. 
2000;279:H1534-1539 
	 138 
76. Narayan S, Janicki JS, Shroff SG, Pick R, Weber KT. Myocardial collagen 
and mechanics after preventing hypertrophy in hypertensive rats. 
American journal of hypertension. 1989;2:675-682 
77. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, 
et al. Myocardial stiffness is determined by ventricular fibrosis, but not by 
compensatory or excessive hypertrophy in hypertensive heart. 
Cardiovascular research. 2002;55:76-82 
78. O'Callaghan CJ, Williams B. Mechanical strain-induced extracellular 
matrix production by human vascular smooth muscle cells: Role of tgf-
beta(1). Hypertension. 2000;36:319-324 
79. Brooks WW, Bing OH, Conrad CH, O'Neill L, Crow MT, Lakatta EG, et al. 
Captopril modifies gene expression in hypertrophied and failing hearts of 
aged spontaneously hypertensive rats. Hypertension. 1997;30:1362-1368 
80. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, et al. Role 
of angiotensin ii in renal injury of deoxycorticosterone acetate-salt 
hypertensive rats. Hypertension. 1994;24:195-204 
81. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et 
al. Inhibition of plasminogen activators or matrix metalloproteinases 
prevents cardiac rupture but impairs therapeutic angiogenesis and causes 
cardiac failure. Nature medicine. 1999;5:1135-1142 
82. Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, et al. 
Increased expression of plasminogen activator inhibitor-1 in 
cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. 
The American journal of pathology. 2004;164:449-456 
83. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A 
mutant, noninhibitory plasminogen activator inhibitor type 1 decreases 
matrix accumulation in experimental glomerulonephritis. The Journal of 
clinical investigation. 2003;112:379-388 
84. Breitkopf-Heinlein K, Meyer C, Konig C, Gaitantzi H, Addante A, Thomas 
M, et al. Bmp-9 interferes with liver regeneration and promotes liver 
fibrosis. Gut. 2017;66:939-954 
85. Bi J, Ge S. Potential roles of bmp9 in liver fibrosis. Int J Mol Sci. 
2014;15:20656-20667 
86. Munoz-Felix JM, Cuesta C, Perretta-Tejedor N, Subileau M, Lopez-
Hernandez FJ, Lopez-Novoa JM, et al. Identification of bone 
morphogenetic protein 9 (bmp9) as a novel profibrotic factor in vitro. Cell 
Signal. 2016;28:1252-1261 
87. Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, Gressner AM, 
et al. Id1 is a critical mediator in tgf-beta-induced transdifferentiation of rat 
hepatic stellate cells. Hepatology. 2006;43:1032-1041 
88. Munoz-Felix JM, Gonzalez-Nunez M, Lopez-Novoa JM. Alk1-smad1/5 
signaling pathway in fibrosis development: Friend or foe? Cytokine Growth 
Factor Rev. 2013;24:523-537 
89. Manning AM, Bell FP, Rosenbloom CL, Chosay JG, Simmons CA, 
Northrup JL, et al. Nf-kappa b is activated during acute inflammation in 
	 139 
vivo in association with elevated endothelial cell adhesion molecule gene 
expression and leukocyte recruitment. J Inflamm. 1995;45:283-296 
90. Landmesser U, Harrison DG. Oxidative stress and vascular damage in 
hypertension. Coron Artery Dis. 2001;12:455-461 
91. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, et al. 
Role of inflammation in the development of renal damage and dysfunction 
in angiotensin ii-induced hypertension. Hypertension. 2008;52:256-263 
92. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: Oxidative stress 
and inflammation in the pathogenesis of hypertension. Nat Clin Pract 
Nephrol. 2006;2:582-593 
93. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. Nad(p)h oxidase 
mediates angiotensin ii-induced vascular macrophage infiltration and 
medial hypertrophy. Arteriosclerosis, thrombosis, and vascular biology. 
2003;23:776-782 
94. Neumann P, Gertzberg N, Johnson A. Tnf-alpha induces a decrease in 
enos promoter activity. Am J Physiol Lung Cell Mol Physiol. 
2004;286:L452-459 
95. Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis 
factor-alpha in angiotensin ii-mediated effects on salt appetite, 
hypertension, and cardiac hypertrophy. Hypertension. 2008;51:1345-1351 
96. Duerrschmid C, Trial J, Wang Y, Entman ML, Haudek SB. Tumor necrosis 
factor: A mechanistic link between angiotensin-ii-induced cardiac 
inflammation and fibrosis. Circulation. Heart failure. 2015;8:352-361 
97. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, et 
al. Interleukin-6 induces oxidative stress and endothelial dysfunction by 
overexpression of the angiotensin ii type 1 receptor. Circulation research. 
2004;94:534-541 
98. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi 
H. Interleukin 6 knockout prevents angiotensin ii hypertension: Role of 
renal vasoconstriction and janus kinase 2/signal transducer and activator 
of transcription 3 activation. Hypertension. 2010;56:879-884 
99. Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther 
JM, et al. Inflammation and hypertension: The interplay of interleukin-6, 
dietary sodium, and the renin-angiotensin system in humans. American 
journal of hypertension. 2011;24:1143-1148 
100. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration 
of interleukin-6 and the risk of future myocardial infarction among 
apparently healthy men. Circulation. 2000;101:1767-1772 
101. Lee DL, Leite R, Fleming C, Pollock JS, Webb RC, Brands MW. 
Hypertensive response to acute stress is attenuated in interleukin-6 
knockout mice. Hypertension. 2004;44:259-263 
102. Lamarca B, Brewer J, Wallace K. Il-6-induced pathophysiology during pre-
eclampsia: Potential therapeutic role for magnesium sulfate? Int J 
Interferon Cytokine Mediat Res. 2011;2011:59-64 
	 140 
103. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, et al. 
Angiotensin ii induces interleukin-6 in humans through a mineralocorticoid 
receptor-dependent mechanism. Hypertension. 2006;48:1050-1057 
104. Lee DL, Sturgis LC, Labazi H, Osborne JB, Jr., Fleming C, Pollock JS, et 
al. Angiotensin ii hypertension is attenuated in interleukin-6 knockout 
mice. American journal of physiology. Heart and circulatory physiology. 
2006;290:H935-940 
105. Vazquez-Oliva G, Fernandez-Real JM, Zamora A, Vilaseca M, Badimon L. 
Lowering of blood pressure leads to decreased circulating interleukin-6 in 
hypertensive subjects. J Hum Hypertens. 2005;19:457-462 
106. Chava KR, Karpurapu M, Wang D, Bhanoori M, Kundumani-Sridharan V, 
Zhang Q, et al. Creb-mediated il-6 expression is required for 15(s)-
hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell 
migration. Arteriosclerosis, thrombosis, and vascular biology. 
2009;29:809-815 
107. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. Il-6 
deficiency protects against angiotensin ii induced endothelial dysfunction 
and hypertrophy. Arteriosclerosis, thrombosis, and vascular biology. 
2007;27:2576-2581 
108. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, 
et al. Rho-kinase mediates angiotensin ii-induced monocyte 
chemoattractant protein-1 expression in rat vascular smooth muscle cells. 
Hypertension. 2001;38:100-104 
109. Moore JP, Vinh A, Tuck KL, Sakkal S, Krishnan SM, Chan CT, et al. M2 
macrophage accumulation in the aortic wall during angiotensin ii infusion 
in mice is associated with fibrosis, elastin loss, and elevated blood 
pressure. American journal of physiology. Heart and circulatory 
physiology. 2015;309:H906-917 
110. Chan CT, Moore JP, Budzyn K, Guida E, Diep H, Vinh A, et al. Reversal 
of vascular macrophage accumulation and hypertension by a ccr2 
antagonist in deoxycorticosterone/salt-treated mice. Hypertension. 
2012;60:1207-1212 
111. Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in 
hypertension. Frontiers in physiology. 2012;3:128 
112. Franco M, Martinez F, Quiroz Y, Galicia O, Bautista R, Johnson RJ, et al. 
Renal angiotensin ii concentration and interstitial infiltration of immune 
cells are correlated with blood pressure levels in salt-sensitive 
hypertension. Am J Physiol Regul Integr Comp Physiol. 2007;293:R251-
256 
113. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin 
EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative 
stress in resistance arteries of angiotensin ii-infused macrophage colony-
stimulating factor-deficient mice: Evidence for a role in inflammation in 
angiotensin-induced vascular injury. Arteriosclerosis, thrombosis, and 
vascular biology. 2005;25:2106-2113 
	 141 
114. Harrison DG, Guzik TJ. Macrophages come to mind as keys to cognitive 
decline. The Journal of clinical investigation. 2016;126:4393-4395 
115. Shirai T, Hilhorst M, Harrison DG, Goronzy JJ, Weyand CM. Macrophages 
in vascular inflammation--from atherosclerosis to vasculitis. Autoimmunity. 
2015;48:139-151 
116. Kotsias F, Hoffmann E, Amigorena S, Savina A. Reactive oxygen species 
production in the phagosome: Impact on antigen presentation in dendritic 
cells. Antioxid Redox Signal. 2013;18:714-729 
117. Idris-Khodja N, Mian MO, Paradis P, Schiffrin EL. Dual opposing roles of 
adaptive immunity in hypertension. European heart journal. 2014;35:1238-
1244 
118. Minutti CM, Jackson-Jones LH, Garcia-Fojeda B, Knipper JA, Sutherland 
TE, Logan N, et al. Local amplifiers of il-4ralpha-mediated macrophage 
activation promote repair in lung and liver. Science. 2017;356:1076-1080 
119. Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, et 
al. Macrophage function in tissue repair and remodeling requires il-4 or il-
13 with apoptotic cells. Science. 2017;356:1072-1076 
120. Bouchery T, Harris NL. Specific repair by discerning macrophages. 
Science. 2017;356:1014 
121. Angelini DJ, Su Q, Yamaji-Kegan K, Fan C, Teng X, Hassoun PM, et al. 
Resistin-like molecule-beta in scleroderma-associated pulmonary 
hypertension. Am J Respir Cell Mol Biol. 2009;41:553-561 
122. Yamaji-Kegan K, Su Q, Angelini DJ, Myers AC, Cheadle C, Johns RA. 
Hypoxia-induced mitogenic factor (himf/fizz1/relmalpha) increases lung 
inflammation and activates pulmonary microvascular endothelial cells via 
an il-4-dependent mechanism. J Immunol. 2010;185:5539-5548 
123. Galastri S, Zamara E, Milani S, Novo E, Provenzano A, Delogu W, et al. 
Lack of cc chemokine ligand 2 differentially affects inflammation and 
fibrosis according to the genetic background in a murine model of 
steatohepatitis. Clinical science. 2012;123:459-471 
124. El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL, Frid MG, et 
al. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic 
macrophage phenotype in pulmonary hypertension. J Immunol. 
2014;193:597-609 
125. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. 
Functional polarization of tumour-associated macrophages by tumour-
derived lactic acid. Nature. 2014;513:559-563 
126. Fielding CA, Jones GW, McLoughlin RM, McLeod L, Hammond VJ, Uceda 
J, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. 
Immunity. 2014;40:40-50 
127. Vannella KM, Barron L, Borthwick LA, Kindrachuk KN, Narasimhan PB, 
Hart KM, et al. Incomplete deletion of il-4ralpha by lysm(cre) reveals 
distinct subsets of m2 macrophages controlling inflammation and fibrosis 
in chronic schistosomiasis. PLoS pathogens. 2014;10:e1004372 
	 142 
128. Yildirim A, Russell J, Yan LS, Senchenkova EY, Granger DN. Leukocyte-
dependent responses of the microvasculature to chronic angiotensin ii 
exposure. Hypertension. 2012;60:1503-1509 
129. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. 
Role of the t cell in the genesis of angiotensin ii induced hypertension and 
vascular dysfunction. The Journal of experimental medicine. 
2007;204:2449-2460 
130. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte 
responses exacerbate angiotensin ii-dependent hypertension. Am J 
Physiol Regul Integr Comp Physiol. 2010;298:R1089-1097 
131. Mattson DL, Lund H, Guo C, Rudemiller N, Geurts AM, Jacob H. Genetic 
mutation of recombination activating gene 1 in dahl salt-sensitive rats 
attenuates hypertension and renal damage. Am J Physiol Regul Integr 
Comp Physiol. 2013;304:R407-414 
132. Itani HA, Harrison DG. Memories that last in hypertension. American 
journal of physiology. Renal physiology. 2015;308:F1197-1199 
133. Wei Z, Spizzo I, Diep H, Drummond GR, Widdop RE, Vinh A. Differential 
phenotypes of tissue-infiltrating t cells during angiotensin ii-induced 
hypertension in mice. PloS one. 2014;9:e114895 
134. Herrera J, Chavez M, Marin C. Transient improvement of hypertension-
induced chronic renal failure with mycophenolate mofetil treatment. Ren 
Fail. 2006;28:749-751 
135. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. 
Mycophenolate mofetil administration reduces renal inflammation, 
oxidative stress, and arterial pressure in rats with lead-induced 
hypertension. American journal of physiology. Renal physiology. 
2007;293:F616-623 
136. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, et al. 
Regulation of t-cell function by endogenously produced angiotensin ii. Am 
J Physiol Regul Integr Comp Physiol. 2009;296:R208-216 
137. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, et al. T 
regulatory lymphocytes prevent angiotensin ii-induced hypertension and 
vascular injury. Hypertension. 2011;57:469-476 
138. De Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate 
hypertension and kidney damage in dahl salt-sensitive rats. Am J Physiol 
Regul Integr Comp Physiol. 2010;298:R1136-1142 
139. Filip M, Maciag J, Nosalski R, Korbut R, Guzik T. [endothelial dysfunction 
related to oxidative stress and inflammation in perivascular adipose 
tissue]. Postepy Biochem. 2012;58:186-194 
140. Nosalski R, Guzik TJ. Perivascular adipose tissue inflammation in 
vascular disease. Br J Pharmacol. 2017;174:3496-3513 
141. Gopal K, Nagarajan P, Shankar EM, Kamarul T, Kumar JM. High-fat diet- 
and angiotensin ii-induced aneurysm concurrently elicits splenic 
hypertrophy. European journal of clinical investigation. 2014;44:1169-1176 
	 143 
142. Yang M, Chen J, Zhao J, Meng M. Etanercept attenuates myocardial 
ischemia/reperfusion injury by decreasing inflammation and oxidative 
stress. PloS one. 2014;9:e108024 
143. Vanhoutte D, Schellings MW, Gotte M, Swinnen M, Herias V, Wild MK, et 
al. Increased expression of syndecan-1 protects against cardiac dilatation 
and dysfunction after myocardial infarction. Circulation. 2007;115:475-482 
144. Suthahar N, Meijers WC, Sillje HHW, de Boer RA. From inflammation to 
fibrosis-molecular and cellular mechanisms of myocardial tissue 
remodelling and perspectives on differential treatment opportunities. 
Current heart failure reports. 2017;14:235-250 
145. Gerriets T, Stolz E, Walberer M, Muller C, Kluge A, Bachmann A, et al. 
Noninvasive quantification of brain edema and the space-occupying effect 
in rat stroke models using magnetic resonance imaging. Stroke; a journal 
of cerebral circulation. 2004;35:566-571 
146. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, et al. 
Pretreatment with eplerenone reduces stroke volume in mouse middle 
cerebral artery occlusion model. Eur J Pharmacol. 2007;566:153-159 
147. Pham M, Kleinschnitz C, Helluy X, Bartsch AJ, Austinat M, Behr VC, et al. 
Enhanced cortical reperfusion protects coagulation factor xii-deficient mice 
from ischemic stroke as revealed by high-field mri. NeuroImage. 
2010;49:2907-2914 
148. Bodary PF, Sambaziotis C, Wickenheiser KJ, Rajagopalan S, Pitt B, 
Eitzman DT. Aldosterone promotes thrombosis formation after arterial 
injury in mice. Arteriosclerosis, thrombosis, and vascular biology. 
2006;26:233 
149. Calo LA, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, et al. 
Effect of aldosterone and glycyrrhetinic acid on the protein expression of 
pai-1 and p22(phox) in human mononuclear leukocytes. The Journal of 
clinical endocrinology and metabolism. 2004;89:1973-1976 
150. Gromotowicz A, Szemraj J, Stankiewicz A, Zakrzeska A, Mantur M, 
Jaroszewicz E, et al. Study of the mechanisms of aldosterone 
prothrombotic effect in rats. Journal of the renin-angiotensin-aldosterone 
system : JRAAS. 2011;12:430-439 
151. Ma J, Albornoz F, Yu C, Byrne DW, Vaughan DE, Brown NJ. Differing 
effects of mineralocorticoid receptor-dependent and -independent 
potassium-sparing diuretics on fibrinolytic balance. Hypertension. 
2005;46:313-320 
152. Tittel AP, Heuser C, Ohliger C, Llanto C, Yona S, Hammerling GJ, et al. 
Functionally relevant neutrophilia in cd11c diphtheria toxin receptor 
transgenic mice. Nature methods. 2012;9:385-390 
 
 
	 144 
CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
Overview 
Previous work from our lab has demonstrated that macrophage activation 
and polarization are important for inflammation in response to cardiac damage 
and ischemic stroke1, 2. The mineralocorticoid receptor controls macrophage 
polarization, and ablation of the mineralocorticoid receptor in macrophages 
results in an alternatively activated (M2) profile and suppresses classical 
activation (M1). This change in macrophage polarization contributes to the 
protective effect of mineralocorticoid receptor deficiency on L-NG-nitroarginine 
methyl ester (L-NAME)/AngII-induced cardiac and vascular remodeling1 and 
neuroprotection in experimental stroke2. Most importantly, these results indicate 
that macrophages are critical target cell types for mineralocorticoid receptor 
antagonists that have been widely used in the treatment of cardiovascular 
diseases.  
Based on these previous findings, the original goal of the present study 
was to regulate macrophage polarization by modifying macrophage-specific 
molecules that control macrophage phenotype and test the importance of 
macrophages as a target cell type in the cardiac injury models myocardial 
infarction and AngII/Salt-induced hypertensive cardiac injury. IL4Rα signaling is a 
well established and potent inducer of alternative activation (M2) in 
macrophages, and M2 macrophages are significantly involved in resolution of 
inflammation, wound healing and tissue repair3, 4, and pathological fibrosis5, 6. We 
hypothesized that macrophage IL4Rα signaling inhibits inflammatory responses, 
but promotes fibrosis in cardiovascular remodeling post injury through M2 
macrophage activation and polarization; therefore blocking IL4Rα signaling in 
macrophages could exaggerate systemic inflammation, but ameliorate fibrosis, 
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leading to alterations in cardiovascular remodeling and subsequent changes in 
cardiac function.  
In order to test this hypothesis, we generated myeloid-specific IL4Rα 
knockout mice (MyIL4RαKO), which have genetic ablation of IL4Rα in myeloid 
lineage cells including monocytes, macrophages and neutrophils. We subjected 
these mice to cardiac injury/stress using experimental myocardial infarction and 
AngII/Salt-induced hypertensive cardiac injury models and investigated whether 
macrophages are the main target cell type of endogenous IL4/IL-13 signaling 
during cardiac remodeling and whether myeloid-specific IL4Rα signaling affects 
inflammation, pro-fibrotic remodeling and cardiac function.  
Based on the expression of M1/M2 macrophage markers, in vitro 
macrophages isolated from MyIL4RαKO mice showed significantly blunted 
responses to the M2 macrophage stimulus IL-4 and in contrast had markedly 
increased responses to the M1 macrophage stimulus LPS. This demonstrates 
the importance of IL4Rα signaling in macrophage polarization, particularly with 
respect to the activation and polarization of M2 macrophages.  
During myocardial infarction (MI), the infarct size of MyIL4RαKO mice was 
significantly decreased at 1-week post MI and the infarct thickness was 
significantly increased at 3-week. This suggests that IL4Rα in macrophages is an 
important target for endogenous IL-4/IL-13 and that myeloid IL4Rα signaling is 
importantly involved in cardiac remodeling post MI. In addition, IL4Rα deletion in 
myeloid cells enhanced perivascular fibrosis and caused more severe cardiac 
dysfunction, suggesting a protective role for myeloid IL4Rα signaling in cardiac 
remodeling post MI. Surprisingly, there was no obvious change in alternatively 
activated M2-like macrophage populations in infarct tissues post-MI, which 
indicates that the increased adverse cardiac remodeling caused by lacking of 
IL4Rα in myeloid cells is not through a simple global change of M2-like 
macrophages. Taken together, myeloid IL4Rα signaling is necessary for 
appropriate cardiac remodeling post MI, and macrophages are important target 
cell types for IL-4/IL-13 signaling, therefore myeloid IL4Rα signaling may be a 
potential therapeutic strategy for patients post MI. 
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In AngII/Salt-induced hypertensive cardiac injury, myeloid-specific IL4Rα 
ablation caused significant upregulation of ROS generation-related genes, 
indicating there is enhanced inflammation in MyIL4RαKO mice. This is 
accompanied by a substantial decrease in cardiovascular fibrosis, which may 
attribute to the significant down-regulation of TGFβ signaling and Gal3 signaling. 
The results above suggest that myeloid IL4Rα signaling is importantly involved 
the suppression of oxidative stress development and pro-fibrotic cardiovascular 
remodeling, two opposite effects regarding cardiac function. By performing 
echocardiography, we found that cardiac and aortic function of MyIL4RαKO mice 
was largely preserved in chronic hypertension, while that of control mice was 
significantly impaired. Surprisingly, but consistent with the infarction model, the 
changes in cardiovascular remodeling were not simply due to the disturbed 
macrophage polarization because no in vivo changes  in M1/M2 macrophages 
were detected by flow cytometry. In conclusion, myeloid IL4Rα signaling is 
significantly involved in cardiovascular remodeling induced by chronic 
hypertensive injury, and myeloid lineage cells are critical targets of endogenous 
IL-4/IL-13. Importantly, instead of M1/M2 macrophage polarization alteration, 
increased systemic inflammation and decreased pro-fibrotic remodeling in 
MyIL4RαKO mice is mediated by a more complicated mechanism of myeloid 
cells, which needs to be determined in the future. 
Overall in this dissertation, we demonstrated the following important 
findings: 1) myeloid cells are critical targets of endogenous IL-4/IL-13 signaling; 2) 
myeloid IL4Rα signaling involves more than simply regulating M1/M2 
macrophage polarization, and the present M1/M2 paradigm is inadequate; 3) 
IL4Rα signaling differentially affects resident and monocyte-derived infiltrating 
macrophages; 4) the effect of myeloid IL4Rα signaling on cardiac and vascular 
remodeling varies depending on the type and severity of the injury/stress. The 
last two conclusions were not specifically emphasized, but will be discussed later 
in this chapter.  
Myeloid cells are critical targets of IL-4/IL-13 
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IL-4 and IL-13 are anti-inflammatory cytokines, and the signaling pathways 
driven by these two cytokines have been shown to be very important in cardiac 
and vascular remodeling after injury. IL-4 administration improved post-MI 
prognosis and cardiac function7. Cardiac fibrosis induced by pressure overload 
was considerably attenuated by anti-IL-4 neutralizing antibody8, and IL-4 
deficient mice displayed reduced interstitial myocardial fibrosis in response to 
AngII9. However, the target cell type(s) of IL-4/IL-13 in cardiovascular remodeling 
have been unclear. 
IL4Rα is the common chain of IL-4/IL-13 receptors by which IL-4 and IL-13 
activate their signaling pathways, therefore we employed the use of myeloid 
specific IL4Rα deficient mice to identify the contribution of macrophages in 
endogenous IL-4/IL-13 mediated cardiovascular remodeling. By blocking IL4Rα 
signaling specifically in myeloid cells, infarct size post-MI was decreased 
temporarily, perivascular fibrosis was increased and cardiac function was more 
significantly impaired post-MI. Both interstitial and peri-vascular fibrosis were 
significantly decreased during AngII/Salt-induced hypertensive injury. These 
results indicate that myeloid cells are important mediators of endogenous IL-4/IL-
13-induced changes in cardiovascular remodeling during acute and chronic 
cardiac injury. Macrophages represent the largest population of myeloid lineage 
cells in the heart and vasculature in the models we tested, and these results 
highlight a significant role of macrophages in IL4Rα signaling-mediated 
remodeling. This is further supported by the similar degree of fibrosis detected in 
global IL4Rα deficient and myeloid-specific IL4Rα deficient mice during a chronic 
pancreatitis model. They found that myeloid-specific IL4Rα knockout 
phenocopied the global IL4Rα deficient mice indicating that myeloid cells were 
the critical cell types mediating the fibrotic effects of IL4Rα signaling10.  
The significant role of myeloid cells or macrophages in IL4Rα signaling-
mediated cardiac and vascular remodeling in our studies could be confirmed by 
generating the whole body IL4Rα knockout (IL4Rα-/-) mice, and then comparing 
the remodeling phenotypes between IL4Rα-/- and MyIL4RαKO mice. If IL4Rα-/- 
mice phenocopy the myeloid-specific IL4Rα deficient mice, that would indicate 
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myeloid cells/macrophages are critical cell specific targets in endogenous IL-4/IL-
13 mediated cardiovascular remodeling. An alternative scenario would be to 
administer IL-4 in MyIL4RαKO and control mice that are subjected to myocardial 
infarction. If administration of IL-4 decreases cardiac damage and improves 
cardiac function in control mice but not in MyIL4RαKO mice, that would also 
demonstrate a predominant role for myeloid cells or macrophages in IL-4-
mediated protection.  
Myeloid cells include monocytes/macrophages and neutrophils, and both 
monocytes/macrophages and neutrophils express IL4Rα, so we cannot exclude 
the possible contribution of neutrophils in our studies. Although we did measure 
the neutrophil population in our studies by flow cytometry, further experiments 
testing the response of neutrophils to IL-4 or other inflammatory stimuli during 
IL4Rα deficiency would provide additional insight. Furthermore, to particularly 
delineate the contribution of neutrophils in IL4Rα signaling-mediated 
cardiovascular remodeling after injury/stress, neutrophil-specific IL4Rα knockout 
using the Mrp8 (S100A8)-Cre would be a possible approach.  
Inadequacy of M1/M2 macrophage paradigm 
IL4Rα signaling is a well-established mechanism of IL-4-induced M2 
macrophage activation and polarization. Consistent with this role, IL-4 stimulation 
of IL4RαKO macrophages showed a dampened response in polarization 
compared with macrophages from control mice. Although we saw some similar 
changes at baseline in cardiac tissue, we did not see this phenotype in vivo in 
cardiac injury models. No change was detected in M2-like macrophages 
characterized by CD11b+F4/80+CD206+ in injured tissues between MyIL4RαKO 
and control mice either after MI or hypertensive cardiac injury. This raises the 
question that after injury macrophage polarization is not changed by deleting 
IL4Rα, or the properties of macrophages are changed but the present M1/M2 
paradigm is not adequate to describe it? 
This would indicate a diminished role for endogenous IL-4/IL-13 since the 
in vitro data clearly showed that deficiency of IL4Rα in macrophages significantly 
decreased the expression of M2 macrophage markers, but increased the M1 
	 149 
macrophage markers. In vivo, the lack of IL4Rα in myeloid cells caused 
substantial alteration in cardiovascular remodeling: enhanced cardiac dysfunction 
post-MI and attenuated cardiac and vascular fibrosis post hypertensive injury. 
Since macrophages represent one of the major myeloid cell types in the injured 
myocardium, and the infiltration of neutrophils was not largely changed in 
MyIL4Rα mice, the significant differences in cardiovascular remodeling caused 
by myeloid-specific IL4Rα ablation is likely to be mediated through its effects on 
macrophages.  
It is likely that the deficiency of IL4Rα did change the properties of 
macrophage in vivo, however, the present M1/M2 model we used is not sufficient 
enough to reveal these changes. This indicates the inadequacy of the M1/M2 
dichotomy since the M1/M2 model is based on the in vitro activation of 
macrophages, which stimulates macrophages with a defined set of factors. This 
does not resemble anything that occurs in vivo11. Instead of M1 and M2, two 
polarized extremes, macrophages exist as a wide spectrum that line between M1 
and M2. Presently, we lack markers to characterize the intermediates. Current 
markers only characterize the two extremes, for example TNFα and CD206 are 
commonly used in flow cytometry to identify M1 and M2 macrophages 
respectively. The transcriptional profiles of human macrophages display a broad 
transcriptional range that challenges the M1/M2 paradigm11. Third, stimuli in 
cardiovascular diseases may activate macrophages that are considerably 
deviated from the M1/M2 axis.  
Based on the rationale above, in order to characterize macrophages from 
MyIL4RαKO mice in cardiovascular remodeling more broadly, in addition to the 
current M1 and M2 macrophage markers that are more involved in M2a subset, 
the genes to be determined can be more extended, such as the genes typically 
expressed by M2b, M2c and M2d subsets. Additionally, instead of measuring 
gene expression in the tissue, specifically sort pure macrophage population from 
injured tissues by flow cytometry and then determine the expression of M1/M2 
macrophage related genes by RNA sequencing and qRT-PCR would definitely 
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provide more information about the role of IL4Rα signaling in macrophage 
polarization during cardiovascular remodeling.  
IL4Rα signaling in resident and infiltrating macrophages 
We have consistently shown in our studies that the expression of certain 
genes is significantly changed in heart and aorta at basal levels as a result of 
myeloid IL4Rα deletion. However, these differences disappear in the 
inflammatory state after MI and AngII/Salt-induced hypertensive injury. These 
genes include BNP, Arg1, TNFα, IL-1β, MCP-1, IL-6, Nox1 and Nox4 in heart, 
and Col1A1, MMP2, MMP8, PDGFα and Gal-3 in aorta. This is a wide range of 
genes involved in a variety of pathophysiological processes such as hypertrophy, 
inflammation, oxidative stress, fibrosis, and M2 macrophage polarization, which 
suggests a systemic effect rather than a random event caused by myeloid cells 
lacking IL4Rα. The main difference of myeloid cells in the determined tissues at 
steady state and those at inflammatory state is that, the macrophages at steady 
state are resident macrophages while the macrophages upon inflammation are 
infiltrating macrophages.  
Most resident macrophages in steady state originate from the embryonic 
yolk sac, while macrophages in the inflammatory state are mainly from circulating 
monocytes derived from bone marrow hematopoietic stem cells, although 
proliferation of resident macrophages also contributes. The distinct origin of 
resident and infiltrating macrophages may explain the significant differences in 
gene expression at basal level that disappear after inflammation. This may also 
partially contribute to the different responses of MyIL4RαKO mice in terms of 
cardiac function in two different models: severe acute injury in MI and the more 
mild hypertensive injury induced by AngII/Salt, because compared with control 
mice, MyIL4Rα mice displayed worse cardiac function after MI, but a more 
preserved cardiac function in response to hypertension. In MI induced by 
permanent occlusion, resident macrophages can be replaced by monocyte-
derived infiltrating macrophages12. In hypertensive cardiac injury induced by 
AngII and high salt, where the injury is more mild and chronic, cardiac 
macrophages are also replaced by hematopoietic-derived monocytes although it 
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is possible that a more mild and chronic progression of injury will result in 
maintaining a macrophage population that originates from local proliferation of 
the resident macrophage pool. 
Although it is suggestive that IL4Rα signaling may differentially regulate 
resident and infiltrating macrophages, the gene expression data that we acquired 
is all based on analysis of transcripts from cardiac tissue rather than purified 
macrophages. In order to test our hypothesis, it would be necessary to isolate 
macrophages from sham and injured cardiac tissue using cell sorting, and then 
perform RNA sequencing and qRT-PCR to characterize their transcriptional 
profile, including genes associated with hypertrophy, ROS generation, 
inflammation progression and fibrosis. This would help to distinguish resident and 
infiltrating macrophages and to demonstrate the involvement of IL4Rα signaling 
in these two distinct macrophage populations. In addition, CCR2 is currently 
considered as a marker that is positive in monocyte-derived infiltrating 
macrophages but negative in yolk sac-derived resident macrophages13, 14, so 
specifically sort CCR2- and CCR2+ cells from control and MyIL4RαKO mice in MI 
and AngII/salt-induced injury model, and then determine their transcriptional 
prolife can more specifically demonstrate the role of IL4Rα signaling tissue 
resident and monocyte-derived infiltrating macrophages.  
The fate of embryonic yolk sac-originated, resident macrophages and 
bone marrow hematopoietic stem cell-derived infiltrating macrophages after 
injury and their contribution in the modulation of the post injury inflammation is 
still unknown. In order to investigate how IL4Rα signaling differentially regulates 
resident and infiltrating macrophages during cardiac injury, lineage tracing 
experiments could be employed. This would identify changes in the proliferation 
of resident macrophages and also the recruitment and proliferation of 
hematopoietic-derived infiltrating macrophages. MyIL4RαKO mice could be 
crossed to a GFP reporter line and MyIL4RαKO/GFP bone marrow chimeras 
could be generated to create myeloid IL4RαKO in the resident cardiac 
macrophage population or in the circulating hematopoietic-derived 
monocyte/macrophage lineage. We can then trace the number and recruitment 
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of GFP-labeled resident macrophages or non-GFP-labeled infiltrating 
macrophages after injury in MyIL4RαKO mice in order to clarify the involvement 
of IL4Rα signaling in the proliferation and recruitment of these two distinct 
macrophage population. Alternately, the temporally regulated CX3CR1CreERT2 Cre 
line could be used to generate IL4Rα knockout in the resident cardiac 
macrophage population, but not the infiltrating macrophage population. Since the 
resident cardiac macrophage population is maintained through self-renewal, 
transient tamoxifen administration will cause IL4Rα gene inactivation that will be 
maintained indefinitely through local proliferation. In contrast, IL4Rα gene 
inactivation in circulating monocytes will be transient since they are continuously 
replaced by new hematopoietic stem cell-derived monocytes, therefore after 2-4 
weeks all circulating monocytes will have wild type IL4Rα.  
It has been reported that monocytes/macrophage turnover and flux occurs 
extremely rapidly during MI and these cells are also capable of exiting the heart 
during inflammation15. In order to investigate macrophage and monocyte kinetics 
and whether IL4Rα signaling is involved in the modulation of macrophage exit, 
dioctadecyloxacarbocyanine (DiO) can be used to label tissue-specific resident 
macrophages. Through intramyocardial injection of DiO, resident macrophages in 
heart but not circulating cells can be labeled. In order to trace the exit of cardiac 
resident macrophages during inflammation, we can detect DiO+ macrophages in 
heart, lymph nodes, spleen and bone marrow after injury with flow cytometry, and 
identify if IL4Rα signaling affects macrophage kinetics and the regulation of 
cardiac resident macrophage exit.  
Macrophage-specific transcriptional profile assay and lineage tracing of 
embryonically-derived resident macrophage and monocyte-derived infiltrating 
macrophage populations after injury can collectively distinguish the role of IL4Rα 
signaling in these two distinctive macrophage subsets. Furthermore, these future 
experiments can provide valuable mechanistic information about myeloid IL4Rα 
signaling and identify the contribution of resident and infiltrating macrophages in 
cardiac remodeling post MI or AngII and high salt. 
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